<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 10, 1999
CHEMDEX CORPORATION
(Exact name of registrant as specified in its charter)
0-26811
(Commission File Number)
Delaware 77-0465469
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation)
1500 Plymouth Street, Mountain View, CA 94043
(Address of principal executive offices, with zip code)
650-567-8900
(Registrant's telephone number, including area code)
3950 Fabian Way, Palo Alto, CA 94303
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events.
(a) On December 13, 1999, Chemdex and Tenet Healthcare Corporation
announced the formation of a new company to provide business-to-
business e-commerce solutions to the healthcare industry. Further
details are set forth in the press release attached hereto as Exhibit
99.1
(b) On December 20, 1999, Chemdex announced that it had made a $10 million
investment in TRADEX Technologies, Inc., a provider of solutions for
net markets. TRADEX is in the process of being acquired by Ariba, Inc.
Further details are set forth in the press release attached hereto as
Exhibit 99.2
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
10.34 Joint Venture Agreement dated as of December 10, 1999 between
Tenet HealthSystem Medical Inc. and Chemdex Corporation.
10.35 Form of Tenet/NewCo Agreement dated as of January___, 2000
between Tenet HealthSystem Medical, Inc., Tendex, Inc.,
Promedix.com, Inc. and Chemdex Corporation. *
10.36 Form of Chemdex License and Services Agreement dated as of
January___, 2000 between Chemdex Corporation, Promedix.com,
Inc., Tendex, Inc. and Tenet HealthSystem Medical, Inc. *
99.1 Press release dated December 13, 1999, announcing the joint
venture with Tenet Healthcare Corporation.
99.2 Press release dated December 20, 1999, announcing the
investment in TRADEX.
_______________________
* Confidential Treatment Requested.
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CHEMDEX CORPORATION
Date: January 03, 2000 By: /s/ James G. Stewart
------------------------------
James G. Stewart
Chief Financial Officer
-3-
<PAGE>
EXHIBIT 10.34
_______________________________
JOINT VENTURE AGREEMENT
_______________________________
Between
Tenet HealthSystem Medical, Inc.
And
Chemdex Corporation
Dated as of December 10, 1999
<PAGE>
JOINT VENTURE AGREEMENT
-----------------------
This JOINT VENTURE AGREEMENT (this "Agreement") is made and entered into as
---------
of December 10, 1999 by and between Tenet HealthSystem Medical Inc., a Delaware
corporation ("Tenet"), and Chemdex Corporation, a Delaware corporation
("Chemdex").
WHEREAS, the parties desire to form a joint venture company on the terms
and conditions set forth in this Agreement.
NOW, THEREFORE, the parties hereby agree as follows:
ARTICLE I
DEFINITIONS
For purposes of this Agreement, the following terms shall have the meanings
set forth respectively after each:
1.1 "Board" shall mean the Board of Directors of the Company, designated
-----
in accordance with Section 5.1 and the Voting Agreement.
1.2 "Charter Documents" shall mean the Company's Restated Certificate and
-----------------
Bylaws.
1.3 "Common Shares" shall mean shares of the Common Stock of the Company,
-------------
as authorized by the Articles of Incorporation.
1.4 "Chemdex Common Stock Purchase Agreement" shall mean that certain
---------------------------------------
Common Stock Purchase Agreement, in the form attached hereto as Exhibit D, to be
---------
entered into by the Company and Chemdex as of the Closing.
1.5 "Chemdex License and Services Agreement" shall mean that certain
--------------------------------------
Chemdex License and Services Agreement in the form attached hereto as Exhibit B,
---------
to be entered into by the Company, Chemdex, Promedix and Tenet as of the
Closing.
1.6 "Holder" shall mean Tenet or Chemdex, as applicable. "Holders" shall
------ -------
mean Tenet and Chemdex.
1.7 "Investors' Rights Agreement" shall mean that certain Investors'
---------------------------
Rights Agreement, in the form attached hereto as Exhibit F, to be entered into
---------
by the Company, Tenet and Chemdex as of the Closing.
1.8 "Key Employees" shall mean the employees of Tenet identified by the
-------------
Transaction Team in writing as critical to the success of the Company.
-2-
<PAGE>
1.9 "Operating Plan" shall mean the Operating Plan for the Company (as
--------------
defined below), as the same may be amended from time to herein time as set forth
herein, which Operating Plan shall be updated no less frequently than once each
calendar year.
1.10 "Promedix" shall mean Promedix, Inc., a Delaware corporation.
--------
1.11 "Preferred Shares" shall mean shares of the Series A Preferred Stock
----------------
of the Company, as authorized by the Restated Certificate.
1.12 "Related Agreements" shall mean the Tenet/Newco Agreement, the
------------------
Chemdex License and Services Agreement, the Tenet Common Stock Purchase
Agreement, the Chemdex Common Stock Purchase Agreement, the Series A Purchase
Agreement, the Investors' Rights Agreement and the Voting Agreement.
1.13 "Restated Certificate" shall have the meaning set forth in Section
--------------------
3.4 hereof.
1.14 "Securities" shall mean all Common Shares, Preferred Shares and any
----------
other equity securities of the Company or instruments exercisable for or
convertible into Common Shares or other equity securities of the Company.
1.15 "Series A Purchase Agreement" shall mean that certain Series A Stock
---------------------------
Purchase Agreement, in the form attached hereto as Exhibit E, to be entered into
---------
by the Company, Tenet and Chemdex as of the Closing.
1.16 "Tenet Common Stock Purchase Agreement" shall mean that certain
-------------------------------------
Common Stock Purchase Agreement, in the form attached hereto as Exhibit C, to be
---------
entered into by the Company and Tenet as of the Closing.
1.17 "Tenet/Newco Agreement" shall mean that certain Tenet/Newco
---------------------
Agreement, in the form attached hereto as Exhibit A, to be entered into by the
---------
Company, Chemdex, Tenet and Promedix as of the Closing.
1.18 "Voting Agreement" shall mean that certain Voting Agreement, in the
----------------
form attached hereto as Exhibit G, to be entered into by the Company, Tenet and
---------
Chemdex as of the Closing.
ARTICLE II
FORMATION OF THE COMPANY
2.1 Name. The name of the joint venture company is Tendex, Inc. (the
----
"Company").
2.2 Organization. The Company was incorporated in Delaware on December 9,
------------
1999. The Company's initial Certificate of Incorporation and Bylaws are
attached hereto as Exhibit I and Exhibit J, respectively.
--------- ---------
-3-
<PAGE>
2.3 Term. The Company shall continue in effect perpetually, subject to
----
earlier termination in accordance with Section 8.2 of this Agreement.
2.4 Purposes and Powers. The objective of the Company is to provide an e-
-------------------
commerce procurement solution initially for commodity medical products to
hospitals, integrated delivery networks and not for profit chains, with the goal
to expand to pharamacuticals products, hospitality services and general
maintenance and operational products.
ARTICLE III
CAPITALIZATION OF COMPANY
3.1 Capitalization and Capital Stock. On or before the Closing (as
--------------------------------
defined below) the Company shall adopt and file with the Secretary of State of
the State of Delaware the Amended and Restated Certificate of Incorporation in
the form attached hereto as Exhibit K (the "Restated Certificate"). Upon the
--------- --------------------
filing of the Restated Certificate, the Company shall have an authorized
capitalization of fifteen million (15,000,000) shares consisting of ten million
(10,000,000) shares of Common Stock and five million (5,000,000) shares of
Preferred Stock, with the rights, preferences and restrictions set forth in the
Restated Certificate.
3.2 Sale and Purchase of Shares.
---------------------------
(a) Tenet Contribution. At the Closing, the Company will issue to
------------------
Tenet three (3) shares of its Common Stock at a purchase price of $0.0001 per
share and 3,800,000 shares of its Series A Preferred Stock, with such value as
to be agreed upon prior to the Closing by the parties hereto, in consideration
of Tenet entering into the Tenet/Newco Agreement. Tenet shall also have
arranged for Morgan Guaranty Trust Company of New York to provide to NewCo a
line of credit in an amount no less than $5 million. If requested by such
lender, Tenet shall guarantee the obligations of NewCo under such line of
credit.
(b) Chemdex Contribution. At the Closing, the Company will issue to
--------------------
Chemdex one (1) share of its Common Stock at a purchase price of $0.0001 per
share and 1,200,000 shares of its Series A Preferred Stock, with such value as
to be agreed upon prior to the Closing by the parties hereto, in consideration
of Chemdex entering into the Chemdex License and Services Agreement.
(c) Ownership of the Company. At the Closing, the Company will be 76%
------------------------
owned by Tenet and 24% owned by Chemdex.
3.3 Closing.
-------
(a) Time and Place. The closing for the initial issuances of shares
--------------
as set forth in Section 3.2 (the "Closing") shall take place at such place and
-------
time and on such date as the parties hereto may agree, such time and date to be
as soon as reasonably practicable following the execution of this Agreement. At
the Closing, certificates representing the shares to be issued
-4-
<PAGE>
to each party shall be delivered by, or on behalf of, the Company against
payment therefor. The certificates shall be registered in such names as the
parties shall instruct.
(b) Closing Conditions.
------------------
(i) On or prior to the Closing, Tenet and the Company shall
have entered into the Tenet Common Stock Purchase Agreement.
(ii) On or prior to the Closing, Chemdex and the Company shall
have entered into the Chemdex Common Stock Purchase Agreement.
(iii) On or prior to the Closing, Tenet, Chemdex and the Company
shall have entered into the Series A Purchase Agreement, the Investors' Rights
Agreement and the Voting Agreement.
(iv) On or prior to the Closing, Tenet, Chemdex, the Company and
Promedix shall have entered into the Tenet/Newco Agreement.
(v) On or prior to the Closing, Chemdex, the Company and
Promedix shall have entered into the Chemdex License and Services Agreement.
(vi) The waiting period with respect to the consummation of the
transactions contemplated by this Agreement under the Hart-Scott-Rodino
Antitrust Improvement Act of 1976, as amended, if applicable, shall have expired
or been terminated.
ARTICLE IV
[Intentionally left blank]
ARTICLE V
MANAGEMENT OF COMPANY
5.1 Board of Directors. The Board shall be initially comprised of three
------------------
persons. Subject to the terms and conditions of the Voting Agreement, the
initial board composition will include two directors designated by Tenet and one
director designated by Chemdex.
5.2 Statutory Auditors. If required by law, the Company shall have one
------------------
statutory auditor (the "Statutory Auditor"), who shall be designated by the
-----------------
Board of Directors of the Company.
5.3 Transition Team. A team consisting of Skip Klintworth, Paul Kusserow,
---------------
David Ricker and Andrew Carragher (the "Transition Team") shall provide
---------------
transitional planning services to the Company from the date of this Agreement
through the earlier of (I) the Company's hiring of a Chief Executive Officer or
(ii) the Closing.
-5-
<PAGE>
5.4 Advisory Board. As soon as reasonably practicable following the hiring
--------------
of the Company's Chief Executive Officer, the Company shall establish an
advisory board to provide consultations and advice pertaining to medical and
health trends related to the Company's business. The members of the advisory
board shall be recommended by the Company's Chief Executive Officer and approved
by the Board of Directors of the Company.
ARTICLE VI
ACCOUNTING, RECORDS, REPORTS AND MEETINGS
6.1 Fiscal Year. The fiscal year of the Company shall be from January 1
-----------
to December 31 of each year.
6.2 Bank Account. Company moneys shall be deposited in the name of the
------------
Company in one or more financial institutions to be designated by the Board and
may be withdrawn on the signatures of such officers of the Company as the Board
may designate from time to time.
6.3 Confidential Nature of Information. Each party shall hold and shall
----------------------------------
cause its respective representatives to hold in confidence all confidential
information, including, without limitation, business and financial information,
made available to it or its representatives by the other party, directly or
through the Company, and shall not use or disclose such information to third
parties without the written consent of the other party, unless such information
(I) becomes generally available to the public other than as a result of a
disclosure by such party or its representatives, (ii) becomes available to such
party from other sources not known by such party to be bound by a
confidentiality obligation, or (iii) is independently acquired by such party as
a result of work carried out by any employee or representative of such party to
whom no disclosure of such information has been made.
6.4 Operating Plan. No later than forty five (45) days prior to the
--------------
commencement of each fiscal year of the Company, Tenet and Chemdex will mutually
agree as to the Operating Plan for the ensuing fiscal year, which shall include
projections of revenue, expenses and net income on a quarterly basis. Tenet and
Chemdex agree to use their best efforts in good faith to agree on such Operating
Plan, taking into account, all relevant business factors relating to the Company
and its business, which factors shall include, but not be limited to, the
Operating Plan and the Company's performance for recent prior periods, the size
and the growth rates of the Company's markets and the related competitive
environment.
-6-
<PAGE>
ARTICLE VII
RESTRICTION ON TRANSFER
Each party agrees not to sell, make any short sale of, loan, grant any
option for the purchase of, or otherwise dispose of any Securities without the
prior written consent of the Company and the other party to this Agreement, for
such period of time that expires upon 18 months from the date of this Agreement.
ARTICLE VIII
TERMINATION
8.1 Term of the Agreement. This Agreement shall remain in effect unless
---------------------
and until terminated pursuant to Section 8.2.
8.2 Termination of the Agreement.
----------------------------
(a) Termination by Mutual Consent. This Agreement may be terminated
-----------------------------
by the mutual written consent of the parties.
(b) Termination for Breach. If either party fails in any material
----------------------
respect to perform or fulfill in the time and manner herein provided any
obligation or condition herein required or required pursuant to the Related
Agreements to be performed or fulfilled by such party, and if such default shall
continue for sixty (60) days after written notice thereof from the other party,
then the other party shall have the right to terminate this Agreement by written
notice of termination to the defaulting party at any time after such sixty (60)
days.
(c) Termination for Insolvency. Either party may terminate this
--------------------------
Agreement upon written notice to the other party in the event that (I) the other
party shall become insolvent or bankrupt, (ii) an application shall be made to
have the other party declared insolvent or bankrupt, which application is not
lifted or withdrawn within ninety (90) days following filing, (iii) a receiver
or trustee shall be appointed with respect to the other party, or (iv) the other
party shall make an assignment for the benefit of creditors.
(d) Termination for Deadlock. In the event Tenet and Chemdex are
------------------------
unable to reach agreement with respect to any action requiring Tenet and
Chemdex's approval pursuant to Section 5, either party may give written notice
of deadlock to the other party. In the event no agreement is reached with
respect to such matter within sixty (60) days of the date such notice is given,
either party may terminate this Agreement by written notice of termination to
the other party.
(e) Termination on IPO. This Agreement shall terminate upon the
------------------
consummation of the initial public offering by the Company of shares of its
Common Stock pursuant to a registration statement on Form S-1 under the
Securities Act of 1933, as amended.
-7-
<PAGE>
8.3 Dissolution. In the event that this Agreement is terminated, the
-----------
parties shall promptly dissolve the Company and cause the Company's debts to be
paid to the extent the Company's assets are available to do so and the remaining
assets to be distributed to the Holders in accordance with their rights as
equity holders of the Company.
8.4 Survival. Termination of this Agreement for any reason shall not
--------
release either party from any liability which at the time of termination has
already accrued to the other party or which thereafter may accrue in respect of
any act or omission prior to such termination. The provisions of Articles VIII
and Section 6.5 shall survive any termination or expiration of this Agreement.
ARTICLE IX
WARRANTIES AND REPRESENTATIONS OF THE HOLDERS
---------------------------------------------
Each Holder hereby represents and warrants to each of the other Holders
that, as of the Effective Date and as of the date of the Closing, the following
statements are and shall be true and correct in all material respects:
9.1 Organization and Good Standing. Holder is a corporation duly
------------------------------
organized and validly existing under the laws of the jurisdiction in which such
Holder is incorporated and has the corporate power and authority to enter into
this Agreement and the Related Agreements to which it is a party and to perform
its obligations hereunder and thereunder.
9.2 Authorization. All corporate action on the part of Holder necessary
-------------
for the authorization, execution and delivery of this Agreement and the Related
Agreements to which it is a party and for the performance of all of its
obligations hereunder and thereunder has been taken and this Agreement and the
Related Agreements to which it is a party, when fully executed and delivered,
shall each constitute a valid, legally binding and enforceable obligation of
Holder.
9.3 Government and Other Consents. No consent, authorization, license,
-----------------------------
permit, registration or approval of, or exemption or other action by, any
governmental or public body or authority is required in connection with Holder's
execution and delivery of this Agreement and the Related Agreements to which it
is a party or with the performance by Holder of its obligations hereunder or
thereunder.
9.4 Effect of Agreement. Holder's execution and delivery of this
-------------------
Agreement and Related Agreements to which it is a party, performance of its
obligations hereunder and thereunder, and its consummation of the transactions
contemplated hereby and thereby will not, to Holder's knowledge, (I) violate any
provision of any law, statute, rule or regulation to which Holder is subject,
(ii) violate any judgment, order, writ, injunction or decree of any court
applicable to Holder, (iii) have any effect on the compliance of Holder with any
laws, statutes, rules, regulations, orders, decrees, licenses, permits or
authorizations which would materially and adversely affect Holder, (iv) result
in the breach of, or be in conflict with, any term, covenant, condition or
provision of, or affect the validity, enforceability and subsistence of any
agreement,
-8-
<PAGE>
lease or other commitment to which Holder is a party and which would materially
and adversely affect Holder, or (v) result in the creation or imposition of any
lien, pledge, mortgage, claim, charge, or encumbrance upon any assets of Holder.
9.5 Brokers. Holder has not incurred and will not incur any liability for
-------
brokers' or finders' fees or any similar charges in connection with the
transactions contemplated by this Agreement and the Related Agreements to which
it is a party.
ARTICLE X
MISCELLANEOUS
10.1 Notices. Except as otherwise provided herein, any notice or other
-------
communication to be given hereunder shall be in writing and shall be (as elected
by the party giving such notice): (I) personally delivered; (ii) transmitted by
postage prepaid registered or certified airmail, return receipt requested; (iii)
transmitted by electronic mail via the Internet with receipt being acknowledged
by the recipient by return electronic mail (with a copy of such transmission
concurrently transmitted by postage prepaid registered or certified airmail,
return receipt requested); (iv) transmitted by facsimile (with a copy of such
transmission by postage prepaid registered or certified airmail, return receipt
requested); or (v) deposited prepaid with a nationally recognized overnight
courier service. Unless otherwise provided herein, all notices shall be deemed
to have been duly given on: (x) the date of receipt (or if delivery is refused,
the date of such refusal) if delivered personally, by electronic mail, facsimile
or by courier; or (y) three (3) days after the date of posting if transmitted by
mail. All notices and other communications shall be addressed as follows:
(i) If to Tenet:
3820 State Street
Santa Barbara, CA 93105
Attention: General Counsel
Telephone: (805) 563-7000
Facsimile: (805) 563-7070
With a copy to:
Gibson, Dunn & Crutcher
1530 Page Mill Road
Palo Alto, CA 94304
Attention: Gregory T. Davidson
Telephone: (650) 849-5300
Facsimile: (650) 849-5333
-9-
<PAGE>
(ii) If to Chemdex
1500 Plymouth Street
Mountain View, CA 94043
Attention: David P. Perry
Telephone: 650-567-8900
Facsimile: 650-567-8950
With a copy to:
Venture Law Group
A Professional Corporation
2800 Sand Hill Road
Menlo Park, CA 94025
Attention: Jeffrey Y. Suto
Telephone: (650) 854-4488
Facsimile: (650) 233-8386
Or in each case to such other address or facsimile number as the party may
have furnished to the other party in writing.
10.2 Execution in Counterparts. This Agreement may be executed in any
-------------------------
number of counterparts with the same effect as if all parties hereto had all
signed the same document. All counterparts shall be construed together and
shall constitute one agreement.
10.3 Captions. Sections, titles or captions in no way define, limit,
--------
extend or describe the scope of this Agreement nor the intent of any of its
provisions.
10.5 Severability. If one or more provisions of this Agreement are held to
------------
be unenforceable under applicable law, the parties agree to renegotiate such
provision in good faith, in order to maintain the economic position enjoyed by
each party as close as possible to that under the provision rendered
unenforceable. In the event that the parties cannot reach a mutually agreeable
and enforceable replacement for such provision, then (I) such provision shall be
excluded from this Agreement, (ii) the balance of the Agreement shall be
interpreted as if such provision were so excluded and (iii) the balance of the
Agreement shall be enforceable in accordance with its terms.
10.6 Entire Agreement. This Agreement, together with the Related
----------------
Agreements, contain the entire agreement of the parties with respect to the
subject matter hereof, and supersedes all other agreements or understandings of
any kind.
10.7 Amendment. This Agreement may be amended only by a written instrument
---------
signed by both parties.
-10-
<PAGE>
10.8 Assignment. This Agreement may not be assigned by either party
----------
hereto except with the written consent of the other party; provided, however,
that this Agreement may be assigned by a party to a corporation which shall
succeed to the business of such party by merger, consolidation, or the transfer
of all or substantially all of the assets of such party and which shall
expressly assume the obligations of such party hereunder.
10.9 Governing Law and Jurisdiction. This Agreement shall be governed by
------------------------------
and construed in accordance with the laws of the State of California.
10.10. Jurisdiction; Venue. The parties hereby agree that all disputes
-------------------
arising out of this Agreement shall be subject to the exclusive jurisdiction of
and venue in the federal and state courts within Santa Clara County, California.
The parties hereto hereby consent to the personal and exclusive jurisdiction and
venue of these courts.
10.11 Waiver. No waiver by any party of any default in the performance of
------
or compliance with any provision herein shall be deemed to be a waiver of the
performance and compliance as to any other provision, or as to such provision in
the future; nor shall any delay or omission of any party to exercise any right
hereunder in any manner impair the exercise of any such right accruing to it
thereafter. No remedy expressly granted herein to any party shall be deemed to
exclude any other remedy which would otherwise be available.
10.12 No Third Party Beneficiaries. Nothing herein express or implied, is
----------------------------
intended to or shall be construed to confer upon or give to any person, firm,
corporation or legal entity, other than the parties hereto and their affiliates,
any interests, rights, remedies or other benefits with respect to or in
connection with any agreement or provision contained herein or contemplated
hereby.
10.13 Press Release; Publicity. Immediately after the signing of this
------------------------
Agreement, the parties shall agree on the text of a joint press release or
separate press releases regarding the transactions contemplated by this
Agreement. Except as set forth in the preceding sentence and except as required
by law, neither party shall issue or cause to be issued any press release,
public announcement or other public statement (including without limitation, any
public filings) with respect to the transactions contemplated by this Agreement
and the agreements referenced herein without the prior written consent of the
other party, which consent shall not be unreasonably delayed or withheld. In
the event that any party is requested or becomes legally compelled (including
without limitation, pursuant to securities laws and regulations) to disclose any
information regarding the transactions contemplated by this Agreement and the
agreements referenced herein, such party (the "Disclosing Party") shall provide
the other party (the "Non-Disclosing Party") with prompt written notice of that
fact so that the Non-Disclosing Party may have a reasonable period of time to
review, comment upon and approve such disclosure (which approval shall not be
unreasonably delayed or withheld) and so that the appropriate party may seek
(with the cooperation and reasonable efforts of the other party) a protective
order, confidential treatment or other appropriate remedy. In such event, the
Disclosing Party shall furnish only that portion of the information which is
legally required and shall exercise
-11-
<PAGE>
reasonable efforts to obtain reliable assurance that confidential treatment will
be accorded such information to the extent reasonably requested by any Non-
Disclosing Party.
[SIGNATURE PAGE FOLLOWS]
-12-
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement
effective as of the date first written above.
TENET HEALTHSYSTEM MEDICAL, INC.
By: /s/ Jeffrey Barbakow
---------------------------
Name: Jeffrey Barbakow
-------------------------
(print)
Title: CEO/ Chairman
-----------------------
Address:
CHEMDEX CORPORATION
By: /s/ David Perry
--------------------------
Name: David Perry
-------------------------
(print)
Title: CEO
------------------------
Address:
<PAGE>
EXHIBIT A
Tenet/Newco Agreement
Refer to Exhibit 10.35 of Form 8K
<PAGE>
EXHIBIT B
CHEMDEX LICENSE AND SERVICES AGREEMENT
Refer to Exhibit 10.36 of 8-K
<PAGE>
EXHIBIT C
Tenet Common Stock Purchase Agreement
<PAGE>
TENDEX, INC.
COMMON STOCK PURCHASE AGREEMENT
-------------------------------
This Common Stock Purchase Agreement (the "Agreement") is made as of
---------
December _________, 1999 by and between Tendex, Inc., a Delaware corporation
(the "Company"), and Tenet HealthSystem Medical, Inc. ("Purchaser").
------- ---------
1. Sale of Stock. Subject to the terms and conditions of this Agreement,
-------------
on the Purchase Date (as defined below) the Company will issue and sell to
Purchaser, and Purchaser agrees to purchase from the Company, three (3) shares
of the Company's Common Stock (the "Shares") at a purchase price of $0.0001 per
------
Share for a total purchase price of $0.0003. The term "Shares" refers to the
------
purchased Shares and all securities received in replacement of or in connection
with the Shares pursuant to stock dividends or splits, all securities received
in replacement of the Shares in a recapitalization, merger, reorganization,
exchange or the like, and all new, substituted or additional securities or other
properties to which Purchaser is entitled by reason of Purchaser's ownership of
the Shares.
2. Purchase. The purchase and sale of the Shares under this Agreement
--------
shall occur at the principal office of the Company simultaneously with the
execution of this Agreement by the parties or on such other date as the Company
and Purchaser shall agree (the "Purchase Date"). On the Purchase Date, the
-------------
Company will deliver to Purchaser a certificate representing the Shares to be
purchased by Purchaser (which shall be issued in Purchaser's name) against
payment of the purchase price therefor by Purchaser by (a) check made payable to
the Company, (b) cancellation of indebtedness of the Company to Purchaser, or
(c) by a combination of the foregoing.
3. Limitations on Transfer. In addition to any other limitation on
-----------------------
transfer created by applicable securities laws, Purchaser shall not assign,
encumber or dispose of any interest in the Shares except in compliance with the
provisions below and applicable securities laws.
(a) Right of First Refusal. Before any Shares held by Purchaser or
----------------------
any transferee of Purchaser (either being sometimes referred to herein as the
"Holder") may be sold or otherwise transferred (including transfer by gift or
------
operation of law), the Company or its assignee(s) shall have a right of first
refusal to purchase the Shares on the terms and conditions set forth in this
Section 3(a) (the "Right of First Refusal").
----------------------
(i) Notice of Proposed Transfer. The Holder of the Shares shall
---------------------------
deliver to the Company a written notice (the "Notice") stating: (A) the Holder's
------
bona fide intention to sell or otherwise transfer such Shares; (B) the name of
each proposed purchaser or other transferee ("Proposed Transferee"); (C) the
-------------------
number of Shares to be transferred to each Proposed Transferee; and (D) the
terms and conditions of each proposed sale or transfer. The Holder shall offer
the Shares at the same price (the "Offered Price") and upon the same terms (or
-------------
terms as similar as reasonably possible) to the Company or its assignee(s).
<PAGE>
(ii) Exercise of Right of First Refusal. At any time within 30
----------------------------------
days after receipt of the Notice, the Company and/or its assignee(s) may, by
giving written notice to the Holder, elect to purchase all, but not less than
all, of the Shares proposed to be transferred to any one or more of the Proposed
Transferees, at the purchase price determined in accordance with subsection
(iii) below.
(iii) Purchase Price. The purchase price ("Purchase Price") for
-------------- --------------
the Shares purchased by the Company or its assignee(s) under this Section 3(a)
shall be the Offered Price. If the Offered Price includes consideration other
than cash, the cash equivalent value of the non-cash consideration shall be
determined by the Board of Directors of the Company in good faith.
(iv) Payment. Payment of the Purchase price shall be made, at
-------
the option of the Company or its assignee(s), in cash (by check), by
cancellation of all or a portion of any outstanding indebtedness of the Holder
to the Company (or, in the case of repurchase by an assignee, to the assignee),
or by any combination thereof within 30 days after receipt of the Notice or on
the manner and at the times set forth in the Notice.
(v) Holder's Right to Transfer. If all of the Shares proposed
--------------------------
in the Notice to be transferred to a given Proposed Transferee are not purchased
by the Company and/or its assignee(s) as provided in this Section 3(a), then the
Holder may sell or otherwise transfer such Shares to that Proposed Transferee at
the Offered Price or at a higher price, provided that such sale or other
transfer is consummated within 60 days after the date of the Notice and provided
further that any such sale or other transfer is effected in accordance with any
applicable securities laws and the Proposed Transferee agrees in writing that
the provisions of this Section 3 shall continue to apply to the Shares in the
hands of such Proposed Transferee. If the Shares described in the Notice are not
transferred to the Proposed Transferee within such period, or if the Holder
proposes to change the price or other terms to make them more favorable to the
Proposed Transferee, a new Notice shall be given to the Company, and the Company
and/or its assignees shall again be offered the Right of First Refusal before
any Shares held by the Holder may be sold or otherwise transferred.
(vi) Exception for Certain Family Transfers. Anything to the
--------------------------------------
contrary contained in this Section 3(a) notwithstanding, the transfer of any or
all of the Shares during Purchaser's lifetime or on Purchaser's death by will or
intestacy to Purchaser's Immediate Family or a trust for the benefit of
Purchaser or Purchaser's Immediate Family shall be exempt from the provisions of
this Section 3(a). "Immediate Family" as used herein shall mean spouse, lineal
----------------
descendant or antecedent, father, mother, brother or sister. In such case, the
transferee or other recipient shall receive and hold the Shares so transferred
subject to the provisions of this Section 3, and there shall be no further
transfer of such Shares except in accordance with the terms of this Section 3.
(b) Involuntary Transfer.
--------------------
(i) Company's Right to Purchase upon Involuntary Transfer. In
-----------------------------------------------------
the event, at any time after the date of this Agreement, of any transfer by
operation of law or
-2-
<PAGE>
other involuntary transfer (including divorce or death, but excluding in the
event of death a transfer to Immediate Family as set forth in Section 3(a)(vi)
above) of all or a portion of the Shares by the record holder thereof, the
Company shall have the right to purchase all of the Shares transferred at the
greater of the purchase price paid by Purchaser pursuant to this Agreement or
the fair market value of the Shares on the date of transfer. Upon such a
transfer, the person acquiring the Shares shall promptly notify the Secretary of
the Company of such transfer. The right to purchase such Shares shall be
provided to the Company for a period of 30 days following receipt by the Company
of written notice by the person acquiring the Shares.
(ii) Price for Involuntary Transfer. With respect to any stock
------------------------------
to be transferred pursuant to Section 3(b)(i), the price per Share shall be a
price set by the Board of Directors of the Company that will reflect the current
value of the stock in terms of present earnings and future prospects of the
Company. The Company shall notify Purchaser or his or her executor of the price
so determined within 30 days after receipt by it of written notice of the
transfer or proposed transfer of Shares. However, if Purchaser does not agree
with the valuation as determined by the Board of Directors of the Company,
Purchaser shall be entitled to have the valuation determined by an independent
appraiser to be mutually agreed upon by the Company and Purchaser and whose fees
shall be borne equally by the Company and Purchaser.
(c) Assignment. The right of the Company to purchase any part of the
----------
Shares may be assigned in whole or in part to any stockholder or stockholders of
the Company or other persons or organizations.
(d) Restrictions Binding on Transferees. All transferees of Shares
-----------------------------------
or any interest therein will receive and hold such Shares or interest subject to
the provisions of this Agreement. Any sale or transfer of the Shares shall be
void unless the provisions of this Agreement are satisfied.
(e) Termination of Rights. The Right of First Refusal and the
---------------------
Company's right to repurchase the Shares in the event of an involuntary transfer
pursuant to Section 3(b) above shall terminate upon the first sale of Common
Stock of the Company to the general public pursuant to a registration statement
filed with and declared effective by the Securities and Exchange Commission
under the Securities Act of 1933, as amended (the "Securities Act").
--------------
(f) Market Standoff Agreement. In connection with the initial public
-------------------------
offering of the Company's securities and upon request of the Company or the
underwriters managing such offering of the Company's securities, Purchaser
agrees not to sell, make any short sale of, loan, grant any option for the
purchase of, or otherwise dispose of any securities of the Company (other than
those included in the registration) without the prior written consent of the
Company or such underwriters, as the case may be, for such period of time (not
to exceed 180 days) from the effective date of such registration as may be
requested by the Company or such managing underwriters and to execute an
agreement reflecting the foregoing as may be requested by the underwriters at
the time of the Company's initial public offering.
4. Investment and Taxation Representations. In connection with the
---------------------------------------
purchase of the Shares, Purchaser represents to the Company the following:
-3-
<PAGE>
(a) Purchaser is aware of the Company's business affairs and
financial condition and has acquired sufficient information about the Company to
reach an informed and knowledgeable decision to acquire the Shares. Purchaser is
purchasing the Shares for investment for his or her own account only and not
with a view to, or for resale in connection with, any "distribution" thereof
within the meaning of the Securities Act.
(b) Purchaser understands that the Shares have not been registered
under the Securities Act by reason of a specific exemption therefrom, which
exemption depends upon, among other things, the bona fide nature of Purchaser's
investment intent as expressed herein.
(c) Purchaser understands that the Shares are "restricted securities"
under applicable U.S. federal and state securities laws and that, pursuant to
these laws, Purchaser must hold the Shares indefinitely unless they are
registered with the Securities and Exchange Commission and qualified by state
authorities, or an exemption from such registration and qualification
requirements is available. Purchaser acknowledges that the Company has no
obligation to register or qualify the Shares for resale. Purchaser further
acknowledges that if an exemption from registration or qualification is
available, it may be conditioned on various requirements including, but not
limited to, the time and manner of sale, the holding period for the Shares, and
requirements relating to the Company which are outside of the Purchaser's
control, and which the Company is under no obligation and may not be able to
satisfy.
(d) Purchaser understands that Purchaser may suffer adverse tax
consequences as a result of Purchaser's purchase or disposition of the Shares.
Purchaser represents that Purchaser has consulted any tax consultants Purchaser
deems advisable in connection with the purchase or disposition of the Shares and
that Purchaser is not relying on the Company for any tax advice.
5. Restrictive Legends and Stop-Transfer Orders.
--------------------------------------------
(a) Legends. The certificate or certificates representing the Shares
-------
shall bear the following legends (as well as any legends required by applicable
state and federal corporate and securities laws):
(i) THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND
NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE
SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR
DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT RELATED THERETO OR AN
OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE
COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED
UNDER THE SECURITIES ACT OF 1933.
-4-
<PAGE>
(ii) THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE
TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF
AN AGREEMENT BETWEEN THE COMPANY AND THE
STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE
SECRETARY OF THE COMPANY.
(iii) Any legend required to be placed thereon by the
California Commissioner of Corporations.
(b) Stop-Transfer Notices. Purchaser agrees that, in order to ensure
---------------------
compliance with the restrictions referred to herein, the Company may issue
appropriate "stop transfer" instructions to its transfer agent, if any, and
that, if the Company transfers its own securities, it may make appropriate
notations to the same effect in its own records.
(c) Refusal to Transfer. The Company shall not be required (i) to
-------------------
transfer on its books any Shares that have been sold or otherwise transferred in
violation of any of the provisions of this Agreement or (ii) to treat as owner
of such Shares or to accord the right to vote or pay dividends to any purchaser
or other transferee to whom such Shares shall have been so transferred.
(d) Removal of Legend. When all of the following events have
-----------------
occurred, the Shares then held by Purchaser will no longer be subject to the
legend referred to in Section 5(a)(ii): (i) the termination of the Right of
First Refusal; and (ii) the expiration or termination of the market standoff
provisions of Section 3(f) (and of any agreement entered pursuant to Section
3(f)). After such time, and upon Purchaser's request, a new certificate or
certificates representing the Shares not repurchased shall be issued without the
legend referred to in Section 5(a)(ii), and delivered to Purchaser.
6. No Employment Rights. Nothing in this Agreement shall affect in any
--------------------
manner whatsoever the right or power of the Company, or a parent or subsidiary
of the Company, to terminate Purchaser's employment or consulting relationship,
for any reason, with or without cause.
7. Miscellaneous.
-------------
(a) Governing Law. This Agreement and all acts and transactions
-------------
pursuant hereto and the rights and obligations of the parties hereto shall be
governed, construed and interpreted in accordance with the laws of the State of
California, without giving effect to principles of conflicts of law.
(b) Entire Agreement; Enforcement of Rights. This Agreement sets
---------------------------------------
forth the entire agreement and understanding of the parties relating to the
subject matter herein and merges all prior discussions between them. No
modification of or amendment to this Agreement, nor any waiver of any rights
under this Agreement, shall be effective unless in
-5-
<PAGE>
writing signed by the parties to this Agreement. The failure by either party to
enforce any rights under this Agreement shall not be construed as a waiver of
any rights of such party.
(c) Severability. If one or more provisions of this Agreement are
------------
held to be unenforceable under applicable law, the parties agree to renegotiate
such provision in good faith. In the event that the parties cannot reach a
mutually agreeable and enforceable replacement for such provision, then (i) such
provision shall be excluded from this Agreement, (ii) the balance of the
Agreement shall be interpreted as if such provision were so excluded and (iii)
the balance of the Agreement shall be enforceable in accordance with its terms.
(d) Construction. This Agreement is the result of negotiations
------------
between and has been reviewed by each of the parties hereto and their respective
counsel, if any; accordingly, this Agreement shall be deemed to be the product
of all of the parties hereto, and no ambiguity shall be construed in favor of or
against any one of the parties hereto.
(e) Notices. Any notice required or permitted by this Agreement
-------
shall be in writing and shall be deemed sufficient when delivered personally or
sent by telegram or fax or 48 hours after being deposited in the U.S. mail, as
certified or registered mail, with postage prepaid, and addressed to the party
to be notified at such party's address or fax number as set forth below or as
subsequently modified by written notice.
(f) Counterparts. This Agreement may be executed in two or more
------------
counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument.
(g) Successors and Assigns. The rights and benefits of this
----------------------
Agreement shall inure to the benefit of, and be enforceable by the Company's
successors and assigns. The rights and obligations of Purchaser under this
Agreement may only be assigned with the prior written consent of the Company.
(h) California Corporate Securities Law. THE SALE OF THE SECURITIES
-----------------------------------
WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE
COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE
SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR
PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT
FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA
CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY
CONDITIONED UPON THE QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.
[Signature Page Follows]
-6-
<PAGE>
The parties have executed this Agreement as of the date first set forth
above.
TENDEX, INC.
By:________________________________
Title:_____________________________
Address:
PURCHASER:
TENET HEALTHSYSTEM MEDICAL, INC.
___________________________________
(Signature)
Address:
-7-
<PAGE>
RECEIPT
-------
TENDEX, INC. hereby acknowledges receipt of payment in the amount of
$0.0003 given by TENET HEALTHSYSTEM MEDICAL, INC. as consideration for
- -------
Certificate No. _______ for 3 (Three) shares of Common Stock of TENDEX, INC..
Dated: ________________
TENDEX, INC.
By:_______________________________
Title:____________________________
<PAGE>
EXHIBIT D
Chemdex Common Stock Purchase Agreement
<PAGE>
TENDEX, INC.
COMMON STOCK PURCHASE AGREEMENT
-------------------------------
This Common Stock Purchase Agreement (the "Agreement") is made as of
---------
December _______, 1999 by and between Tendex, Inc., a Delaware corporation
(the "Company"), and Chemdex Corporation ("Purchaser").
------- ---------
1. Sale of Stock. Subject to the terms and conditions of this
-------------
Agreement, the Purchase Date (as defined below) the Company will issue and sell
to Purchaser, and Purchaser agrees to purchase from the Company, one (1) share
of the Company's Common Stock (the "Shares") at a purchase price of $0.0001 per
------
for a total purchase price of $0.0001. The term "Shares" refers to the Shares
------
and all securities received in replacement of or in connection with the Shares
pursuant to stock dividends or splits, all securities received in replacement of
the Shares in a recapitalization, merger, reorganization, exchange or the like,
and all new, substituted or additional securities or other properties to which
Purchaser is entitled by reason of Purchaser's ownership of the Shares.
2. Purchase. The purchase and sale of the Shares under this Agreement
--------
shall occur at the principal office of the Company simultaneously with the
execution of this Agreement by the parties or on such other date as the Company
and Purchaser shall agree (the "Purchase Date"). On the Purchase Date, the
-------------
Company will deliver to Purchaser a certificate representing the Shares to be
purchased by Purchaser (which shall be issued in Purchaser's name) against
payment of the purchase price therefor by Purchaser by (a) check made payable to
the Company, (b) cancellation of indebtedness of the Company to Purchaser, or
(c) by a combination of the foregoing.
3. Limitations on Transfer. In addition to any other limitation on
-----------------------
transfer created by applicable securities laws, Purchaser shall not assign,
encumber or dispose of any interest in the Shares except in compliance with the
provisions below and applicable securities laws.
(a) Right of First Refusal. Before any Shares held by Purchaser
----------------------
or any transferee of Purchaser (either being sometimes referred to herein as the
"Holder") may be sold or otherwise transferred (including transfer by gift or
------
operation of law), the Company or its assignee(s) shall have a right of first
refusal to purchase the Shares on the terms and conditions set forth in this
Section 3(a) (the "Right of First Refusal").
----------------------
(i) Notice of Proposed Transfer. The Holder of the Shares shall
---------------------------
deliver to the Company a written notice (the "Notice") stating: (A) the Holder's
------
bona fide intention to sell or otherwise transfer such Shares; (B) the name of
each proposed purchaser or other transferee ("Proposed Transferee"); (C) number
-------------------
of Shares to be transferred to each Proposed Transferee; and (D) the terms and
conditions of each proposed sale or transfer. The Holder shall offer the Shares
at the same price (the "Offered Price") and upon the same terms (or as similar
-------------
as reasonably possible) to the Company or its assignee(s).
<PAGE>
(ii) Exercise of Right of First Refusal. At any time within 30
----------------------------------
days after receipt of the Notice, the Company and/or its assignee(s) may, by
giving written notice to the Holder, elect to purchase all, but not less than
all, of the Shares proposed to be transferred to any one or more of the Proposed
Transferees, at the purchase price determined in accordance with subsection
(iii) below.
(iii) Purchase Price. The purchase price ("Purchase Price")
-------------- --------------
the Shares purchased by the Company or its assignee(s) under this Section 3(a)
shall be the Offered Price. If the Offered Price includes consideration other
than cash, the cash equivalent value of the non-cash consideration shall be
determined by the Board of Directors of the Company in good faith.
(iv) Payment. Payment of the Purchase Price shall be made, at the
-------
of the Company or its assignee(s), in cash (by check), by cancellation of all
or a portion of any outstanding indebtedness of the Holder to the Company (or,
in the case of repurchase by an assignee, to the assignee), or by any
combination thereof within 30 days after receipt of the Notice or in the manner
and at the times set forth in the Notice.
(v) Holder's Right to Transfer. If all of the Shares proposed in
--------------------------
the Notice to be transferred to a given Proposed Transferee are not purchased by
the Company and/or its assignee(s) as provided in this Section 3(a), then the
Holder may sell or otherwise transfer such Shares to that Proposed Transferee at
the Offered Price or at a higher price, provided that such sale or other
transfer is consummated within 60 days after the date of the Notice and provided
further that any such sale or other transfer is effected in accordance with any
applicable securities laws and the Proposed Transferee agrees in writing that
the provisions of this Section 3 shall continue to apply to the Shares in the
hands of such Proposed Transferee. If the Shares described in the Notice are not
transferred to the Proposed Transferee within such period, or if the Holder
proposes to change the price or other terms to make them more favorable to the
Proposed Transferee, a new Notice shall be given to the Company, and the Company
and/or its assignees shall again be offered the Right of First Refusal before
any Shares held by the Holder may be sold or otherwise transferred.
(vi) Exception for Certain Family Transfers. Anything to the
--------------------------------------
contrary contained in this Section 3(a) notwithstanding, the transfer of any or
all of the Shares during Purchaser's lifetime or on Purchaser's death by will or
intestacy to Purchaser's Immediate Family or a trust for the benefit of
Purchaser or Purchaser's Immediate Family shall be exempt from the provisions of
this Section 3(a). "Immediate Family" as used herein shall mean spouse, lineal
----------------
descendant or antecedent, father, mother, brother or sister. In such case, the
transferee or other recipient shall receive and hold the Shares so transferred
subject to the provisions of this Section 3, and there shall be no further
transfer of such Shares except in accordance with the terms of this Section 3.
(b) Involuntary Transfer.
--------------------
(i) Company's Right to Purchase upon Involuntary Transfer. In the
-----------------------------------------------------
event, at any time after the date of this Agreement, of any transfer by
operation of law or
-2-
<PAGE>
other involuntary transfer (including divorce or death, but excluding in the
event of death a transfer to Immediate Family as set forth in Section 3(a)(vi)
above) of all or a portion of the Shares by the record holder thereof, the
Company shall have the right to purchase all of the Shares transferred at the
greater of the purchase price paid by Purchaser pursuant to this Agreement or
the fair market value of the Shares on the date of transfer. Upon such a
transfer, the person acquiring the Shares shall promptly notify the Secretary of
the Company of such transfer. The right to purchase such Shares shall be
provided to the Company for a period of 30 days following receipt by the Company
of written notice by the person acquiring the Shares.
(ii) Price for Involuntary Transfer. With respect to any stock to
------------------------------
be transferred pursuant to Section 3(b)(i), the price per Share shall be a price
set by the Board of Directors of the Company that will reflect the current value
of the stock in terms of present earnings and future prospects of the Company.
The Company shall notify Purchaser or his or her executor of the price so
determined within 30 days after receipt by it of written notice of the transfer
or proposed transfer of Shares. However, if Purchaser does not agree with the
valuation as determined by the Board of Directors of the Company, Purchaser
shall be entitled to have the valuation determined by an independent appraiser
to be mutually agreed upon by the Company and Purchaser and whose fees shall be
borne equally by the Company and Purchaser.
(c) Assignment. The right of the Company to purchase any part of the
----------
Shares may be assigned in whole or in part to any stockholder or stockholders of
the Company or other persons or organizations.
(d) Restrictions Binding on Transferees. All transferees of Shares
-----------------------------------
or any interest therein will receive and hold such Shares or interest subject to
the provisions of this Agreement. Any sale or transfer of the Shares shall be
void unless the provisions of this Agreement are satisfied.
(e) Termination of Rights. The Right of First Refusal and the
---------------------
Company's right to repurchase the Shares in the event of an involuntary transfer
pursuant to Section 3(b) above shall terminate upon the first sale of Common
Stock of the Company to the general public pursuant to a registration statement
filed with and declared effective by the Securities and Exchange Commission
under the Securities Act of 1933, as amended (the "Securities Act").
--------------
(f) Market Standoff Agreement. In connection with the initial public
-------------------------
offering of the Company's securities and upon request of the Company or the
underwriters managing such offering of the Company's securities, Purchaser
agrees not to sell, make any short sale of, loan, grant any option for the
purchase of, or otherwise dispose of any securities of the Company (other than
those included in the registration) without the prior written consent of the
Company or such underwriters, as the case may be, for such period of time (not
to exceed 180 days) from the effective date of such registration as may be
requested by the Company or such managing underwriters and to execute an
agreement reflecting the foregoing as may be requested by the underwriters at
the time of the Company's initial public offering.
4. Investment and Taxation Representations. In connection with the
---------------------------------------
purchase of the Shares, Purchaser represents to the Company the following:
-3-
<PAGE>
(a) Purchaser is aware of the Company's business affairs and financial
condition and has acquired sufficient information about the Company to reach an
informed and knowledgeable decision to acquire the Shares. Purchaser is
purchasing the Shares for investment for his or her own account only and not
with a view to, or for resale in connection with, any "distribution" thereof
within the meaning of the Securities Act.
(b) Purchaser understands that the Shares have not been registered
under the Securities Act by reason of a specific exemption therefrom, which
exemption depends upon, among other things, the bona fide nature of Purchaser's
investment intent as expressed herein.
(c) Purchaser understands that the Shares are "restricted securities"
under applicable U.S. federal and state securities laws and that, pursuant to
these laws, Purchaser must hold the Shares indefinitely unless they are
registered with the Securities and Exchange Commission and qualified by state
authorities, or an exemption from such registration and qualification
requirements is available. Purchaser acknowledges that the Company has no
obligation to register or qualify the Shares for resale. Purchaser further
acknowledges that if an exemption from registration or qualification is
available, it may be conditioned on various requirements including, but not
limited to, the time and manner of sale, the holding period for the Shares, and
requirements relating to the Company which are outside of the Purchaser's
control, and which the Company is under no obligation and may not be able to
satisfy.
(d) Purchaser understands that Purchaser may suffer adverse tax
consequences as a result of Purchaser's purchase or disposition of the Shares.
Purchaser represents that Purchaser has consulted any tax consultants Purchaser
deems advisable in connection with the purchase or disposition of the Shares and
that Purchaser is not relying on the Company for any tax advice.
5. Restrictive Legends and Stop-Transfer Orders.
--------------------------------------------
(a) Legends. The certificate or certificates representing the Shares
-------
shall bear the following legends (as well as any legends required by applicable
state and federal corporate and securities laws):
(i) THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND
NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE
SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR
DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE
REGISTRATION STATEMENT RELATED THERETO OR AN
OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE
COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED
UNDER THE SECURITIES ACT OF 1933.
-4-
<PAGE>
(ii) THE SHARES REPRESENTED BY THIS CERTIFICATE MAY BE
TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF
AN AGREEMENT BETWEEN THE COMPANY AND THE
STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE
SECRETARY OF THE COMPANY.
(iii) Any legend required to be placed thereon by the
California Commissioner of Corporations.
(b) Stop-Transfer Notices. Purchaser agrees that, in order to ensure
---------------------
compliance with the restrictions referred to herein, the Company may issue
appropriate "stop transfer" instructions to its transfer agent, if any, and
that, if the Company transfers its own securities, it may make appropriate
notations to the same effect in its own records.
(c) Refusal to Transfer. The Company shall not be required (i) to
-------------------
transfer on its books any Shares that have been sold or otherwise transferred in
violation of any of the provisions of this Agreement or (ii) to treat as owner
of such Shares or to accord the right to vote or pay dividends to any purchaser
or other transferee to whom such Shares shall have been so transferred.
(d) Removal of Legend. When all of the following events have
-----------------
occurred, the Shares then held by Purchaser will no longer be subject to the
legend referred to in Section 5(a)(ii): (i) the termination of the Right of
First Refusal; and (ii) the expiration or termination of the market standoff
provisions of Section 3(f) (and of any agreement entered pursuant to Section
3(f)). After such time, and upon Purchaser's request, a new certificate or
certificates representing the Shares not repurchased shall be issued without the
legend referred to in Section 5(a)(ii), and delivered to Purchaser.
6. No Employment Rights. Nothing in this Agreement shall affect in any
--------------------
manner whatsoever the right or power of the Company, or a parent or subsidiary
of the Company, to terminate Purchaser's employment or consulting relationship,
for any reason, with or without cause.
7. Miscellaneous.
-------------
(a) Governing Law. This Agreement and all acts and transactions
-------------
pursuant hereto and the rights and obligations of the parties hereto shall be
governed, construed and interpreted in accordance with the laws of the State of
California, without giving effect to principles of conflicts of law.
(b) Entire Agreement; Enforcement of Rights. This Agreement sets
---------------------------------------
forth the entire agreement and understanding of the parties relating to the
subject matter herein and merges all prior discussions between them. No
modification of or amendment to this Agreement, nor any waiver of any rights
under this Agreement, shall be effective unless in
-5-
<PAGE>
writing signed by the parties to this Agreement. The failure by either party to
enforce any rights under this Agreement shall not be construed as a waiver of
any rights of such party.
(c) Severability. If one or more provisions of this Agreement are
------------
held to be unenforceable under applicable law, the parties agree to renegotiate
such provision in good faith. In the event that the parties cannot reach a
mutually agreeable and enforceable replacement for such provision, then (i) such
provision shall be excluded from this Agreement, (ii) the balance of the
Agreement shall be interpreted as if such provision were so excluded and (iii)
the balance of the Agreement shall be enforceable in accordance with its terms.
(d) Construction. This Agreement is the result of negotiations
------------
between and has been reviewed by each of the parties hereto and their respective
counsel, if any; accordingly, this Agreement shall be deemed to be the product
of all of the parties hereto, and no ambiguity shall be construed in favor of or
against any one of the parties hereto.
(e) Notices. Any notice required or permitted by this Agreement shall
-------
be in writing and shall be deemed sufficient when delivered personally or sent
by telegram or fax or 48 hours after being deposited in the U.S. mail, as
certified or registered mail, with postage prepaid, and addressed to the party
to be notified at such party's address or fax number as set forth below or as
subsequently modified by written notice.
(f) Counterparts. This Agreement may be executed in two or more
------------
counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument.
(g) Successors and Assigns. The rights and benefits of this Agreement
----------------------
shall inure to the benefit of, and be enforceable by the Company's successors
and assigns. The rights and obligations of Purchaser under this Agreement may
only be assigned with the prior written consent of the Company.
(h) California Corporate Securities Law. THE SALE OF THE SECURITIES
-----------------------------------
WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE
COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE
SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR
PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT
FROM QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA
CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY
CONDITIONED UPON THE QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.
[Signature Page Follows]
-6-
<PAGE>
The parties have executed this Agreement as of the date first set forth
above.
TENDEX, INC.
By:________________________________
Title:_____________________________
Address:
PURCHASER:
CHEMDEX CORPORATION
___________________________________
(Signature)
Address:
-7-
<PAGE>
RECEIPT
-------
TENDEX, INC. hereby acknowledges receipt of payment in the amount of
$0.0001 given by CHEMDEX CORPORATION as consideration for Certificate
- -------
No. ______ for 1 (One) share of Common Stock of TENDEX, INC..
Dated: ________________
TENDEX, INC.
By:___________________________
Title:________________________
<PAGE>
EXHIBIT E
Series A Stock Purchase Agreement
<PAGE>
TENDEX, INC.
SERIES A PREFERRED STOCK PURCHASE AGREEMENT
December __, 1999
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
1. Purchase and Sale of Preferred Stock.................................. 1
1.1 Sale and Issuance of Series A Preferred Stock.................... 1
1.2 Closing; Delivery................................................ 1
2. Representations and Warranties of the Company......................... 1
2.1 Capitalization................................................... 1
2.2 Authorization.................................................... 2
2.3 Valid Issuance of Securities..................................... 2
2.4 Governmental Consents............................................ 2
3. Representations and Warranties of the Purchasers...................... 3
3.1 Authorization.................................................... 3
3.2 Purchase Entirely for Own Account................................ 3
3.3 Disclosure of Information........................................ 3
3.4 Restricted Securities............................................ 3
3.5 No Public Market................................................. 4
3.6 Legends.......................................................... 4
3.7 Accredited Investor.............................................. 4
3.8 Foreign Investors................................................ 4
4. Conditions of the Purchasers' Obligations at Closing.................. 4
4.1 Representations and Warranties................................... 5
4.2 Performance...................................................... 5
4.3 Compliance Certificate........................................... 5
4.4 Qualifications................................................... 5
4.5 Board of Directors............................................... 5
4.6 Investors' Rights Agreement...................................... 5
4.7 Voting Agreement................................................. 5
4.8 Restated Certificate............................................. 5
4.9 Confidential Information and Invention Assignment Agreement...... 5
4.10 Hart-Scott-Rodino................................................ 5
5. Conditions of the Company's Obligations at Closing.................... 5
5.1 Representations and Warranties................................... 6
5.2 Performance...................................................... 6
5.3 Qualifications................................................... 6
5.4 Hart-Scott-Rodino................................................ 6
6. Miscellaneous......................................................... 6
6.1 Survival of Warranties........................................... 6
6.2 Transfer; Successors and Assigns................................. 6
6.3 Governing Law.................................................... 6
</TABLE>
-i-
<PAGE>
<TABLE>
<S> <C>
6.4 Counterparts..................................................... 6
6.5 Titles and Subtitles............................................. 6
6.6 Notices.......................................................... 7
6.7 Finder's Fee..................................................... 7
6.8 Fees and Expenses................................................ 7
6.9 Amendments and Waivers........................................... 7
6.10 Severability..................................................... 7
6.11 Delays or Omissions.............................................. 7
6.12 Entire Agreement................................................. 8
6.13 Corporate Securities Law......................................... 8
</TABLE>
-ii-
<PAGE>
TENDEX, INC.
SERIES A PREFERRED STOCK PURCHASE AGREEMENT
-------------------------------------------
This Series A Preferred Stock Purchase Agreement (the "Agreement") is made
---------
as of the _____ day of December, 1999, by and between Tendex, Inc., a Delaware
corporation (the "Company") and the investors listed on Exhibit A attached
------- ---------
hereto (each a "Purchaser" and together the "Purchasers").
--------- ----------
The parties hereby agree as follows:
1. Purchase and Sale of Preferred Stock.
------------------------------------
1.1 Sale and Issuance of Series A Preferred Stock.
---------------------------------------------
(a) The Company shall adopt and file with the Secretary of State of
the State of Delaware on or before the Closing (as defined below) the Amended
and Restated Certificate of Incorporation in the form attached hereto as
Exhibit B (the "Restated Certificate").
- --------- --------------------
(b) Subject to the terms and conditions of this Agreement, each
Purchaser agrees to purchase at the Closing and the Company agrees to sell and
issue to each Purchaser at the Closing that number of shares of Series A
Preferred Stock set forth opposite each such Purchaser's name on Exhibit A
---------
attached hereto at a purchase price of $1.00 per share. The shares of Series A
Preferred Stock issued to the Purchaser pursuant to this Agreement shall be
hereinafter referred to as the "Stock."
-----
1.2 Closing; Delivery.
-----------------
(a) The purchase and sale of the Stock shall take place at the
offices of Gibson, Dunn & Crutcher LLP 1530 Page Mill Road, Palo Alto, CA 94304,
Attn: Gregory T. Davidson, at _____ __.m., on _______, ____, or at such other
time and place as the Company and the Purchasers mutually agree upon, orally or
in writing (which time and place are designated as the "Closing").
-------
(b) At the Closing, the Company shall deliver to each Purchaser a
certificate representing the Stock being purchased thereby against payment of
the purchase price therefor by check payable to the Company or by wire transfer
to the Company's bank account.
2. Representations and Warranties of the Company. The Company hereby
---------------------------------------------
represents and warrants to each Purchaser that:
2.1 Capitalization. The authorized capital of the Company consists,
--------------
or will consist, immediately prior to the Closing, of:
(a) 5,000,000 shares of Preferred Stock, of which 5,000,000
shares have been designated Series A Preferred Stock, none of which are issued
and outstanding
<PAGE>
immediately prior to the Closing. The rights, privileges and preferences of the
Preferred Stock are as stated in the Restated Certificate.
(b) 10,000,000 shares of Common Stock, four (4) shares of which are
issued and outstanding immediately prior to the Closing. All of the outstanding
shares of Common Stock have been duly authorized, fully paid and are
nonassessable and issued in compliance with all applicable federal and state
securities laws.
2.2 Authorization. All corporate action on the part of the Company,
-------------
its officers, directors and stockholders necessary for the authorization,
execution and delivery of this Agreement, the Investors' Rights Agreement, in
the form attached hereto as Exhibit C (the "Investors' Rights Agreement"), and
--------- ---------------------------
the Voting Agreement in the form attached hereto as Exhibit D (the "Voting
--------- ------
Agreement" and collectively with this Agreement and the Investors' Rights
- ---------
Agreement, the "Agreements"), the performance of all obligations of the Company
----------
hereunder and thereunder and the authorization, issuance and delivery of the
Stock and the Common Stock issuable upon conversion of the Stock (together, the
"Securities") has been taken or will be taken prior to the Closing, and the
----------
Agreements, when executed and delivered by the Company, shall constitute valid
and legally binding obligations of the Company, enforceable against the Company
in accordance with their terms except (i) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance, and other laws of
general application affecting enforcement of creditors' rights generally, as
limited by laws relating to the availability of specific performance, injunctive
relief, or other equitable remedies, or (ii) to the extent the indemnification
provisions contained in the Investors' Rights Agreement may be limited by
applicable federal or state securities laws.
2.3 Valid Issuance of Securities. The Stock that is being issued to
----------------------------
the Purchasers hereunder, when issued, sold and delivered in accordance with the
terms hereof for the consideration expressed herein, will be duly and validly
issued, fully paid and nonassessable and free of restrictions on transfer other
than restrictions on transfer under this Agreement, the Investors' Rights
Agreement and applicable state and federal securities laws. Based in part upon
the representations of the Purchasers in this Agreement and subject to the
provisions of Section 2.6 below, the Stock will be issued in compliance with all
applicable federal and state securities laws. The Common Stock issuable upon
conversion of the Stock has been duly and validly reserved for issuance, and
upon issuance in accordance with the terms of the Restated Certificate, shall be
duly and validly issued, fully paid and nonassessable and free of restrictions
on transfer other than restrictions on transfer under this Agreement, the
Investors' Rights Agreement and applicable federal and state securities laws and
will be issued in compliance with all applicable federal and state securities
laws.
2.4 Governmental Consents. No consent, approval, order or
---------------------
authorization of, or registration, qualification, designation, declaration or
filing with, any federal, state or local governmental authority on the part of
the Company is required in connection with the consummation of the transactions
contemplated by this Agreement, except for filings pursuant to Section 25102(f)
of the California Corporate Securities Law of 1968, as amended, and the rules
-2-
<PAGE>
thereunder, other applicable state securities laws and Regulation D of the
Securities Act of 1933, as amended (the "Securities Act").
--------------
3. Representations and Warranties of the Purchasers. Each Purchaser
------------------------------------------------
hereby represents and warrants to the Company that:
3.1 Authorization. Such Purchaser has full power and authority to
-------------
enter into this Agreement. The Agreements, when executed and delivered by the
Purchaser, will constitute valid and legally binding obligations of the
Purchaser, enforceable in accordance with their terms, except (a) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
conveyance, and any other laws of general application affecting enforcement of
creditors' rights generally, and as limited by laws relating to the availability
of a specific performance, injunctive relief, or other equitable remedies, or
(b) to the extent the indemnification provisions contained in the Investors'
Rights Agreement may be limited by applicable federal or state securities laws.
3.2 Purchase Entirely for Own Account. This Agreement is made with
---------------------------------
the Purchaser in reliance upon the Purchaser's representation to the Company,
which by the Purchaser's execution of this Agreement, the Purchaser hereby
confirms, that the Securities to be acquired by the Purchaser will be acquired
for investment for the Purchaser's own account, not as a nominee or agent, and
not with a view to the resale or distribution of any part thereof, and that the
Purchaser has no present intention of selling, granting any participation in, or
otherwise distributing the same. By executing this Agreement, the Purchaser
further represents that the Purchaser does not presently have any contract,
undertaking, agreement or arrangement with any person to sell, transfer or grant
participations to such person or to any third person, with respect to any of the
Securities. The Purchaser has not been formed for the specific purpose of
acquiring the Securities.
3.3 Disclosure of Information. The Purchaser has had an opportunity
-------------------------
to discuss the Company's business, management, financial affairs and the terms
and conditions of the offering of the Stock with the Company's management and
has had an opportunity to review the Company's facilities. The Purchaser
understands that such discussions, as well as the Business Plan and any other
written information delivered by the Company to the Purchaser, were intended to
describe the aspects of the Company's business which it believes to be material.
3.4 Restricted Securities. The Purchaser understands that the
---------------------
Securities have not been, and will not be, registered under the Securities Act,
by reason of a specific exemption from the registration provisions of the
Securities Act which depends upon, among other things, the bona fide nature of
the investment intent and the accuracy of the Purchaser's representations as
expressed herein. The Purchaser understands that the Securities are "restricted
securities" under applicable U.S. federal and state securities laws and that,
pursuant to these laws, the Purchaser must hold the Securities indefinitely
unless they are registered with the Securities and Exchange Commission and
qualified by state authorities, or an exemption from such registration and
qualification requirements is available. The Purchaser acknowledges that the
Company has no obligation to register or qualify the Securities for resale
except as set forth in the Investors'
-3-
<PAGE>
Rights Agreement. The Purchaser further acknowledges that if an exemption from
registration or qualification is available, it may be conditioned on various
requirements including, but not limited to, the time and manner of sale, the
holding period for the Securities, and on requirements relating to the Company
which are outside of the Purchaser's control, and which the Company is under no
obligation and may not be able to satisfy.
3.5 No Public Market. The Purchaser understands that no public
----------------
market now exists for any of the securities issued by the Company, and that the
Company has made no assurances that a public market will ever exist for the
Securities.
3.6 Legends. The Purchaser understands that the Securities and any
-------
securities issued in respect of or exchange for the Securities, may bear one or
all of the following legends:
(a) "THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR
DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN
EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A
FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER
THE SECURITIES ACT OF 1933."
(b) Any legend set forth in the other Agreements.
(c) Any legend required by the Blue Sky laws of any state to the
extent such laws are applicable to the shares represented by the certificate so
legended.
3.7 Accredited Investor. The Purchaser is an accredited investor as
-------------------
defined in Rule 501(a) of Regulation D promulgated under the Securities Act.
3.8 Foreign Investors. If the Purchaser is not a United States
-----------------
person (as defined by Section 7701(a)(30) of the Internal Revenue Code of 1986,
as amended), such Purchaser hereby represents that it has satisfied itself as to
the full observance of the laws of its jurisdiction in connection with any
invitation to subscribe for the Stock or any use of this Agreement, including
(i) the legal requirements within its jurisdiction for the purchase of the
Stock, (ii) any foreign exchange restrictions applicable to such purchase, (iii)
any governmental or other consents that may need to be obtained, and (iv) the
income tax and other tax consequences, if any, that may be relevant to the
purchase, holding, redemption, sale, or transfer of the Stock. Such Purchaser's
subscription and payment for and continued beneficial ownership of the Stock,
will not violate any applicable securities or other laws of the Purchaser's
jurisdiction.
4. Conditions of the Purchasers' Obligations at Closing. The obligations
----------------------------------------------------
of each Purchaser to the Company under this Agreement are subject to the
fulfillment, on or before the Closing, of each of the following conditions,
unless otherwise waived:
-4-
<PAGE>
4.1 Representations and Warranties. The representations and
------------------------------
warranties of the Company contained in Section 2 shall be true and correct in
all material respects on and as of the Closing with the same effect as though
such representations and warranties had been made on and as of the date of the
Closing.
4.2 Performance. The Company shall have performed and complied with
-----------
all covenants, agreements, obligations and conditions contained in this
Agreement that are required to be performed or complied with by it on or before
the Closing.
4.3 Compliance Certificate. The President of the Company shall
----------------------
deliver to the Purchasers at the Closing a certificate certifying that the
conditions specified in Sections 4.1 and 4.2 have been fulfilled.
4.4 Qualifications. All authorizations, approvals or permits, if
--------------
any, of any governmental authority or regulatory body of the United States or of
any state that are required in connection with the lawful issuance and sale of
the Stock pursuant to this Agreement shall be obtained and effective as of the
Closing,
4.5 Board of Directors. As of the Closing, the Board shall be
------------------
comprised of Jeffrey C. Barbakow, Trevor Fetter and David P. Perry.
4.6 Investors' Rights Agreement. The Company and each Purchaser
---------------------------
shall have executed and delivered the Investors' Rights Agreement in
substantially the form attached as Exhibit C.
---------
4.7 Voting Agreement. The Company and each Purchaser shall have
----------------
executed and delivered the Voting Agreement in substantially the form attached
as Exhibit D.
---------
4.8 Restated Certificate. The Company shall have filed the Restated
--------------------
Certificate with the Secretary of State of Delaware on or prior to the Closing
Date, which shall continue to be in full force and effect as of the Closing
Date.
4.9 Confidential Information and Invention Assignment Agreement.
-----------------------------------------------------------
The Company and each of its employees shall have entered into the Company's
standard form Confidential Information and Invention Assignment Agreement, in
substantially the form provided to the Purchasers.
4.10 Hart-Scott-Rodino. The waiting period with respect to the
-----------------
consummation of the transactions contemplated by this Agreement under the Hart-
Scott-Rodino Antitrust Improvement Act of 1976, as amended, if applicable, shall
have expired or been terminated.
5. Conditions of the Company's Obligations at Closing. The obligations
--------------------------------------------------
of the Company to each Purchaser under this Agreement are subject to the
fulfillment, on or before the Closing, of each of the following conditions,
unless otherwise waived:
-5-
<PAGE>
5.1 Representations and Warranties. The representations and
------------------------------
warranties of each Purchaser contained in Section 3 shall be true and correct on
and as of the Closing with the same effect as though such representations and
warranties had been made on and as of the Closing.
5.2 Performance. All covenants, agreements and conditions contained
-----------
in this Agreement to be performed by the Purchasers on or prior to the Closing
shall have been performed or complied with in all material respects.
5.3 Qualifications. All authorizations, approvals or permits, if
--------------
any, of any governmental authority or regulatory body of the United States or of
any state that are required in connection with the lawful issuance and sale of
the Stock pursuant to this Agreement shall be obtained and effective as of the
Closing.
5.4 Hart-Scott-Rodino. The waiting period with respect to the
-----------------
consummation of the transactions contemplated by this Agreement under the Hart-
Scott-Rodino Antitrust Improvement Act of 1976, as amended, if applicable, shall
have expired or been terminated.
6. Miscellaneous.
-------------
6.1 Survival of Warranties. Unless otherwise set forth in this
----------------------
Agreement, the warranties, representations and covenants of the Company and the
Purchasers contained in or made pursuant to this Agreement shall survive the
execution and delivery of this Agreement and the Closing for a period of one (1)
year following the Closing.
6.2 Transfer; Successors and Assigns. The terms and conditions of
--------------------------------
this Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or
their respective successors and assigns any rights, remedies, obligations, or
liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement.
6.3 Governing Law. This Agreement and all acts and transactions
-------------
pursuant hereto and the rights and obligations of the parties hereto shall be
governed, construed and interpreted in accordance with the laws of the State of
California, without giving effect to principles of conflicts of law.
6.4 Counterparts. This Agreement may be executed in two or more
------------
counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument.
6.5 Titles and Subtitles. The titles and subtitles used in this
--------------------
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.
-6-
<PAGE>
6.6 Notices. Any notice required or permitted by this Agreement
-------
shall be in writing and shall be deemed sufficient upon delivery, when delivered
personally or by overnight courier or sent by telegram or fax, or forty-eight
(48) hours after being deposited in the U.S. mail, as certified or registered
mail, with postage prepaid, addressed to the party to be notified at such
party's address as set forth on the signature page or Exhibit A hereto, or as
---------
subsequently modified by written notice, and copies to (i) Venture Law Group
2775 Sand Hill Road, Menlo Park, CA 94025, Attn: Jeffrey Y. Suto and (ii)
Gibson, Dunn & Crutcher LLP 1530 Page Mill Road, Palo Alto, CA 94304, Attn:
Gregory T. Davidson.
6.7 Finder's Fee. Each party represents that it neither is nor will
------------
be obligated for any finder's fee or commission in connection with this
transaction. Each Purchaser agrees to indemnify and to hold harmless the Company
from any liability for any commission or compensation in the nature of a
finder's fee (and the costs and expenses of defending against such liability or
asserted liability) for which each Purchaser or any of its officers, employees,
or representatives is responsible. The Company agrees to indemnify and hold
harmless each Purchaser from any liability for any commission or compensation in
the nature of a finder's fee (and the costs and expenses of defending against
such liability or asserted liability) for which the Company or any of its
officers, employees or representatives is responsible.
6.8 Fees and Expenses. Each Party shall pay its own fees and
-----------------
expenses of with respect to this Agreement, the documents referred to herein and
the transactions contemplated hereby and thereby.
6.9 Amendments and Waivers. Any term of this Agreement may be
----------------------
amended or waived only with the written consent of the Company and the holders
of at least eighty percent (80%) of the Common Stock issued or issuable upon
conversion of the Stock. Any amendment or waiver effected in accordance with
this Section 6.10 shall be binding upon the Purchasers and each transferee of
the Stock (or the Common Stock issuable upon conversion thereof), each future
holder of all such securities, and the Company.
6.10 Severability. If one or more provisions of this Agreement are
------------
held to be unenforceable under applicable law, the parties agree to renegotiate
such provision in good faith. In the event that the parties cannot reach a
mutually agreeable and enforceable replacement for such provision, then (a) such
provision shall be excluded from this Agreement, (b) the balance of the
Agreement shall be interpreted as if such provision were so excluded and (c) the
balance of the Agreement shall be enforceable in accordance with its terms.
6.11 Delays or Omissions. No delay or omission to exercise any
-------------------
right, power or remedy accruing to any party under this Agreement, upon any
breach or default of any other party under this Agreement, shall impair any such
right, power or remedy of such non-breaching or non-defaulting party nor shall
it be construed to be a waiver of any such breach or default, or an acquiescence
therein, or of or in any similar breach or default thereafter occurring; nor
shall any waiver of any single breach or default be deemed a waiver of any other
breach or default theretofore or thereafter occurring. Any waiver, permit,
consent or approval of any kind or character on the part of any party of any
breach or default under this Agreement, or any waiver
-7-
<PAGE>
on the part of any party of any provisions or conditions of this Agreement, must
be in writing and shall be effective only to the extent specifically set forth
in such writing. All remedies, either under this Agreement or by law or
otherwise afforded to any party, shall be cumulative and not alternative.
6.12 Entire Agreement. This Agreement, and the documents referred to
----------------
herein constitute the entire agreement between the parties hereto pertaining to
the subject matter hereof, and any and all other written or oral agreements
relating to the subject matter hereof existing between the parties hereto are
expressly canceled.
6.13 Corporate Securities Law. THE SALE OF THE SECURITIES WHICH ARE
------------------------
THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF
CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE SECURITIES OR
THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO THE
QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT FROM THE
QUALIFICATION BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS
CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON
THE QUALIFICATION BEING OBTAINED UNLESS THE SALE IS SO EXEMPT.
[Signature Pages Follow]
-8-
<PAGE>
The parties have executed this Series A Preferred Stock Purchase Agreement
as of the date first written above.
COMPANY:
TENDEX, INC.
By:________________________________________
Name:______________________________________
Title:_____________________________________
Address:___________________________________
___________________________________
PURCHASERS:
TENET HEALTHSYSTEM MEDICAL, INC.
By:________________________________________
Name:______________________________________
Title:_____________________________________
Address: 3820 State Street
Santa Barbara, CA 93105
Fax: 805-563-7070
Attn: Jeffrey C. Barbakow
CHEMDEX CORPORATION
By:________________________________________
Name:______________________________________
Title:_____________________________________
Address: 1500 Plymouth Street
Mountain View, CA 94043
Fax: 650-567-8950
Attn: Dave Perry
SIGNATURE PAGE TO PURCHASE AGREEMENT
<PAGE>
EXHIBITS
--------
Exhibit A - Schedule of Purchasers
Exhibit B - Form of Amended and Restated Certificate of Incorporation
Exhibit C - Form of Investors' Rights Agreement
Exhibit D - Form of Voting Agreement
<PAGE>
EXHIBIT A
---------
SCHEDULE OF PURCHASERS
Name Shares
---- ------
TENET HEALTHSYSTEM MEDICAL, INC. 3,800,000
CHEMDEX CORPORATION 1,200,000
<PAGE>
EXHIBIT B
---------
FORM OF AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
Refer to Exhibit K of Joint Venture Agreement
<PAGE>
EXHIBIT C
---------
FORM OF INVESTORS' RIGHTS AGREEMENT
Refer to Exhibit F of Joint Venture Agreement
<PAGE>
EXHIBIT D
---------
FORM OF VOTING AGREEMENT
Refer to Exhibit G of Joint Venture Agreement
<PAGE>
EXHIBIT F
Investors' Rights Agreement
<PAGE>
TENDEX, INC.
INVESTORS' RIGHTS AGREEMENT
December ___, 1999
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
1. Registration Rights.................................................................... 1
1.1 Definitions....................................................................... 1
1.2 Company Registration.............................................................. 2
1.3 Form S-3 Registration............................................................. 3
1.4 Obligations of the Company........................................................ 3
1.5 Furnish Information............................................................... 5
1.6 Expenses of Registration.......................................................... 5
1.7 Underwriting Requirements......................................................... 6
1.8 Delay of Registration............................................................. 6
1.9 Indemnification................................................................... 6
1.10 Reports Under Securities Exchange Act of 1934..................................... 8
1.11 Assignment of Registration Rights................................................. 9
1.12 Market Stand-Off Agreement........................................................ 9
1.13 Termination of Registration Rights................................................ 10
2. Covenants of the Company............................................................... 10
2.1 Delivery of Financial Statements.................................................. 10
2.2 Inspection........................................................................ 11
2.3 Right of First Refusal............................................................ 11
2.4 Termination of Covenants.......................................................... 13
3. Miscellaneous.......................................................................... 13
3.1 Termination of Entire Agreement Upon Change of Control............................ 13
3.2 Successors and Assigns............................................................ 13
3.3 Amendments and Waivers............................................................ 13
3.4 Notices........................................................................... 14
3.5 Severability...................................................................... 14
3.6 Governing Law..................................................................... 14
3.7 Counterparts...................................................................... 14
3.8 Titles and Subtitles.............................................................. 14
3.9 Aggregation of Stock.............................................................. 14
</TABLE>
Exhibit A Investors
-i-
<PAGE>
TENDEX, INC.
INVESTORS' RIGHTS AGREEMENT
---------------------------
This Investors' Rights Agreement (the "Agreement") is made as of the ____
---------
day of December, 1999, by and among Tendex, Inc., a Delaware corporation (the
"Company"), the investors listed on Exhibit A hereto, each of which is herein
------- ---------
referred to as an "Investor."
--------
RECITALS
--------
The Company and the Investors have entered into a Series A Preferred Stock
Purchase Agreement (the "Purchase Agreement") of even date herewith pursuant to
------------------
which the Company desires to sell to the Investors and the Investors desire to
purchase from the Company shares of the Company's Series A Preferred Stock. A
condition to the Investors' obligations under the Purchase Agreement is that the
Company and the Investors enter into this Agreement in order to provide the
Investors with (i) certain rights to register shares of the Company's Common
Stock issuable upon conversion of the Series A Preferred Stock held by the
Investors, (ii) certain rights to receive or inspect information pertaining to
the Company, and (iii) a right of first offer with respect to certain issuances
by the Company of its securities. The Company and the Investors each desire to
induce the Investors to purchase shares of Series A Preferred Stock pursuant to
the Purchase Agreement by agreeing to the terms and conditions set forth herein.
AGREEMENT
---------
The parties hereby agree as follows:
1. Registration Rights. The Company and the Investors covenant and agree
-------------------
as follows:
1.1 Definitions. For purposes of this Section 1:
-----------
(a) The terms "register," "registered," and "registration" refer
-------- ---------- ------------
to a registration effected by preparing and filing a registration statement or
similar document in compliance with the Securities Act of 1933, as amended (the
"Securities Act"), and the declaration or ordering of effectiveness of such
--------------
registration statement or document;
(b) The term "Registrable Securities" means (i) the shares of
----------------------
Common Stock issuable or issued upon conversion of the Series A Preferred Stock,
(ii) the shares of Common Stock held by each Investor, and (iii) any other
shares of Common Stock of the Company issued as (or issuable upon the conversion
or exercise of any warrant, right or other security which is issued as) a
dividend or other distribution with respect to, or in exchange for or in
replacement of, the shares listed in (i) and (ii); provided, however, that the
-------- -------
foregoing definition shall exclude in all cases any Registrable Securities sold
by a person in a transaction in which his or her rights under this Agreement are
not assigned. Notwithstanding the foregoing, Common Stock or other securities
shall only be treated as Registrable Securities if and so long as they have
1
<PAGE>
not been (A) sold to or through a broker or dealer or underwriter in a public
distribution or a public securities transaction, or (B) sold in a transaction
exempt from the registration and prospectus delivery requirements of the
Securities Act under Section 4(1) thereof so that all transfer restrictions, and
restrictive legends with respect thereto, if any, are removed upon the
consummation of such sale;
(c) The number of shares of "Registrable Securities then
---------------------------
outstanding" shall be determined by the number of shares of Common Stock
- -----------
outstanding which are, and the number of shares of Common Stock issuable
pursuant to then exercisable or convertible securities which are, Registrable
Securities;
(d) The term "Holder" means any person owning or having the
------
right to acquire Registrable Securities or any assignee thereof in accordance
with Section 1.11 of this Agreement;
(e) The term "Form S-3" means such form under the Securities Act
--------
as in effect on the date hereof or any successor form under the Securities Act
that permits significant incorporation by reference of the Company's subsequent
public filings under the Securities Exchange Act of 1934;
(f) The term "SEC" means the Securities and Exchange Commission;
---
and
(g) The term "Qualified IPO" means a firm commitment
-------------
underwritten public offering by the Company of shares of its Common Stock
pursuant to a registration statement on Form S-1 under the Securities Act, the
public offering price of which is not less than $3.00 per share (appropriately
adjusted for any stock split, dividend, combination or other recapitalization)
and which results in aggregate cash proceeds to the Company of $15,000,000 (net
of underwriting discounts and commissions).
1.2 Company Registration. If (but without any obligation to do so)
--------------------
the Company proposes to register (including for this purpose a registration
effected by the Company for stockholders other than the Holders) any of its
stock under the Securities Act in connection with the public offering of such
securities solely for cash (other than a registration relating solely to the
sale of securities to participants in a Company stock plan or a transaction
covered by Rule 145 under the Securities Act, a registration in which the only
stock being registered is Common Stock issuable upon conversion of debt
securities which are also being registered, or any registration on any form
which does not include substantially the same information as would be required
to be included in a registration statement covering the sale of the Registrable
Securities), the Company shall, at such time, promptly give each Holder written
notice of such registration. Upon the written request of each Holder given
within twenty (20) days after mailing of such notice by the Company in
accordance with Section 3.4, the Company shall, subject to the provisions of
Section 1.7, cause to be registered under the Securities Act all of the
Registrable Securities that each such Holder has requested to be registered.
-2-
<PAGE>
1.3 Form S-3 Registration. In case the Company shall receive from any
---------------------
Holder or Holders of not less than ten percent (10%) of the Registrable
Securities a written request or requests that the Company effect a registration
on Form S-3 and any related qualification or compliance with respect to all or a
part of the Registrable Securities owned by such Holder or Holders, the Company
will:
(a) promptly give written notice of the proposed registration,
and any related qualification or compliance, to all other Holders; and
(b) as soon as practicable, effect such registration and all
such qualifications and compliances as may be so requested and as would permit
or facilitate the sale and distribution of all or such portion of such Holder's
or Holders' Registrable Securities as are specified in such request, together
with all or such portion of the Registrable Securities of any other Holder or
Holders joining in such request as are specified in a written request given
within 15 days after receipt of such written notice from the Company; provided,
--------
however, that the Company shall not be obligated to effect any such
- -------
registration, qualification or compliance, pursuant to this Section 1.3: (i) if
Form S-3 is not available for such offering by the Holders; (ii) if the Holders,
together with the holders of any other securities of the Company entitled to
inclusion in such registration, propose to sell Registrable Securities and such
other securities (if any) at an aggregate price to the public (net of any
underwriters' discounts or commissions) of less than $500,000; (iii) if the
Company shall furnish to the Holders a certificate signed by the President of
the Company stating that in the good faith judgment of the Board of Directors of
the Company, it would be seriously detrimental to the Company and its
stockholders for such Form S-3 Registration to be effected at such time, in
which event the Company shall have the right to defer the filing of the Form S-3
registration statement for a period of not more than 120 days after receipt of
the request of the Holder or Holders under this Section 1.3; provided, however,
-------- -------
that the Company shall not utilize this right more than once in any twelve month
period; (iv) if the Company has, within the twelve (12) month period preceding
the date of such request, already effected two registrations on Form S-3 for the
Holders pursuant to this Section 1.3; (v) in any particular jurisdiction in
which the Company would be required to qualify to do business or to execute a
general consent to service of process in effecting such registration,
qualification or compliance; or (vi) during the period ending one hundred eighty
(180) days after the effective date of a registration statement subject to
Section 1.2.
(c) Subject to the foregoing, the Company shall file a
registration statement covering the Registrable Securities and other securities
so requested to be registered as soon as practicable after receipt of the
request or requests of the Holders. Registrations effected pursuant to this
Section 1.3 shall not be counted registrations effected pursuant to Sections
1.2.
1.4 Obligations of the Company. Whenever required under this
--------------------------
Section 1 to effect the registration of any Registrable Securities, the Company
shall, as expeditiously as reasonably possible:
(a) Prepare and file with the SEC a registration statement with
respect to such Registrable Securities and use its best efforts to cause such
registration statement to
-3-
<PAGE>
become effective, and, upon the request of the Holders of a majority of the
Registrable Securities registered thereunder, keep such registration statement
effective for up to one hundred twenty (120) days. The Company shall not be
required to file, cause to become effective or maintain the effectiveness of any
registration statement that contemplates a distribution of securities on a
delayed or continuous basis pursuant to Rule 415 under the Securities Act.
(b) Prepare and file with the SEC such amendments and
supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the
provisions of the Securities Act with respect to the disposition of all
securities covered by such registration statement for up to one hundred twenty
(120) days.
(c) Furnish to the Holders such numbers of copies of a
prospectus, including a preliminary prospectus, in conformity with the
requirements of the Securities Act, and such other documents as they may
reasonably request in order to facilitate the disposition of Registrable
Securities owned by them.
(d) Use its best efforts to register and qualify the securities
covered by such registration statement under such other securities or Blue Sky
laws of such jurisdictions as shall be reasonably requested by the Holders,
provided that the Company shall not be required in connection therewith or as a
- --------
condition thereto to qualify to do business or to file a general consent to
service of process in any such states or jurisdictions.
(e) In the event of any underwritten public offering, enter into
and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter of such offering. Each Holder
participating in such underwriting shall also enter into and perform its
obligations under such an agreement.
(f) Notify each Holder of Registrable Securities covered by such
registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event
as a result of which the prospectus included in such registration statement, as
then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the
statements therein not misleading in the light of the circumstances then
existing, such obligation to continue for one hundred twenty (120) days.
(g) Cause all such Registrable Securities registered pursuant
hereunder to be listed on each securities exchange on which similar securities
issued by the Company are then listed.
(h) Provide a transfer agent and registrar for all Registrable
Securities registered pursuant hereunder and a CUSIP number for all such
Registrable Securities, in each case not later than the effective date of such
registration.
(i) Use its best efforts to furnish, at the request of any
Holder requesting registration of Registrable Securities pursuant to this
Section 1, on the date that such
-4-
<PAGE>
Registrable Securities are delivered to the underwriters for sale in connection
with a registration pursuant to this Section 1, if such securities are being
sold through underwriters, or, if such securities are not being sold through
underwriters, on the date that the registration statement with respect to such
securities becomes effective, (i) an opinion, dated such date, of the counsel
representing the Company for the purposes of such registration, in form and
substance as is customarily given to underwriters in an underwritten public
offering, addressed to the underwriters, if any, and to the Holders requesting
registration of Registrable Securities and (ii) a letter dated such date, from
the independent certified public accountants of the Company, in form and
substance as is customarily given by independent certified public accountants to
underwriters in an underwritten public offering, addressed to the underwriters,
if any, and to the Holders requesting registration of Registrable Securities.
1.5 Furnish Information. It shall be a condition precedent to the
-------------------
obligations of the Company to take any action pursuant to this Section 1 with
respect to the Registrable Securities of any selling Holder that such Holder
shall furnish to the Company such information regarding itself, the Registrable
Securities held by it, and the intended method of disposition of such securities
as shall be required to effect the registration of such Holder's Registrable
Securities. The Company shall have no obligation with respect to any
registration requested pursuant to Section 1.3 of this Agreement if, as a result
of the application of the preceding sentence, the number of shares or the
anticipated aggregate offering price of the Registrable Securities to be
included in the registration does not equal or exceed the number of shares or
the anticipated aggregate offering price required to originally trigger the
Company's obligation to initiate such registration as specified in subsection
1.3(b)(ii).
1.6 Expenses of Registration.
------------------------
(a) Company Registration. All expenses other than underwriting
--------------------
discounts and commissions incurred in connection with registrations, filings or
qualifications of Registrable Securities pursuant to Section 1.3 for each Holder
(which right may be assigned as provided in Section 1.11), including (without
limitation) all registration, filing, and qualification fees, printers' and
accounting fees, fees and disbursements of counsel for the Company and the
reasonable fees and disbursements of one counsel for the selling Holder or
Holders selected by them with the approval of the Company, which approval shall
not be unreasonably withheld, shall be borne by the Company.
(b) Registration on Form S-3. All expenses incurred in
------------------------
connection with a registration requested pursuant to Section 1.3, including
(without limitation) all registration, filing, qualification, printers' and
accounting fees and the reasonable fees and disbursements of one counsel for the
selling Holder or Holders selected by them with the approval of the Company,
which approval shall not be unreasonably withheld, and counsel for the Company,
and any underwriters' discounts or commissions associated with Registrable
Securities, shall be borne pro rata by the Holder or Holders participating in
the Form S-3 Registration.
-5-
<PAGE>
1.7 Underwriting Requirements. In connection with any offering
-------------------------
involving an underwriting of shares of the Company's capital stock, the Company
shall not be required under Section 1.2 to include any of the Holders'
securities in such underwriting unless they accept the terms of the underwriting
as agreed upon between the Company and the underwriters selected by it (or by
other persons entitled to select the underwriters), and then only in such
quantity as the underwriters determine in their sole discretion will not
jeopardize the success of the offering by the Company. If the total amount of
securities, including Registrable Securities, requested by stockholders to be
included in such offering exceeds the amount of securities sold other than by
the Company that the underwriters determine in their sole discretion is
compatible with the success of the offering, then the Company shall be required
to include in the offering only that number of such securities, including
Registrable Securities, which the underwriters determine in their sole
discretion will not jeopardize the success of the offering (the securities so
included to be apportioned pro rata among the selling stockholders according to
the total amount of securities entitled to be included therein owned by each
selling stockholder or in such other proportions as shall mutually be agreed to
by such selling stockholders) but in no event shall the amount of securities of
the selling Holders included in the offering be reduced below twenty percent
(20%) of the total amount of securities included in such offering, unless such
offering is the initial public offering of the Company's securities, in which
case, the selling stockholders may be excluded if the underwriters make the
determination described above and no other stockholder's securities are
included. For purposes of the preceding parenthetical concerning apportionment,
for any selling stockholder which is a holder of Registrable Securities and
which is a partnership or corporation, the partners, retired partners and
stockholders of such holder, or the estates and family members of any such
partners and retired partners and any trusts for the benefit of any of the
foregoing persons shall be deemed to be a single "selling stockholder," and any
pro-rata reduction with respect to such "selling stockholder" shall be based
-------------------
upon the aggregate amount of shares carrying registration rights owned by all
entities and individuals included in such "selling stockholder," as defined in
this sentence.
1.8 Delay of Registration. No Holder shall have any right to obtain
---------------------
or seek an injunction restraining or otherwise delaying any such registration as
the result of any controversy that might arise with respect to the
interpretation or implementation of this Section 1.
1.9 Indemnification. In the event any Registrable Securities are
---------------
included in a registration statement under this Section 1:
(a) To the extent permitted by law, the Company will indemnify
and hold harmless each Holder, any underwriter (as defined in the Securities
Act) for such Holder and each person, if any, who controls such Holder or
underwriter within the meaning of the Securities Act or the Securities Exchange
Act of 1934, as amended (the "Exchange Act"), against any losses, claims,
------------
damages, or liabilities (joint or several) to which they may become subject
under the Securities Act, the Exchange Act or other federal or state law,
insofar as such losses, claims, damages, or liabilities (or actions in respect
thereof) arise out of or are based upon any of the following statements,
omissions or violations (collectively a "Violation"): (i) any untrue statement
---------
or alleged untrue statement of a material fact contained in such registration
statement,
-6-
<PAGE>
including any preliminary prospectus or final prospectus contained therein or
any amendments or supplements thereto, (ii) the omission or alleged omission to
state therein a material fact required to be stated therein, or necessary to
make the statements therein not misleading, or (iii) any violation or alleged
violation by the Company of the Securities Act, the Exchange Act, any state
securities law or any rule or regulation promulgated under the Securities Act,
the Exchange Act or any state securities law; and the Company will pay to each
such Holder, underwriter or controlling person, as incurred, any legal or other
expenses reasonably incurred by them in connection with investigating or
defending any such loss, claim, damage, liability, or action; provided, however,
-------- -------
that the indemnity agreement contained in this subsection 1.9(a) shall not apply
to amounts paid in settlement of any such loss, claim, damage, liability, or
action if such settlement is effected without the consent of the Company (which
consent shall not be unreasonably withheld), nor shall the Company be liable to
any Holder, underwriter or controlling person for any such loss, claim, damage,
liability, or action to the extent that it arises out of or is based upon a
Violation which occurs in reliance upon and in conformity with written
information furnished expressly for use in connection with such registration by
any such Holder, underwriter or controlling person.
(b) To the extent permitted by law, each selling Holder will
indemnify and hold harmless the Company, each of its directors, each of its
officers who has signed the registration statement, each person, if any, who
controls the Company within the meaning of the Securities Act, any underwriter,
any other Holder selling securities in such registration statement and any
controlling person of any such underwriter or other Holder, against any losses,
claims, damages, or liabilities (joint or several) to which any of the foregoing
persons may become subject, under the Securities Act, the Exchange Act or other
federal or state law, insofar as such losses, claims, damages, or liabilities
(or actions in respect thereto) arise out of or are based upon any Violation, in
each case to the extent (and only to the extent) that such Violation occurs in
reliance upon and in conformity with written information furnished by such
Holder expressly for use in connection with such registration; and each such
Holder will pay, as incurred, any legal or other expenses reasonably incurred by
any person intended to be indemnified pursuant to this subsection 1.9(b), in
connection with investigating or defending any such loss, claim, damage,
liability, or action; provided, however, that the indemnity agreement contained
-------- -------
in this subsection 1.9(b) shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability or action if such settlement is effected
without the consent of the Holder, which consent shall not be unreasonably
withheld; provided, that in no event shall any indemnity under this subsection
--------
1.9(b) exceed the net proceeds from the offering received by such Holder, except
in the case of willful fraud by such Holder.
(c) Promptly after receipt by an indemnified party under this
Section 1.9 of notice of the commencement of any action (including any
governmental action), such indemnified party will, if a claim in respect thereof
is to be made against any indemnifying party under this Section 1.9, deliver to
the indemnifying party a written notice of the commencement thereof and the
indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party
similarly noticed, to assume the defense thereof with counsel mutually
satisfactory to the parties; provided, however, that an indemnified party
-------- -------
(together with all other indemnified parties which may be
-7-
<PAGE>
represented without conflict by one counsel) shall have the right to retain one
separate counsel, with the reasonable fees and expenses to be paid by the
indemnifying party, if representation of such indemnified party by the counsel
retained by the indemnifying party would be inappropriate due to actual or
potential differing interests between such indemnified party and any other party
represented by such counsel in such proceeding. The failure to deliver written
notice to the indemnifying party within a reasonable time of the commencement of
any such action, if prejudicial to its ability to defend such action, shall
relieve such indemnifying party of any liability to the indemnified party under
this Section 1.9, but the omission so to deliver written notice to the
indemnifying party will not relieve it of any liability that it may have to any
indemnified party otherwise than under this Section 1.9.
(d) If the indemnification provided for in this Section 1.9 is
held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any loss, liability, claim, damage or expense referred to
therein, then the indemnifying party, in lieu of indemnifying such indemnified
party hereunder, shall contribute to the amount paid or payable by such
indemnified party as a result of such loss, liability, claim, damage, or expense
in such proportion as is appropriate to reflect the relative fault of the
indemnifying party on the one hand and of the indemnified party on the other in
connection with the statements or omissions that resulted in such loss,
liability, claim, damage or expense as well as any other relevant equitable
considerations; provided, that in no event shall any contribution by a Holder
--------
under this Subsection 1.9(d) exceed the net proceeds from the offering received
by such Holder, except in the case of willful fraud by such Holder. The relative
fault of the indemnifying party and of the indemnified party shall be determined
by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission to state a material fact relates to
information supplied by the indemnifying party or by the indemnified party and
the parties' relative intent, knowledge, access to information, and opportunity
to correct or prevent such statement or omission.
(e) Notwithstanding the foregoing, to the extent that the
provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are
in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.
(f) The obligations of the Company and Holders under this
Section 1.9 shall survive the completion of any offering of Registrable
Securities in a registration statement under this Section 1, and otherwise.
1.10 Reports Under Securities Exchange Act of 1934. With a view to
---------------------------------------------
making available to the Holders the benefits of Rule 144 promulgated under the
Securities Act and any other rule or regulation of the SEC that may at any time
permit a Holder to sell securities of the Company to the public without
registration or pursuant to a registration on Form S-3, the Company agrees to:
(a) make and keep public information available, as those terms
are understood and defined in SEC Rule 144, at all times after ninety (90) days
after the effective
-8-
<PAGE>
date of the first registration statement filed by the Company for the offering
of its securities to the general public so long as the Company remains subject
to the periodic reporting requirements under Sections 13 or 15(d) of the
Exchange Act;
(b) take such action, including the voluntary registration of
its Common Stock under Section 12 of the Exchange Act, as is necessary to enable
the Holders to utilize Form S-3 for the sale of their Registrable Securities,
such action to be taken as soon as practicable after the end of the fiscal year
in which the first registration statement filed by the Company for the offering
of its securities to the general public is declared effective;
(c) file with the SEC in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act;
and
(d) furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (i) a written statement by the
Company that it has complied with the reporting requirements of SEC Rule 144 (at
any time after ninety (90) days after the effective date of the first
registration statement filed by the Company), the Securities Act and the
Exchange Act (at any time after it has become subject to such reporting
requirements), or that it qualifies as a registrant whose securities may be
resold pursuant to Form S-3 (at any time after it so qualifies), (ii) a copy of
the most recent annual or quarterly report of the Company and such other reports
and documents so filed by the Company, and (iii) such other information as may
be reasonably requested in availing any Holder of any rule or regulation of the
SEC which permits the selling of any such securities without registration or
pursuant to such form.
1.11 Assignment of Registration Rights. The rights to cause the
---------------------------------
Company to register Registrable Securities pursuant to this Section 1 may be
assigned (but only with all related obligations) by a Holder to a transferee or
assignee of at least 500,000 shares of such securities, provided the Company is,
--------
within a reasonable time after such transfer, furnished with written notice of
the name and address of such transferee or assignee and the securities with
respect to which such registration rights are being assigned; and provided,
--------
further, that such assignment shall be effective only if immediately following
- -------
such transfer the further disposition of such securities by the transferee or
assignee is restricted under the Securities Act. For the purposes of determining
the number of shares of Registrable Securities held by a transferee or assignee,
the holdings of transferees and assignees of a partnership who are partners or
retired partners of such partnership (including spouses and ancestors, lineal
descendants and siblings of such partners or spouses who acquire Registrable
Securities by gift, will or intestate succession) shall be aggregated together
and with the partnership; provided that all assignees and transferees who would
not qualify individually for assignment of registration rights shall have a
single attorney-in-fact for the purpose of exercising any rights, receiving
notices or taking any action under Section 1.
1.12 "Market Stand-Off" Agreement.
---------------------------
(a) Market-Standoff Period; Agreement. In connection with the
---------------------------------
initial public offering of the Company's securities and upon request of the
Company or the underwriters managing such offering of the Company's securities,
each Holder agrees not to sell,
-9-
<PAGE>
make any short sale of, loan, grant any option for the purchase of, or otherwise
dispose of any securities of the Company (other than those included in the
registration) without the prior written consent of the Company or such
underwriters, as the case may be, for such period of time that expires upon the
later of the date that is (i) 180 days from the effective date of such
registration as may be requested by the Company or such managing underwriters or
(ii) 18 months from the date of this Agreement, and to execute an agreement
reflecting the foregoing as may be requested by the underwriters at the time of
the Company's initial public offering. In addition, the Holder agrees to be
bound by similar restrictions, and to sign a similar agreement, in connection
with no more than one additional registration statement filed within twelve
months after the closing date of the initial public offering, provided that the
--------
duration of the market-standoff period with respect to such additional
registration shall not exceed 90 days from the effective date of such additional
registration statement.
(b) Limitations. The obligations described in Section 1.14(a)
-----------
shall apply only if all officers and directors of the Company, all one-percent
securityholders, and all other persons with registration rights (whether or not
pursuant to this Agreement) enter into similar agreements, and shall not apply
to a registration relating solely to employee benefit plans, or to a
registration relating solely to a transaction pursuant to Rule 145 under the
Securities Act.
(c) Stop-Transfer Instructions. In order to enforce the
--------------------------
foregoing covenants, the Company may impose stop-transfer instructions with
respect to the securities of each Holder (and the securities of every other
person subject to the restrictions in Section 1.10(a)).
(d) Transferees Bound. Each Holder agrees that it will not
-----------------
transfer securities of the Company unless each transferee agrees in writing to
be bound by all of the provisions of this Section 1.12, provided that this
--------
Section 1.12(d) shall not apply to transfers pursuant to a registration
statement or transfers after the twelve-month anniversary of the effective date
of the Company's initial registration statement subject to this Section 1.12.
1.13 Termination of Registration Rights. No Holder shall be entitled
----------------------------------
to exercise any right provided for in this Section 1 after the earlier of (i)
five (5) years following the consummation of a Qualified IPO , (ii) such time as
Rule 144 or another similar exemption under the Securities Act is available for
the sale of all of such Holder's shares during a three (3)-month period without
registration, or (iii) upon termination of the entire Agreement upon a change in
control of the Company, as provided in Section 3.1.
2. Covenants of the Company.
------------------------
2.1 Delivery of Financial Statements. The Company shall deliver to
--------------------------------
each Holder of at least 500,000 shares of Registrable Securities:
(a) as soon as practicable, but in any event within ninety (90)
days after the end of each fiscal year of the Company, an income statement for
such fiscal year, a balance sheet of the Company and statement of stockholder's
equity as of the end of such year, and a statement of cash flows for such year,
such year-end financial reports to be in reasonable
-10-
<PAGE>
detail, prepared in accordance with generally accepted accounting principles
("GAAP"), and audited and certified by an independent public accounting firm of
----
nationally recognized standing selected by the Company;
(b) as soon as practicable, but in any event within thirty (30)
days after the end of each of the first three (3) quarters of each fiscal year
of the Company, an unaudited profit or loss statement, a statement of cash flows
for such fiscal quarter and an unaudited balance sheet as of the end of such
fiscal quarter;
(c) within thirty (30) days of the end of each month, an
unaudited income statement and a statement of cash flows and balance sheet for
and as of the end of such month, in reasonable detail;
(d) as soon as practicable, but in any event thirty (30) days
prior to the end of each fiscal year, a budget and business plan for the next
fiscal year, prepared on a monthly basis and, as soon as prepared, any other
budgets or revised budgets prepared by the Company; and
(e) with respect to the financial statements called for in
subsections (b) and (c) of this Section 2.1, an instrument executed by the Chief
Financial Officer or President of the Company and certifying that such
financials were prepared in accordance with GAAP consistently applied with prior
practice for earlier periods (with the exception of footnotes that may be
required by GAAP) and fairly present the financial condition of the Company and
its results of operation for the period specified, subject to year-end audit
adjustment, provided that the foregoing shall not restrict the right of the
Company to change its accounting principles consistent with GAAP, if the Board
of Directors determines that it is in the best interest of the Company to do so.
2.2 Inspection. The Company shall permit each Holder of at least
----------
500,000 shares of Registrable Securities at such Holder's expense, to visit and
inspect the Company's properties, to examine its books of account and records
and to discuss the Company's affairs, finances and accounts with its officers,
all at such reasonable times as may be requested by the Investor; provided,
---------
however, that the Company shall not be obligated pursuant to this Section 2.2 to
- -------
provide access to any information which it reasonably considers to be a trade
secret or similar confidential information.
2.3 Right of First Refusal. No Holder or transferee of any
----------------------
Registrable Securities shall sell or in any other way directly or indirectly
Transfer, assign, pledge, distribute, bequeath, devise, encumber or otherwise
dispose of, either voluntarily or involuntarily, with or without consideration
(each, a "Sale") any of the shares of Registrable Securities (the "Holder
---- ------
Shares") except in accordance with the following procedures:
- ------
(a) In the event that such Holder thereof (such Holder being
referred to in this Section 2.3 as a "Selling Stockholder") receives a bona
------------------- ----
fide written offer from a third party (the "Prospective Purchaser") to
---- ---------------------
purchase all or any portion of the Holder Shares owned by the Selling
Stockholder, the Selling Stockholder shall deliver to the
-11-
<PAGE>
Company and to the other Holders (the "Non-Selling Stockholders") a written
------------------------
notice (the "Offer Notice"), which shall be irrevocable, subject to Section
------------
2.3(b), for a period of 30 days after delivery thereof (the "Offer
-----
Period"), offering (the "Offer") all of the Holder Shares proposed to be
------ -----
Sold by the Selling Stockholder to the Prospective Purchaser at the
purchase price and on the terms of the proposed Sale to the Prospective
Purchaser (such Offer Notice to include the foregoing information and all
other relevant terms of the proposed Sale, including the identification of
the Prospective Purchaser). The Non-Selling Stockholders shall have the
right and option, for a period of 30 days after delivery of the Offer
Notice, to accept up to their pro-rata portion of the Holder Shares so
offered at the purchase price and on terms comparable to those stated in
the Offer Notice, based upon the number of shares of Registrable Securities
held by all of the Non-Selling Stockholders. Such acceptance shall be made
by delivering a written notice to the Selling Stockholder within said
30-day period.
(b) Anything contained herein to the contrary notwithstanding,
the Selling Stockholder may withdraw from the proposed Sale to a Prospective
Purchaser and, accordingly, may rescind the Offer by delivering written notice
of such withdrawal to the Company and the Non-Selling Stockholders within the
Offer Period, subject to the reinstatement of the provisions of this Section 2.3
in the event an Investor or transferee thereof subsequently intends to sell the
Holder Shares.
(c) Sales of Holder Shares under the terms of Section 2.3(a)
shall be made at the offices of the Company on a mutually satisfactory business
day within 30 days after the expiration of the Offer Period. Delivery of
certificates or other instruments evidencing such Holder Shares duly endorsed
for transfer shall be made to the Company on such date against payment of the
purchase price therefor.
(d) If an effective acceptance shall not be received pursuant to
Section 2.3(a) with respect to all Holder Shares offered for Sale pursuant to
the Offer Notice, then at any time within 30 days after the expiration of the
Offer Period the Selling Stockholder may Sell all or any part of the remaining
Holder Shares that were not accepted for purchase by the Non-Selling
Stockholders as aforesaid to the Prospective Purchaser at a purchase price no
less than that, and on the terms no more favorable to the Prospective Purchaser
than those, stated in the Offer Notice; provided, however, that the Selling
-------- -------
Stockholder may not, under any circumstances, Sell any Holder Shares to the
Prospective Purchaser if the Board of Directors, in its sole discretion,
determines within the Offer Period that the Prospective Purchaser is a
competitor, or an affiliate of a competitor, of the Company, or that such
Prospective Purchaser's ownership would be contrary to the best interests of the
Company. In the event that the Holder Shares are not Sold by the Selling
Stockholder to the Prospective Purchaser during such 30-day period, the right of
the Selling Stockholder to Sell such remaining Holder Shares to the Prospective
Purchaser shall expire and the obligations of this Section 2.3 shall be
reinstated.
(e) Anything contained herein to the contrary notwithstanding,
any purchaser of Holder Shares pursuant to this Section 2.3 who is not a Holder
shall agree in writing in
-12-
<PAGE>
advance with the parties hereto to be bound by and comply with all applicable
provisions of this Agreement and shall be deemed to be an Investor for all
purposes of this Agreement.
(f) The provisions of this Section 2.3 shall not apply to the
transfer of Holder Shares by a Holder to the spouse or lineal descendants of
such Investor or any trust for the benefit of such persons or to an affiliate or
stockholder of such Holder, provided such transferee has agreed in writing in
--------
advance to be bound by and comply with all provisions of this Agreement to the
same extent as the transferring Holder.
2.4 Termination of Covenants.
------------------------
(a) The covenants set forth in Sections 2.1, 2.2 and 2.3 shall
terminate as to each Holder and be of no further force or effect (i) immediately
prior to the consummation of a Qualified IPO, or (ii) upon termination of the
entire Agreement upon a change in control of the Company, as provided in Section
3.1.
(b) The covenants set forth in Sections 2.1 and 2.2 shall
terminate as to each Holder and be of no further force or effect when the
Company first becomes subject to the periodic reporting requirements of Sections
13 or 15(d) of the Exchange Act, if this occurs earlier than the events
described in Section 2.4(a) above.
3. Miscellaneous.
-------------
3.1 Termination of Entire Agreement Upon Change of Control. This
------------------------------------------------------
Agreement shall terminate, and have no further force and effect, when the
Company shall sell, convey, or otherwise dispose of all or substantially all of
its property or business or merge into or consolidate with any other corporation
(other than a wholly-owned subsidiary corporation) or effect any other
transaction or series of related transactions in which more than 50% of the
voting power of the Company is disposed of, provided that this Agreement shall
--------
not be terminated following a merger effected solely for the purpose of changing
the domicile of the Company.
3.2 Successors and Assigns. Except as otherwise provided in this
----------------------
Agreement, the terms and conditions of this Agreement shall inure to the benefit
of and be binding upon the respective permitted successors and assigns of the
parties (including transferees of any of the Series A Preferred Stock or any
Common Stock issued upon conversion thereof). Nothing in this Agreement, express
or implied, is intended to confer upon any party other than the parties hereto
or their respective successors and assigns any rights, remedies, obligations, or
liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement.
3.3 Amendments and Waivers. Any term of this Agreement may be amended
----------------------
or waived only with the written consent of the Company and the holders of at
least eighty percent (80%) of the Registrable Securities then outstanding, Any
amendment or waiver effected in accordance with this paragraph shall be binding
upon each party to the Agreement, whether or not such party has signed such
amendment or waiver, each future holder of all such Registrable Securities, and
the Company.
-13-
<PAGE>
3.4 Notices. Unless otherwise provided, any notice required or
-------
permitted by this Agreement shall be in writing and shall be deemed sufficient
upon delivery, when delivered personally or by overnight courier or sent by
telegram or fax, or forty-eight (48) hours after being deposited in the U.S.
mail, as certified or registered mail, with postage prepaid, and addressed to
the party to be notified at such party's address or fax number as set forth on
Exhibit A hereto or as subsequently modified by written notice.
- ---------
3.5 Severability. If one or more provisions of this Agreement are
------------
held to be unenforceable under applicable law, the parties agree to renegotiate
such provision in good faith. In the event that the parties cannot reach a
mutually agreeable and enforceable replacement for such provision, then (a) such
provision shall be excluded from this Agreement, (b) the balance of the
Agreement shall be interpreted as if such provision were so excluded and (c) the
balance of the Agreement shall be enforceable in accordance with its terms.
3.6 Governing Law. This Agreement and all acts and transactions
-------------
pursuant hereto shall be governed, construed and interpreted in accordance with
the laws of the State of California, without giving effect to principles of
conflicts of laws.
3.7 Counterparts. This Agreement may be executed in two or more
------------
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
3.8 Titles and Subtitles. The titles and subtitles used in this
--------------------
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.
3.9 Aggregation of Stock. All shares of the Preferred Stock held or
--------------------
acquired by affiliated entities or persons shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement.
[Signature Page Follows]
-14-
<PAGE>
The parties have executed this Investors' Rights Agreement as of the date
first above written.
COMPANY:
TENDEX, INC.
By:_______________________________
Name:_____________________________
Title:____________________________
Address:__________________________
INVESTORS:________________________
TENET HEALTHSYSTEM MEDICAL, INC.
By:_______________________________
Name:_____________________________
Title:____________________________
Address: 3820 State Street
Santa Barbara, CA 93105
Fax: 805-563-7070
Attn: Jeffrey C. Barbakow
CHEMDEX CORPORATION
By:_______________________________
Name:_____________________________
Title:____________________________
Address: 1500 Plymouth Street
Mountain View, CA 94043
Fax: 650-567-8950
Attn: Dave Perry
<PAGE>
EXHIBIT A
---------
INVESTORS
---------
<TABLE>
<CAPTION>
Name No. of Shares of No. of Shares of
---- ---------------- ----------------
Series A Stock Common Stock
-------------- ------------
<S> <C> <C>
TENET HEALTHSYSTEM MEDICAL , INC. 3,800,000 3
CHEMDEX CORPORATION 1,200,000 1
</TABLE>
<PAGE>
EXHIBIT G
Voting Agreement
<PAGE>
TENDEX, INC.
VOTING AGREEMENT
----------------
This Voting Agreement (the "Agreement") is made as of the _____ day of
---------
December 1999, by and among Tendex, Inc., a Delaware corporation (the
"Company"), and the holders of shares of Series A Preferred Stock listed on
-------
Exhibit A (collectively, the "Investors" and individually, the "Investor").
- --------- --------- --------
RECITALS
--------
The Company and the Investors have entered into a Series A Preferred Stock
Purchase Agreement (the "Purchase Agreement") of even date herewith pursuant to
------------------
which the Company desires to sell to the Investors and the Investors desire to
purchase from the Company shares of the Company's Series A Preferred Stock, and
have also entered into a Joint Venture Agreement (the "Joint Venture Agreement")
-----------------------
of even date herewith. A condition to the Investors' obligations under the
Purchase Agreement is that the Company and the Investors enter into this
Agreement for the purpose of setting forth the terms and conditions pursuant to
which the Investors shall vote their shares of the Company's voting stock in
favor of certain designees to the Company's Board of Directors. The Company and
the Investors each desire to facilitate the voting arrangements set forth in
this Agreement, the entrance into the Joint Venture Agreement and the sale and
purchase of shares of Series A Preferred Stock pursuant to the Purchase
Agreement, by agreeing to the terms and conditions set forth below.
AGREEMENT
---------
The parties agree as follows:
1. Election of Directors.
---------------------
1.1 Board Representation. At each annual meeting of the stockholders
--------------------
of the Company, or at any meeting of the stockholders of the Company at which
members of the Board of Directors of the Company are to be elected, or whenever
members of the Board of Directors are to be elected by written consent, the
Investors agree to vote or act with respect to their shares of the Company's
stock so as to elect:
(a) Two (2) members of the Company's Board of Directors
designated by Tenet HealthSystem Medical, Inc. or its affiliates ("Tenet") so
-----
long as there are at least three (3) members of the Board of Directors. If the
number of members of the Board of Directors is five (5) or more, then Tenet
shall be entitled to designate three (3) members.
(b) One (1) member of the Company's Board of Directors designated
by Chemdex Corporation or its affiliates ("Chemdex"). If the number of members
-------
of the Board of Directors is five (5) or more, then Chemdex shall be entitled to
designate two (2) members.
<PAGE>
1.2 Appointment of Directors. In the event of the resignation,
------------------------
death, removal or disqualification of a director selected by Tenet or Chemdex,
as the case may be, Tenet or Chemdex, as the case may be, shall promptly
nominate a new director, and, after written notice of the nomination has been
given by Tenet or Chemdex, as the case may be, to the other parties (and, with
respect to a nominee designated by Tenet or Chemdex, such nominee has been
approved by the Company's directors as provided in Section 1.1 above), each
Investor shall vote its shares of capital stock of the Company to elect such
nominee to the Board of Directors.
1.3 Removal. Tenet or Chemdex, as the case may be, may remove its
-------
designated director(s) at any time and from time to time, with or without cause
(subject to the Certificate of Incorporation and Bylaws of the Company (the
"Charter Documents") as in effect from time to time and any requirements of
- ------------------
law), in their sole discretion, and after written notice to each of the parties
hereto of the new nominee to replace such director and, with respect to a
nominee of Tenet or Chemdex, after such nominee has been approved by the
Company's directors in accordance with Section 1.1 above, each Investor shall
promptly vote its shares of capital stock of the Company to elect such nominee
to the Board of Directors.
1.4 Management of the Company.
-------------------------
(a) The Board of Directors of the Company shall be responsible for
establishing the overall policy and operating procedures with respect to the
business affairs of the Company.
(b) Except as otherwise required by the Charter Documents, mandatory
provisions of law and as otherwise provided herein, resolutions of the Board of
Directors shall be adopted only by the affirmative vote of a majority of the
Directors present at a meeting duly called at which a quorum is present. A
majority of the Board of Directors shall constitute a quorum for the transaction
of business provided at least one director designated by Chemdex and one
director designated by Tenet are present. Board meetings shall be held at the
Company's executive offices or at such other location determined by the Board of
Directors in accordance with applicable law; provided that the Board of
Directors shall meet no less frequently than once every two calendar months.
Any director may attend a Board meeting by conference telephone.
(c) Notwithstanding the general provisions set forth above, in
addition to any special approval requirements under the Charter Documents or
under law, each of the following corporate actions may be taken by the Company
only (i) in the case of any action that is permitted by law or under the Charter
Documents to be taken by the Board of Directors alone, upon authorization by
affirmative vote of at least one Tenet director and at least one Chemdex
director, and (ii) in the case of actions required by law or the Charter
Documents to be approved by the Company's stockholders, upon authorization by
affirmative vote of both Tenet and Chemdex as stockholders:
(i) any merger or consolidation, whether or not the Company is
the surviving corporation; any sale, lease, exchange or other disposition of all
or substantially all of the assets of the Company; any acquisition of all or
substantially all of the capital stock or assets of any other entity; or the
liquidation or voluntary dissolution of the Company;
-2-
<PAGE>
(ii) any sale, lease, exchange or other disposition of substantial
assets (except in the ordinary course of business) of the Company;
(iii) the raising of additional equity capital or the issuance or
sale of any debt or equity securities (including any stockholder loan or
guaranty) and the terms thereof;
(iv) any declaration or payment of any dividend or other
distribution, directly or indirectly, on account of any shares of capital stock
of the Company, or any redemption, retirement, purchase or other acquisition,
directly or indirectly, by the Company of any such shares (or of any warrants,
rights or options to acquire any such shares);
(v) any amendment, alteration or repeal of any provision of the
Charter Documents of the Company;
(vi) any action involving a material change in the operations or
business purpose of the Company or engagement in any business other than as set
forth in Section 2.4 of the Joint Venture Agreement, either directly or through
any corporation or other entity in which the Company has, directly or
indirectly, an equity interest;
(vii) approval of an annual business plan and operating budget for
the Company (which shall be made no later than thirty (30) days prior to the
commencement of each fiscal year of the Company), and any deviation in any
material respect from such business plan or budget as so approved;
(xii) compensation for all executive officers and directors of
the Company; or
(xiii) the filing of a petition for liquidation or dissolution
of the Company in bankruptcy.
The foregoing approval requirements shall at all times also be set
forth in the Charter Documents of the Company, unless amended pursuant to the
provisions of this Agreement and the Charter Documents.
2. Additional Representations and Covenants.
----------------------------------------
2.1 No Revocation. The voting agreements contained herein are
-------------
coupled with an interest and may not be revoked during the term of this
Agreement.
2.2 Change in Number of Directors. The Investors will not vote for
-----------------------------
any amendment or change to the Certificate of Incorporation or Bylaws providing
for the election of more or less than five (5) directors, or any other amendment
or change to the Certificate of Incorporation Bylaws inconsistent with the terms
of this Agreement.
2.3 Legends. Each certificate representing shares of the Company's
-------
capital stock held by the Investors or any assignee of the Investors shall bear
the following legend:
-3-
<PAGE>
"THE SHARES EVIDENCED HEREBY ARE SUBJECT TO A VOTING AGREEMENT BY AND
AMONG THE COMPANY AND CERTAIN STOCKHOLDERS OF THE COMPANY (A COPY OF
WHICH MAY BE OBTAINED FROM THE COMPANY), AND BY ACCEPTING ANY INTEREST
IN SUCH SHARES THE PERSON ACCEPTING SUCH INTEREST SHALL BE DEEMED TO
AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SAID VOTING
AGREEMENT."
3. Termination.
-----------
3.1 Termination Events. This Agreement shall terminate upon the
------------------
earlier of:
(a) A firm commitment underwritten public offering by the
Company of shares of its Common Stock pursuant to a registration statement on
Form S-1 under the Securities Act of 1933, as amended; or
(b) The sale, conveyance or disposal of all or substantially all
of the Company's property or business or the Company's merger into or
consolidation with any other corporation (other than a wholly-owned subsidiary
corporation) or if the Company effects any other transaction or series of
related transactions in which more than fifty percent (50%) of the voting power
of the Company is disposed of, provided that this Section 3.1(b) shall not apply
--------
to a merger effected exclusively for the purpose of changing the domicile of the
Company.
3.2 Removal of Legend. At any time after the termination of this
-----------------
Agreement in accordance with Section 3.1, any holder of a stock certificate
legended pursuant to Section 2.3 may surrender such certificate to the Company
for removal of the legend, and the Company will duly reissue a new certificate
without the legend.
4. Miscellaneous.
-------------
4.1 Successors and Assigns. The terms and conditions of this
----------------------
Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties. Nothing in this Agreement, express or
implied, is intended to confer upon any party other than the parties hereto or
their respective successors and assigns any rights, remedies, obligations, or
liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement.
4.2 Amendments and Waivers. Any term hereof may be amended or waived
----------------------
only with the written consent of the Company, Tenet and Chemdex. Any amendment
or waiver effected in accordance with this Section 4.2 shall be binding upon the
Company and the holders of Series A Preferred Stock, and each of their
respective successors and assigns.
4.3 Notices. Any notice required or permitted by this Agreement
-------
shall be in writing and shall be deemed sufficient on the date of delivery, when
delivered personally or by overnight courier or sent by telegram or fax, or
forty-eight (48) hours after being deposited in the U.S. mail, as certified or
registered mail, with postage prepaid, and addressed to the party to be
-4-
<PAGE>
notified at such party's address or fax number as set forth on the signature
page or on Exhibit A hereto, or as subsequently modified by written notice.
---------
4.4 Severability. If one or more provisions of this Agreement are
------------
held to be unenforceable under applicable law, the parties agree to renegotiate
such provision in good faith. In the event that the parties cannot reach a
mutually agreeable and enforceable replacement for such provision, then (a) such
provision shall be excluded from this Agreement, (b) the balance of the
Agreement shall be interpreted as if such provision were so excluded and (c) the
balance of the Agreement shall be enforceable in accordance with its terms.
4.5 Governing Law. This Agreement and all acts and transactions
-------------
pursuant hereto and the rights and obligations of the parties hereto shall be
governed, construed and interpreted in accordance with the laws of the State of
California, without giving effect to principles of conflicts of law.
4.6 Counterparts. This Agreement may be executed in two or more
------------
counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument.
4.7 Titles and Subtitles. The titles and subtitles used in this
--------------------
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.
[Signature Page Follows]
-5-
<PAGE>
The parties hereto have executed this Voting Agreement as of the date first
written above.
COMPANY:
TENDEX, INC.
By:________________________
Name:______________________
Title:_____________________
Fax:_______________________
INVESTORS:
TENET HEALTHSYSTEM MEDICAL, INC.
By:________________________
Name:______________________
Title:_____________________
Fax:_______________________
CHEMDEX CORPORATION
By:________________________
Name:______________________
Title:_____________________
Fax:_______________________
SIGNATURE PAGE TO VOTING AGREEMENT
<PAGE>
EXHIBIT A
---------
INVESTORS
---------
<TABLE>
<CAPTION>
Name/Address/Fax No. No. of Shares No. of Shares
-------------------- ------------- -------------
Of Series A Stock of Common
----------------- -------------
Stock
-----
<S> <C> <C>
TENET HEALTHSYSTEM MEDICAL, INC. 3,800,000 3
CHEMDEX CORPORATION 1,200,000 1
</TABLE>
<PAGE>
EXHIBIT H
Not Referenced
<PAGE>
EXHIBIT I
Initial Certificate of Incorporation
<PAGE>
CERTIFICATE OF INCORPORATION
OF
TENDEX, INC.
ARTICLE I
The name of the corporation is Tendex, Inc., (the "Corporation").
ARTICLE II
The registered office of the corporation shall be in the City of Dover
County of Kent State of Delaware. The name of the registered agent of the
corporation at such location is Incorporating Services, Ltd..
ARTICLE III
The purpose of the Corporation is to engage in any lawful act or activity
for which corporations may be organized under the General Corporation Law of
Delaware.
ARTICLE IV
The aggregate number of shares which the Corporation shall have authority
to issue is 10,000,000 shares of capital stock all of which shall be designated
"Common Stock" and have a par value of $0.0001 per share.
ARTICLE V
The Board of Directors of the Corporation is expressly authorized to make,
alter or repeal Bylaws of the Corporation.
ARTICLE VI
Elections of directors need not be by written ballot unless otherwise
provided in the Bylaws of the Corporation.
ARTICLE VII
(A) To the fullest extent permitted by the Delaware General Corporation
Law, as the same exists or as may hereafter be amended, a director of the
Corporation shall not be personally liable to the Corporation or its
stockholders for monetary damages for breach of fiduciary duty as a director.
<PAGE>
(B) The Corporation shall indemnify to the fullest extent permitted by law
any person made or threatened to be made a party to an action or proceeding,
whether criminal, civil, administrative or investigative, by reason of the fact
that he, his testator or intestate is or was a director or officer of the
Corporation or any predecessor of the Corporation, or serves or served at any
other enterprise as a director or officer at the request of the Corporation or
any predecessor to the Corporation.
(C) Neither any amendment nor repeal of this Article VII, nor the adoption
of any provision of the Corporation's Certificate of Incorporation inconsistent
with this Article VII, shall eliminate or reduce the effect of this Article VII
in respect of any matter occurring, or any action or proceeding accruing or
arising or that, but for this Article VII, would accrue or arise, prior to such
amendment, repeal or adoption of an inconsistent provision.
ARTICLE VIII
The name and mailing address of the incorporator are as follows:
Jeffrey Y. Suto
Venture Law Group
2775 Sand Hill Road
Menlo Park, CA 94025
-2-
<PAGE>
Executed this ___ day of December, 1999.
/s/ Jeffery Y. Suto
-----------------------------
Jeffrey Y. Suto, Incorporator
-3-
<PAGE>
EXHIBIT J
Bylaws
<PAGE>
BYLAWS
OF
TENDEX, INC.
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
ARTICLE I - CORPORATE OFFICES..................................................... 1
1.1 Registered Office....................................................... 1
1.2 Other Offices........................................................... 1
ARTICLE II - MEETINGS OF STOCKHOLDERS............................................. 1
2.1 Place Of Meetings....................................................... 1
2.2 Annual Meeting.......................................................... 1
2.3 Special Meeting......................................................... 1
2.4 Notice Of Stockholders' Meetings........................................ 2
2.5 Manner Of Giving Notice; Affidavit Of Notice............................ 2
2.6 Quorum.................................................................. 2
2.7 Adjourned Meeting; Notice............................................... 2
2.8 Conduct Of Business..................................................... 3
2.9 Voting.................................................................. 3
2.10 Waiver Of Notice........................................................ 3
2.11 Stockholder Action By Written Consent Without A Meeting................. 3
2.12 Record Date For Stockholder Notice; Voting; Giving Consents............. 4
2.13 Proxies................................................................. 4
ARTICLE III - DIRECTORS........................................................... 5
3.1 Powers.................................................................. 5
3.2 Number Of Directors..................................................... 5
3.3 Election, Qualification And Term Of Office Of Directors................. 5
3.4 Resignation And Vacancies............................................... 5
3.5 Place Of Meetings; Meetings By Telephone................................ 6
3.6 Regular Meetings........................................................ 6
3.7 Special Meetings; Notice................................................ 7
3.8 Quorum.................................................................. 7
3.9 Waiver Of Notice........................................................ 7
3.10 Board Action By Written Consent Without A Meeting....................... 8
3.11 Fees And Compensation Of Directors...................................... 8
3.12 Approval Of Loans To Officers........................................... 8
3.13 Removal Of Directors.................................................... 8
3.14 Chairman Of The Board Of Directors...................................... 8
ARTICLE IV - COMMITTEES........................................................... 9
4.1 Committees Of Directors................................................. 9
4.2 Committee Minutes....................................................... 9
4.3 Meetings And Action Of Committees....................................... 9
</TABLE>
<PAGE>
TABLE OF CONTENTS
(continued)
<TABLE>
<CAPTION>
Page
----
<S> <C>
ARTICLE V - OFFICERS.............................................................. 10
5.1 Officers................................................................ 10
5.2 Appointment Of Officers................................................. 10
5.3 Subordinate Officers.................................................... 10
5.4 Removal And Resignation Of Officers..................................... 10
5.5 Vacancies In Offices.................................................... 10
5.6 Chief Executive Officer................................................. 11
5.7 President............................................................... 11
5.8 Vice Presidents......................................................... 11
5.9 Secretary............................................................... 11
5.10 Chief Financial Officer................................................. 12
5.11 Representation Of Shares Of Other Corporations.......................... 12
5.12 Authority And Duties Of Officers........................................ 12
ARTICLE VI - INDEMNIFICATION OF DIRECTORS, OFFICERS, EMPLOYEES, AND OTHER AGENTS.. 13
6.1 Indemnification Of Directors And Officers............................... 13
6.2 Indemnification Of Others............................................... 13
6.3 Payment Of Expenses In Advance.......................................... 13
6.4 Indemnity Not Exclusive................................................. 13
6.5 Insurance............................................................... 14
6.6 Conflicts............................................................... 14
ARTICLE VII - RECORDS AND REPORTS................................................. 14
7.1 Maintenance And Inspection Of Records................................... 14
7.2 Inspection By Directors................................................. 15
7.3 Annual Statement To Stockholders........................................ 15
ARTICLE VIII - GENERAL MATTERS.................................................... 15
8.1 Checks.................................................................. 15
8.2 Execution Of Corporate Contracts And Instruments........................ 15
8.3 Stock Certificates; Partly Paid Shares.................................. 15
8.4 Special Designation On Certificates..................................... 16
8.5 Lost Certificates....................................................... 16
8.6 Construction; Definitions............................................... 17
8.7 Dividends............................................................... 17
8.8 Fiscal Year............................................................. 17
8.9 Seal.................................................................... 17
8.10 Transfer Of Stock....................................................... 17
</TABLE>
-3-
<PAGE>
TABLE OF CONTENTS
(continued)
<TABLE>
<CAPTION>
Page
----
<S> <C>
8.11 Stock Transfer Agreements............................................... 18
8.12 Registered Stockholders................................................. 18
ARTICLE IX - AMENDMENTS........................................................... 18
</TABLE>
-4-
<PAGE>
BYLAWS
OF
TENDEX, INC.
ARTICLE I
CORPORATE OFFICES
-----------------
1.1 Registered Office.
-----------------
The registered office of the corporation shall be in the City of
Dover County of Kent State of Delaware. The name of the registered agent of the
corporation at such location is Incorporating Services, Ltd.
1.2 Other Offices.
-------------
The Board of Directors may at any time establish other offices at
any place or places where the corporation is qualified to do business.
ARTICLE II
MEETINGS OF STOCKHOLDERS
------------------------
2.1 Place Of Meetings.
-----------------
Meetings of stockholders shall be held at any place, within or
outside the State of Delaware, designated by the Board of Directors. In the
absence of any such designation, stockholders' meetings shall be held at the
registered office of the corporation.
2.2 Annual Meeting.
--------------
The annual meeting of stockholders shall be held on such date, time
and place, either within or without the State of Delaware, as may be designated
by resolution of the Board of Directors each year. At the meeting, directors
shall be elected and any other proper business may be transacted.
2.3 Special Meeting.
---------------
A special meeting of the stockholders may be called at any time by
the Board of Directors, the chairman of the board, the president or by one or
more stockholders holding shares in the aggregate entitled to cast not less than
ten percent of the votes at that meeting.
If a special meeting is called by any person or persons other than
the Board of Directors, the president or the chairman of the board, the request
shall be in writing, specifying the time of such meeting and the general nature
of the business proposed to be transacted, and
1
<PAGE>
shall be delivered personally or sent by registered mail or by telegraphic or
other facsimile transmission to the chairman of the board, the president, any
vice president, or the secretary of the corporation. No business may be
transacted at such special meeting otherwise than specified in such notice. The
officer receiving the request shall cause notice to be promptly given to the
stockholders entitled to vote, in accordance with the provisions of Sections 2.4
and 2.5 of this Article II, that a meeting will be held at the time requested by
the person or persons calling the meeting, not less than thirty-five (35) nor
more than sixty (60) days after the receipt of the request. If the notice is not
given within twenty (20) days after the receipt of the request, the person or
persons requesting the meeting may give the notice. Nothing contained in this
paragraph of this Section 2.3 shall be construed as limiting, fixing, or
affecting the time when a meeting of stockholders called by action of the Board
of Directors may be held.
2.4 Notice Of Stockholders' Meetings.
--------------------------------
All notices of meetings with stockholders shall be in writing and
shall be sent or otherwise given in accordance with Section 2.5 of these Bylaws
not less than ten (10) nor more than sixty (60) days before the date of the
meeting to each stockholder entitled to vote at such meeting. The notice shall
specify the place, date, and hour of the meeting, and, in the case of a special
meeting, the purpose or purposes for which the meeting is called.
2.5 Manner Of Giving Notice; Affidavit Of Notice.
--------------------------------------------
Written notice of any meeting of stockholders, if mailed, is given
when deposited in the United States mail, postage prepaid, directed to the
stockholder at his address as it appears on the records of the corporation. An
affidavit of the secretary or an assistant secretary or of the transfer agent of
the corporation that the notice has been given shall, in the absence of fraud,
be prima facie evidence of the facts stated therein.
2.6 Quorum.
------
The holders of a majority of the stock issued and outstanding and
entitled to vote thereat, present in person or represented by proxy, shall
constitute a quorum at all meetings of the stockholders for the transaction of
business except as otherwise provided by statute or by the certificate of
incorporation. If, however, such quorum is not present or represented at any
meeting of the stockholders, then either (a) the chairman of the meeting or (b)
the stockholders entitled to vote thereat, present in person or represented by
proxy, shall have power to adjourn the meeting from time to time, without notice
other than announcement at the meeting, until a quorum is present or
represented. At such adjourned meeting at which a quorum is present or
represented, any business may be transacted that might have been transacted at
the meeting as originally noticed.
2.7 Adjourned Meeting; Notice.
-------------------------
When a meeting is adjourned to another time or place, unless these
Bylaws otherwise require, notice need not be given of the adjourned meeting if
the time and place thereof are announced at the meeting at which the adjournment
is taken. At the adjourned meeting the
-2-
<PAGE>
corporation may transact any business that might have been transacted at the
original meeting. If the adjournment is for more than thirty (30) days, or if
after the adjournment a new record date is fixed for the adjourned meeting, a
notice of the adjourned meeting shall be given to each stockholder of record
entitled to vote at the meeting.
2.8 Conduct Of Business.
-------------------
The chairman of any meeting of stockholders shall determine the
order of business and the procedure at the meeting, including the manner of
voting and the conduct of business.
2.9 Voting.
------
The stockholders entitled to vote at any meeting of stockholders
shall be determined in accordance with the provisions of Section 2.12 of these
Bylaws, subject to the provisions of Sections 217 and 218 of the General
Corporation Law of Delaware (relating to voting rights of fiduciaries, pledgors
and joint owners of stock and to voting trusts and other voting agreements).
Except as may be otherwise provided in the certificate of
incorporation, each stockholder shall be entitled to one vote for each share of
capital stock held by such stockholder.
2.10 Waiver Of Notice.
----------------
Whenever notice is required to be given under any provision of the
General Corporation Law of Delaware or of the certificate of incorporation or
these Bylaws, a written waiver thereof, signed by the person entitled to notice,
whether before or after the time stated therein, shall be deemed equivalent to
notice. Attendance of a person at a meeting shall constitute a waiver of notice
of such meeting, except when the person attends a meeting for the express
purpose of objecting, at the beginning of the meeting, to the transaction of any
business because the meeting is not lawfully called or convened. Neither the
business to be transacted at, nor the purpose of, any regular or special meeting
of the stockholders need be specified in any written waiver of notice unless so
required by the certificate of incorporation or these Bylaws.
2.11 Stockholder Action By Written Consent Without A Meeting.
-------------------------------------------------------
Unless otherwise provided in the certificate of incorporation, any
action required to be taken at any annual or special meeting of stockholders of
the corporation, or any action that may be taken at any annual or special
meeting of such stockholders, may be taken without a meeting, without prior
notice, and without a vote if a consent in writing, setting forth the action so
taken, is signed by the holders of outstanding stock having not less than the
minimum number of votes that would be necessary to authorize or take such action
at a meeting at which all shares entitled to vote thereon were present and
voted.
Prompt notice of the taking of the corporate action without a
meeting by less than unanimous written consent shall be given to those
stockholders who have not consented in
-3-
<PAGE>
writing. If the action which is consented to is such as would have required the
filing of a certificate under any section of the General Corporation Law of
Delaware if such action had been voted on by stockholders at a meeting thereof,
then the certificate filed under such section shall state, in lieu of any
statement required by such section concerning any vote of stockholders, that
written notice and written consent have been given as provided in Section 228 of
the General Corporation Law of Delaware.
2.12 Record Date For Stockholder Notice; Voting; Giving Consents.
-----------------------------------------------------------
In order that the corporation may determine the stockholders
entitled to notice of or to vote at any meeting of stockholders or any
adjournment thereof, or entitled to express consent to corporate action in
writing without a meeting, or entitled to receive payment of any dividend or
other distribution or allotment of any rights, or entitled to exercise any
rights in respect of any change, conversion or exchange of stock or for the
purpose of any other lawful action, the Board of Directors may fix, in advance,
a record date, which shall not be more than sixty (60) nor less than ten (10)
days before the date of such meeting, nor more than sixty (60) days prior to any
other action.
If the Board of Directors does not so fix a record date:
(a) The record date for determining stockholders entitled to notice
of or to vote at a meeting of stockholders shall be at the close of business on
the day next preceding the day on which notice is given, or, if notice is
waived, at the close of business on the day next preceding the day on which the
meeting is held.
(b) The record date for determining stockholders entitled to consent
to corporate action in writing without a meeting, when no prior action by the
Board of Directors is necessary, shall be the day on which the first written
consent is delivered to the corporation.
(c) The record date for determining stockholders for any other
purpose shall be at the close of business on the day on which the Board of
Directors adopts the resolution relating thereto.
A determination of stockholders of record entitled to notice of or
to vote at a meeting of stockholders shall apply to any adjournment of the
meeting; provided, however, that the Board of Directors may fix a new record
date for the adjourned meeting.
2.13 Proxies.
-------
Each stockholder entitled to vote at a meeting of stockholders or to
express consent or dissent to corporate action in writing without a meeting may
authorize another person or persons to act for such stockholder by a written
proxy, signed by the stockholder and filed with the secretary of the
corporation, but no such proxy shall be voted or acted upon after three (3)
years from its date, unless the proxy provides for a longer period. A proxy
shall be deemed signed if the stockholder's name is placed on the proxy (whether
by manual signature, typewriting, telegraphic transmission or otherwise) by the
stockholder or the stockholder's
-4-
<PAGE>
attorney-in-fact. The revocability of a proxy that states on its face that it is
irrevocable shall be governed by the provisions of Section 212(e) of the General
Corporation Law of Delaware.
ARTICLE III
DIRECTORS
---------
3.1 Powers.
------
Subject to the provisions of the General Corporation Law of Delaware
and any limitations in the certificate of incorporation or these Bylaws relating
to action required to be approved by the stockholders or by the outstanding
shares, the business and affairs of the corporation shall be managed and all
corporate powers shall be exercised by or under the direction of the Board of
Directors.
3.2 Number Of Directors.
-------------------
Upon the adoption of these bylaws, the number of directors
constituting the entire Board of Directors shall be 3. Thereafter, this number
may be changed by a resolution of the Board of Directors or of the stockholders,
subject to Section 3.4 of these Bylaws. No reduction of the authorized number
of directors shall have the effect of removing any director before such
director's term of office expires.
3.3 Election, Qualification And Term Of Office Of Directors.
-------------------------------------------------------
Except as provided in Section 3.4 of these Bylaws, directors shall
be elected at each annual meeting of stockholders to hold office until the next
annual meeting. Directors need not be stockholders unless so required by the
certificate of incorporation or these Bylaws, wherein other qualifications for
directors may be prescribed. Each director, including a director elected to fill
a vacancy, shall hold office until his or her successor is elected and qualified
or until his or her earlier resignation or removal.
Elections of directors need not be by written ballot.
3.4 Resignation And Vacancies.
-------------------------
Any director may resign at any time upon written notice to the
attention of the Secretary of the corporation. When one or more directors so
resigns and the resignation is effective at a future date, a majority of the
directors then in office, including those who have so resigned, shall have power
to fill such vacancy or vacancies, the vote thereon to take effect when such
resignation or resignations shall become effective, and each director so chosen
shall hold office as provided in this section in the filling of other vacancies.
Unless otherwise provided in the certificate of incorporation or
these Bylaws:
(a) Vacancies and newly created directorships resulting from any
increase in the authorized number of directors elected by all of the
stockholders having the right to vote as a
-5-
<PAGE>
single class may be filled by a majority of the directors then in office,
although less than a quorum, or by a sole remaining director.
(b) Whenever the holders of any class or classes of stock or series
thereof are entitled to elect one or more directors by the provisions of the
certificate of incorporation, vacancies and newly created directorships of such
class or classes or series may be filled by a majority of the directors elected
by such class or classes or series thereof then in office, or by a sole
remaining director so elected.
If at any time, by reason of death or resignation or other cause,
the corporation should have no directors in office, then any officer or any
stockholder or an executor, administrator, trustee or guardian of a stockholder,
or other fiduciary entrusted with like responsibility for the person or estate
of a stockholder, may call a special meeting of stockholders in accordance with
the provisions of the certificate of incorporation or these Bylaws, or may apply
to the Court of Chancery for a decree summarily ordering an election as provided
in Section 211 of the General Corporation Law of Delaware.
If, at the time of filling any vacancy or any newly created
directorship, the directors then in office constitute less than a majority of
the whole board (as constituted immediately prior to any such increase), then
the Court of Chancery may, upon application of any stockholder or stockholders
holding at least ten (10) percent of the total number of the shares at the time
outstanding having the right to vote for such directors, summarily order an
election to be held to fill any such vacancies or newly created directorships,
or to replace the directors chosen by the directors then in office as aforesaid,
which election shall be governed by the provisions of Section 211 of the General
Corporation Law of Delaware as far as applicable.
3.5 Place Of Meetings; Meetings By Telephone.
----------------------------------------
The Board of Directors of the corporation may hold meetings, both
regular and special, either within or outside the State of Delaware.
Unless otherwise restricted by the certificate of incorporation or
these Bylaws, members of the Board of Directors, or any committee designated by
the Board of Directors, may participate in a meeting of the Board of Directors,
or any committee, by means of conference telephone or similar communications
equipment by means of which all persons participating in the meeting can hear
each other, and such participation in a meeting shall constitute presence in
person at the meeting.
3.6 Regular Meetings.
----------------
Regular meetings of the Board of Directors may be held without
notice at such time and at such place as shall from time to time be determined
by the board.
-6-
<PAGE>
3.7 Special Meetings; Notice.
------------------------
Special meetings of the Board of Directors for any purpose or
purposes may be called at any time by the chairman of the board, the president,
any vice president, the secretary or any two directors.
Notice of the time and place of special meetings shall be delivered
personally or by telephone to each director or sent by first-class mail or
telegram, charges prepaid, addressed to each director at that director's address
as it is shown on the records of the corporation. If the notice is mailed, it
shall be deposited in the United States mail at least four (4) days before the
time of the holding of the meeting. If the notice is delivered personally or by
telephone or by telegram, it shall be delivered personally or by telephone or to
the telegraph company at least forty-eight (48) hours before the time of the
holding of the meeting. Any oral notice given personally or by telephone may be
communicated either to the director or to a person at the office of the director
who the person giving the notice has reason to believe will promptly communicate
it to the director. The notice need not specify the purpose or the place of the
meeting, if the meeting is to be held at the principal executive office of the
corporation.
3.8 Quorum.
------
At all meetings of the Board of Directors, a majority of the
authorized number of directors shall constitute a quorum for the transaction of
business and the act of a majority of the directors present at any meeting at
which there is a quorum shall be the act of the Board of Directors, except as
may be otherwise specifically provided by statute or by the certificate of
incorporation. If a quorum is not present at any meeting of the Board of
Directors, then the directors present thereat may adjourn the meeting from time
to time, without notice other than announcement at the meeting, until a quorum
is present.
A meeting at which a quorum is initially present may continue to
transact business notwithstanding the withdrawal of directors, if any action
taken is approved by at least a majority of the required quorum for that
meeting.
3.9 Waiver Of Notice.
----------------
Whenever notice is required to be given under any provision of the
General Corporation Law of Delaware or of the certificate of incorporation or
these Bylaws, a written waiver thereof, signed by the person entitled to notice,
whether before or after the time stated therein, shall be deemed equivalent to
notice. Attendance of a person at a meeting shall constitute a waiver of notice
of such meeting, except when the person attends a meeting for the express
purpose of objecting, at the beginning of the meeting, to the transaction of any
business because the meeting is not lawfully called or convened. Neither the
business to be transacted at, nor the purpose of, any regular or special meeting
of the directors, or members of a committee of directors, need be specified in
any written waiver of notice unless so required by the certificate of
incorporation or these Bylaws.
-7-
<PAGE>
3.10 Board Action By Written Consent Without A Meeting.
-------------------------------------------------
Unless otherwise restricted by the certificate of incorporation or
these Bylaws, any action required or permitted to be taken at any meeting of the
Board of Directors, or of any committee thereof, may be taken without a meeting
if all members of the board or committee, as the case may be, consent thereto in
writing and the writing or writings are filed with the minutes of proceedings of
the board or committee. Written consents representing actions taken by the
board or committee may be executed by telex, telecopy or other facsimile
transmission, and such facsimile shall be valid and binding to the same extent
as if it were an original.
3.11 Fees And Compensation Of Directors.
----------------------------------
Unless otherwise restricted by the certificate of incorporation or
these Bylaws, the Board of Directors shall have the authority to fix the
compensation of directors. No such compensation shall preclude any director
from serving the corporation in any other capacity and receiving compensation
therefor.
3.12 Approval Of Loans To Officers.
-----------------------------
The corporation may lend money to, or guarantee any obligation of,
or otherwise assist any officer or other employee of the corporation or of its
subsidiary, including any officer or employee who is a director of the
corporation or its subsidiary, whenever, in the judgment of the directors, such
loan, guaranty or assistance may reasonably be expected to benefit the
corporation. The loan, guaranty or other assistance may be with or without
interest and may be unsecured, or secured in such manner as the Board of
Directors shall approve, including, without limitation, a pledge of shares of
stock of the corporation. Nothing in this section contained shall be deemed to
deny, limit or restrict the powers of guaranty or warranty of the corporation at
common law or under any statute.
3.13 Removal Of Directors.
--------------------
Unless otherwise restricted by statute, by the certificate of
incorporation or by these Bylaws, any director or the entire Board of Directors
may be removed, with or without cause, by the holders of a majority of the
shares then entitled to vote at an election of directors; provided, however,
that if the stockholders of the corporation are entitled to cumulative voting,
if less than the entire Board of Directors is to be removed, no director may be
removed without cause if the votes cast against his removal would be sufficient
to elect him if then cumulatively voted at an election of the entire Board of
Directors.
No reduction of the authorized number of directors shall have the
effect of removing any director prior to the expiration of such director's term
of office.
3.14 Chairman Of The Board Of Directors.
----------------------------------
The corporation may also have, at the discretion of the Board of
Directors, a chairman of the Board of Directors who shall not be considered an
officer of the corporation.
-8-
<PAGE>
ARTICLE IV
COMMITTEES
----------
4.1 Committees Of Directors.
-----------------------
The Board of Directors may designate one or more committees, each
committee to consist of one or more of the directors of the corporation. The
Board may designate 1 or more directors as alternate members of any committee,
who may replace any absent or disqualified member at any meeting of the
committee. In the absence or disqualification of a member of a committee, the
member or members present at any meeting and not disqualified from voting,
whether or not such member or members constitute a quorum, may unanimously
appoint another member of the Board of Directors to act at the meeting in the
place of any such absent or disqualified member. Any such committee, to the
extent provided in the resolution of the Board of Directors, or in these Bylaws,
shall have and may exercise all the powers and authority of the Board of
Directors in the management of the business and affairs of the corporation, and
may authorize the seal of the corporation to be affixed to all papers which may
require it; but no such committee shall have the power or authority in reference
to the following matters: (i) approving or adopting, or recommending to the
stockholders, any action or matter expressly required by this chapter to be
submitted to stockholders for approval or (ii) adopting, amending or repealing
any Bylaw of the corporation.
4.2 Committee Minutes.
-----------------
Each committee shall keep regular minutes of its meetings and report
the same to the Board of Directors when required.
4.3 Meetings And Action Of Committees.
---------------------------------
Meetings and actions of committees shall be governed by, and held
and taken in accordance with, the provisions of Section 3.5 (place of meetings
and meetings by telephone), Section 3.6 (regular meetings), Section 3.7 (special
meetings and notice), Section 3.8 (quorum), Section 3.9 (waiver of notice), and
Section 3.10 (action without a meeting) of these Bylaws, with such changes in
the context of such provisions as are necessary to substitute the committee and
its members for the Board of Directors and its members; provided, however, that
the time of regular meetings of committees may be determined either by
resolution of the Board of Directors or by resolution of the committee, that
special meetings of committees may also be called by resolution of the Board of
Directors and that notice of special meetings of committees shall also be given
to all alternate members, who shall have the right to attend all meetings of the
committee. The Board of Directors may adopt rules for the government of any
committee not inconsistent with the provisions of these Bylaws.
-9-
<PAGE>
ARTICLE V
OFFICERS
--------
5.1 Officers.
--------
The officers of the corporation shall be a president and chief
executive officer, a secretary, and a chief financial officer. The corporation
may also have, at the discretion of the Board of Directors, one or more vice
presidents, one or more assistant secretaries, one or more assistant treasurers,
and any such other officers as may be appointed in accordance with the
provisions of Section 5.3 of these Bylaws. Any number of offices may be held by
the same person.
5.2 Appointment Of Officers.
-----------------------
The officers of the corporation, except such officers as may be
appointed in accordance with the provisions of Sections 5.3 or 5.5 of these
Bylaws, shall be appointed by the Board of Directors, subject to the rights, if
any, of an officer under any contract of employment.
5.3 Subordinate Officers.
--------------------
The Board of Directors may appoint, or empower the chief executive
officer or the president to appoint, such other officers and agents as the
business of the corporation may require, each of whom shall hold office for such
period, have such authority, and perform such duties as are provided in these
Bylaws or as the Board of Directors may from time to time determine.
5.4 Removal And Resignation Of Officers.
-----------------------------------
Subject to the rights, if any, of an officer under any contract of
employment, any officer may be removed, either with or without cause, by an
affirmative vote of the majority of the Board of Directors at any regular or
special meeting of the board or, except in the case of an officer chosen by the
Board of Directors, by any officer upon whom such power of removal may be
conferred by the Board of Directors.
Any officer may resign at any time by giving written notice to the
attention of the Secretary of the corporation. Any resignation shall take
effect at the date of the receipt of that notice or at any later time specified
in that notice; and, unless otherwise specified in that notice, the acceptance
of the resignation shall not be necessary to make it effective. Any resignation
is without prejudice to the rights, if any, of the corporation under any
contract to which the officer is a party.
5.5 Vacancies In Offices.
--------------------
Any vacancy occurring in any office of the corporation shall be
filled by the Board of Directors.
-10-
<PAGE>
5.6 Chief Executive Officer.
-----------------------
Subject to such supervisory powers, if any, as may be given by the
Board of Directors to the chairman of the board, if any, the chief executive
officer of the corporation (if such an officer is appointed) shall, subject to
the control of the Board of Directors, have general supervision, direction, and
control of the business and the officers of the corporation. He or she shall
preside at all meetings of the stockholders and, in the absence or nonexistence
of a chairman of the board, at all meetings of the Board of Directors and shall
have the general powers and duties of management usually vested in the office of
chief executive officer of a corporation and shall have such other powers and
duties as may be prescribed by the Board of Directors or these bylaws.
5.7 President.
---------
Subject to such supervisory powers, if any, as may be given by the
Board of Directors to the chairman of the board (if any) or the chief executive
officer, the president shall have general supervision, direction, and control of
the business and other officers of the corporation. He or she shall have the
general powers and duties of management usually vested in the office of
president of a corporation and such other powers and duties as may be prescribed
by the Board of Directors or these Bylaws.
5.8 Vice Presidents.
---------------
In the absence or disability of the chief executive officer and
president, the vice presidents, if any, in order of their rank as fixed by the
Board of Directors or, if not ranked, a vice president designated by the Board
of Directors, shall perform all the duties of the president and when so acting
shall have all the powers of, and be subject to all the restrictions upon, the
president. The vice presidents shall have such other powers and perform such
other duties as from time to time may be prescribed for them respectively by the
Board of Directors, these Bylaws, the president or the chairman of the board.
5.9 Secretary.
---------
The secretary shall keep or cause to be kept, at the principal
executive office of the corporation or such other place as the Board of
Directors may direct, a book of minutes of all meetings and actions of
directors, committees of directors, and stockholders. The minutes shall show
the time and place of each meeting, the names of those present at directors'
meetings or committee meetings, the number of shares present or represented at
stockholders' meetings, and the proceedings thereof.
The secretary shall keep, or cause to be kept, at the principal
executive office of the corporation or at the office of the corporation's
transfer agent or registrar, as determined by resolution of the Board of
Directors, a share register, or a duplicate share register, showing the names of
all stockholders and their addresses, the number and classes of shares held by
each, the number and date of certificates evidencing such shares, and the number
and date of cancellation of every certificate surrendered for cancellation.
-11-
<PAGE>
The secretary shall give, or cause to be given, notice of all
meetings of the stockholders and of the Board of Directors required to be given
by law or by these Bylaws. He or she shall keep the seal of the corporation, if
one be adopted, in safe custody and shall have such other powers and perform
such other duties as may be prescribed by the Board of Directors or by these
Bylaws.
5.10 Chief Financial Officer.
-----------------------
The chief financial officer shall keep and maintain, or cause to be
kept and maintained, adequate and correct books and records of accounts of the
properties and business transactions of the corporation, including accounts of
its assets, liabilities, receipts, disbursements, gains, losses, capital
retained earnings, and shares. The books of account shall at all reasonable
times be open to inspection by any director.
The chief financial officer shall deposit all moneys and other
valuables in the name and to the credit of the corporation with such
depositories as may be designated by the Board of Directors. He or she shall
disburse the funds of the corporation as may be ordered by the Board of
Directors, shall render to the president, the chief executive officer, or the
directors, upon request, an account of all his or her transactions as chief
financial officer and of the financial condition of the corporation, and shall
have other powers and perform such other duties as may be prescribed by the
Board of Directors or the bylaws.
5.11 Representation Of Shares Of Other Corporations.
----------------------------------------------
The chairman of the board, the chief executive officer, the
president, any vice president, the chief financial officer, the secretary or
assistant secretary of this corporation, or any other person authorized by the
Board of Directors or the chief executive officer or the president or a vice
president, is authorized to vote, represent, and exercise on behalf of this
corporation all rights incident to any and all shares of any other corporation
or corporations standing in the name of this corporation. The authority granted
herein may be exercised either by such person directly or by any other person
authorized to do so by proxy or power of attorney duly executed by the person
having such authority.
5.12 Authority And Duties Of Officers.
--------------------------------
In addition to the foregoing authority and duties, all officers of
the corporation shall respectively have such authority and perform such duties
in the management of the business of the corporation as may be designated from
time to time by the Board of Directors or the stockholders.
-12-
<PAGE>
ARTICLE VI
INDEMNIFICATION OF DIRECTORS, OFFICERS, EMPLOYEES, AND OTHER AGENTS
-------------------------------------------------------------------
6.1 Indemnification Of Directors And Officers.
-----------------------------------------
The corporation shall, to the maximum extent and in the manner
permitted by the General Corporation Law of Delaware, indemnify each of its
directors and officers against expenses (including attorneys' fees), judgments,
fines, settlements and other amounts actually and reasonably incurred in
connection with any proceeding, arising by reason of the fact that such person
is or was an agent of the corporation. For purposes of this Section 6.1, a
"director" or "officer" of the corporation includes any person (a) who is or was
a director or officer of the corporation, (b) who is or was serving at the
request of the corporation as a director or officer of another corporation,
partnership, joint venture, trust or other enterprise, or (c) who was a director
or officer of a corporation which was a predecessor corporation of the
corporation or of another enterprise at the request of such predecessor
corporation.
6.2 Indemnification Of Others.
-------------------------
The corporation shall have the power, to the maximum extent and in
the manner permitted by the General Corporation Law of Delaware, to indemnify
each of its employees and agents (other than directors and officers) against
expenses (including attorneys' fees), judgments, fines, settlements and other
amounts actually and reasonably incurred in connection with any proceeding,
arising by reason of the fact that such person is or was an agent of the
corporation. For purposes of this Section 6.2, an "employee" or "agent" of the
corporation (other than a director or officer) includes any person (a) who is or
was an employee or agent of the corporation, (b) who is or was serving at the
request of the corporation as an employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, or (c) who was an
employee or agent of a corporation which was a predecessor corporation of the
corporation or of another enterprise at the request of such predecessor
corporation.
6.3 Payment Of Expenses In Advance.
------------------------------
Expenses incurred in defending any action or proceeding for which
indemnification is required pursuant to Section 6.1 or for which indemnification
is permitted pursuant to Section 6.2 following authorization thereof by the
Board of Directors shall be paid by the corporation in advance of the final
disposition of such action or proceeding upon receipt of an undertaking by or on
behalf of the indemnified party to repay such amount if it shall ultimately be
determined that the indemnified party is not entitled to be indemnified as
authorized in this Article VI.
6.4 Indemnity Not Exclusive.
-----------------------
The indemnification provided by this Article VI shall not be deemed
exclusive of any other rights to which those seeking indemnification may be
entitled under any bylaw,
-13-
<PAGE>
agreement, vote of shareholders or disinterested directors or otherwise, both as
to action in an official capacity and as to action in another capacity while
holding such office, to the extent that such additional rights to
indemnification are authorized in the certificate of incorporation
6.5 Insurance.
---------
The corporation may purchase and maintain insurance on behalf of any
person who is or was a director, officer, employee or agent of the corporation,
or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or
other enterprise against any liability asserted against him or her and incurred
by him or her in any such capacity, or arising out of his or her status as such,
whether or not the corporation would have the power to indemnify him or her
against such liability under the provisions of the General Corporation Law of
Delaware.
6.6 Conflicts.
---------
No indemnification or advance shall be made under this Article VI,
except where such indemnification or advance is mandated by law or the order,
judgment or decree of any court of competent jurisdiction, in any circumstance
where it appears:
(a) That it would be inconsistent with a provision of the
certificate of incorporation, these Bylaws, a resolution of the stockholders or
an agreement in effect at the time of the accrual of the alleged cause of the
action asserted in the proceeding in which the expenses were incurred or other
amounts were paid, which prohibits or otherwise limits indemnification; or
(b) That it would be inconsistent with any condition expressly
imposed by a court in approving a settlement.
ARTICLE VII
RECORDS AND REPORTS
-------------------
7.1 Maintenance And Inspection Of Records.
-------------------------------------
The corporation shall, either at its principal executive offices or
at such place or places as designated by the Board of Directors, keep a record
of its stockholders listing their names and addresses and the number and class
of shares held by each stockholder, a copy of these Bylaws as amended to date,
accounting books, and other records.
Any stockholder of record, in person or by attorney or other agent,
shall, upon written demand under oath stating the purpose thereof, have the
right during the usual hours for business to inspect for any proper purpose the
corporation's stock ledger, a list of its stockholders, and its other books and
records and to make copies or extracts therefrom. A proper purpose shall mean a
purpose reasonably related to such person's interest as a stockholder. In every
instance where an attorney or other agent is the person who seeks the right to
inspection,
-14-
<PAGE>
the demand under oath shall be accompanied by a power of attorney or such other
writing that authorizes the attorney or other agent to so act on behalf of the
stockholder. The demand under oath shall be directed to the corporation at its
registered office in Delaware or at its principal place of business.
7.2 Inspection By Directors.
-----------------------
Any director shall have the right to examine the corporation's stock
ledger, a list of its stockholders, and its other books and records for a
purpose reasonably related to his or her position as a director. The Court of
Chancery is hereby vested with the exclusive jurisdiction to determine whether a
director is entitled to the inspection sought. The Court may summarily order
the corporation to permit the director to inspect any and all books and records,
the stock ledger, and the stock list and to make copies or extracts therefrom.
The Court may, in its discretion, prescribe any limitations or conditions with
reference to the inspection, or award such other and further relief as the Court
may deem just and proper.
7.3 Annual Statement To Stockholders.
--------------------------------
The Board of Directors shall present at each annual meeting, and at
any special meeting of the stockholders when called for by vote of the
stockholders, a full and clear statement of the business and condition of the
corporation.
ARTICLE VIII
GENERAL MATTERS
---------------
8.1 Checks.
------
From time to time, the Board of Directors shall determine by
resolution which person or persons may sign or endorse all checks, drafts, other
orders for payment of money, notes or other evidences of indebtedness that are
issued in the name of or payable to the corporation, and only the persons so
authorized shall sign or endorse those instruments.
8.2 Execution Of Corporate Contracts And Instruments.
------------------------------------------------
The Board of Directors, except as otherwise provided in these
Bylaws, may authorize any officer or officers, or agent or agents, to enter into
any contract or execute any instrument in the name of and on behalf of the
corporation; such authority may be general or confined to specific instances.
Unless so authorized or ratified by the Board of Directors or within the agency
power of an officer, no officer, agent or employee shall have any power or
authority to bind the corporation by any contract or engagement or to pledge its
credit or to render it liable for any purpose or for any amount.
8.3 Stock Certificates; Partly Paid Shares.
--------------------------------------
The shares of a corporation shall be represented by certificates,
provided that the Board of Directors of the corporation may provide by
resolution or resolutions that some or all of
-15-
<PAGE>
any or all classes or series of its stock shall be uncertificated shares. Any
such resolution shall not apply to shares represented by a certificate until
such certificate is surrendered to the corporation. Notwithstanding the adoption
of such a resolution by the Board of Directors, every holder of stock
represented by certificates and upon request every holder of uncertificated
shares shall be entitled to have a certificate signed by, or in the name of the
corporation by the chairman or vice-chairman of the Board of Directors, or the
president or vice-president, and by the chief financial officer or an assistant
treasurer, or the secretary or an assistant secretary of such corporation
representing the number of shares registered in certificate form. Any or all of
the signatures on the certificate may be a facsimile. In case any officer,
transfer agent or registrar who has signed or whose facsimile signature has been
placed upon a certificate has ceased to be such officer, transfer agent or
registrar before such certificate is issued, it may be issued by the corporation
with the same effect as if he or she were such officer, transfer agent or
registrar at the date of issue.
The corporation may issue the whole or any part of its shares as
partly paid and subject to call for the remainder of the consideration to be
paid therefor. Upon the face or back of each stock certificate issued to
represent any such partly paid shares, upon the books and records of the
corporation in the case of uncertificated partly paid shares, the total amount
of the consideration to be paid therefor and the amount paid thereon shall be
stated. Upon the declaration of any dividend on fully paid shares, the
corporation shall declare a dividend upon partly paid shares of the same class,
but only upon the basis of the percentage of the consideration actually paid
thereon.
8.4 Special Designation On Certificates.
-----------------------------------
If the corporation is authorized to issue more than one class of
stock or more than one series of any class, then the powers, the designations,
the preferences, and the relative, participating, optional or other special
rights of each class of stock or series thereof and the qualifications,
limitations or restrictions of such preferences and/or rights shall be set forth
in full or summarized on the face or back of the certificate that the
corporation shall issue to represent such class or series of stock; provided,
however, that, except as otherwise provided in Section 202 of the General
Corporation Law of Delaware, in lieu of the foregoing requirements there may be
set forth on the face or back of the certificate that the corporation shall
issue to represent such class or series of stock a statement that the
corporation will furnish without charge to each stockholder who so requests the
powers, the designations, the preferences, and the relative, participating,
optional or other special rights of each class of stock or series thereof and
the qualifications, limitations or restrictions of such preferences and/or
rights.
8.5 Lost Certificates.
-----------------
Except as provided in this Section 8.5, no new certificates for
shares shall be issued to replace a previously issued certificate unless the
latter is surrendered to the corporation and cancelled at the same time. The
corporation may issue a new certificate of stock or uncertificated shares in the
place of any certificate previously issued by it, alleged to have been lost,
stolen or destroyed, and the corporation may require the owner of the lost,
stolen or
-16-
<PAGE>
destroyed certificate, or the owner's legal representative, to give the
corporation a bond sufficient to indemnify it against any claim that may be made
against it on account of the alleged loss, theft or destruction of any such
certificate or the issuance of such new certificate or uncertificated shares.
8.6 Construction; Definitions.
-------------------------
Unless the context requires otherwise, the general provisions, rules
of construction, and definitions in the Delaware General Corporation Law shall
govern the construction of these Bylaws. Without limiting the generality of
this provision, the singular number includes the plural, the plural number
includes the singular, and the term "person" includes both a corporation and a
natural person.
8.7 Dividends.
---------
The directors of the corporation, subject to any restrictions
contained in (a) the General Corporation Law of Delaware or (b) the certificate
of incorporation, may declare and pay dividends upon the shares of its capital
stock. Dividends may be paid in cash, in property, or in shares of the
corporation's capital stock.
The directors of the corporation may set apart out of any of the
funds of the corporation available for dividends a reserve or reserves for any
proper purpose and may abolish any such reserve. Such purposes shall include but
not be limited to equalizing dividends, repairing or maintaining any property of
the corporation, and meeting contingencies.
8.8 Fiscal Year.
-----------
The fiscal year of the corporation shall be fixed by resolution of
the Board of Directors and may be changed by the Board of Directors.
8.9 Seal.
----
The corporation may adopt a corporate seal, which may be altered at
pleasure, and may use the same by causing it or a facsimile thereof, to be
impressed or affixed or in any other manner reproduced.
8.10 Transfer Of Stock.
-----------------
Upon surrender to the corporation or the transfer agent of the
corporation of a certificate for shares duly endorsed or accompanied by proper
evidence of succession, assignation or authority to transfer, it shall be the
duty of the corporation to issue a new certificate to the person entitled
thereto, cancel the old certificate, and record the transaction in its books.
-17-
<PAGE>
8.11 Stock Transfer Agreements.
-------------------------
The corporation shall have power to enter into and perform any
agreement with any number of stockholders of any one or more classes of stock of
the corporation to restrict the transfer of shares of stock of the corporation
of any one or more classes owned by such stockholders in any manner not
prohibited by the General Corporation Law of Delaware.
8.12 Registered Stockholders.
-----------------------
The corporation shall be entitled to recognize the exclusive right
of a person registered on its books as the owner of shares to receive dividends
and to vote as such owner, shall be entitled to hold liable for calls and
assessments the person registered on its books as the owner of shares, and shall
not be bound to recognize any equitable or other claim to or interest in such
share or shares on the part of another person, whether or not it shall have
express or other notice thereof, except as otherwise provided by the laws of
Delaware.
ARTICLE IX
AMENDMENTS
----------
The Bylaws of the corporation may be adopted, amended or repealed by
the stockholders entitled to vote; provided, however, that the corporation may,
in its certificate of incorporation, confer the power to adopt, amend or repeal
Bylaws upon the directors. The fact that such power has been so conferred upon
the directors shall not divest the stockholders of the power, nor limit their
power to adopt, amend or repeal Bylaws.
-18-
<PAGE>
CERTIFICATE OF ADOPTION OF BYLAWS
OF
TENDEX, INC.
ADOPTION BY INCORPORATOR
------------------------
The undersigned person appointed in the certificate of incorporation to act
as the Incorporator of Tendex, inc. hereby adopts the foregoing bylaws as the
Bylaws of the corporation.
Executed this _____ day of ____________________.
/s/ Jeffrey Y. Suto
____________________________________________
Jeffrey Y. Suto, Incorporator
CERTIFICATE BY SECRETARY OF ADOPTION BY INCORPORATOR
----------------------------------------------------
The undersigned hereby certifies that the undersigned is the duly elected,
qualified, and acting Secretary of Tendex, Inc., and that the foregoing Bylaws
were adopted as the Bylaws of the corporation on December,___ 1999, by the
person appointed in the certificate of incorporation to act as the Incorporator
of the corporation.
Executed this _____ day of December, 1999.
____________________________________________
David Ricker, Secretary
<PAGE>
EXHIBIT K
Amended and Restated Certificate of Incorporation
<PAGE>
AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
TENDEX, INC.
The undersigned, Andrew Carragher and David Ricker, hereby certify that:
1. They are the duly elected and acting President and Secretary,
respectively, of Tendex, Inc., a Delaware corporation.
2. The Certificate of Incorporation of this corporation was originally
filed with the Secretary of State of Delaware on December 9, 1999.
3. The Certificate of Incorporation of this corporation shall be amended
and restated to read in full as follows:
ARTICLE I
"The name of this corporation is Tendex, Inc. (the "Corporation").
-----------
ARTICLE II
The address of the Corporation's registered office in the State of Delaware
is 1013 Centre Road, City of Wilmington, County of New Castle. The name of its
registered agent at such address is Corporation Service Company.
ARTICLE III
The purpose of the Corporation is to engage in any lawful act or activity
for which corporations may be organized under the Delaware General Corporation
Law.
ARTICLE IV
(A) Classes of Stock. The Corporation is authorized to issue two classes
----------------
of stock to be designated, respectively, "Common Stock" and "Preferred Stock."
------------ ---------------
The total number of shares which the Corporation is authorized to issue is
Fifteen Million (15,000,000) shares, each with a par value of $0.0001 per share.
Ten Million (10,000,000) shares shall be Common Stock and Five Million
(5,000,000) shares shall be Preferred Stock.
(B) Rights, Preferences and Restrictions of Preferred Stock. The Preferred
-------------------------------------------------------
Stock authorized by this Amended and Restated Certificate of Incorporation may
be issued from time to time in one or more series. The first series of Preferred
Stock shall be designated "Series A Preferred Stock" and shall consist of five
------------------------
million (5,000,000) shares. The rights, preferences,
<PAGE>
privileges, and restrictions granted to and imposed on the Series A Preferred
Stock are as set forth below in this Article IV(B).
1. Dividend Provisions. The holders of shares of Series A Preferred
-------------------
Stock shall be entitled to receive dividends, out of any assets legally
available therefor, prior and in preference to any declaration or payment of any
dividend (payable other than in Common Stock or other securities and rights
convertible into or entitling the holder thereof to receive, directly or
indirectly, additional shares of Common Stock of the Corporation) on the Common
Stock of the Corporation, at the rate of [8% of Purchase Price] per share (as
adjusted for stock splits, stock dividends, reclassification and the like) per
annum on each outstanding share of Series A Preferred Stock, payable quarterly
when, as and if declared by the Board of Directors. Such dividends shall not be
cumulative.
2. Liquidation.
-----------
(a) Preference. In the event of any liquidation, dissolution or
----------
winding up of the Corporation, either voluntary or involuntary, the holders of
the Series A Preferred Stock shall be entitled to receive, prior and in
preference to any distribution of any of the assets of the Corporation to the
holders of Common Stock by reason of their ownership thereof, an amount per
share equal to [the Purchase Price as determined by valuation] per share (as
adjusted for stock splits, stock dividends, reclassification and the like) for
each share of Series A Preferred Stock then held by them, plus declared but
unpaid dividends. If, upon the occurrence of such event, the assets and funds
thus distributed among the holders of the Series A Preferred Stock shall be
insufficient to permit the payment to such holders of the full aforesaid
preferential amounts, the entire assets and funds of the Corporation legally
available for distribution shall be distributed ratably among the holders of the
Series A Preferred Stock in proportion to the preferential amount each such
holder is otherwise entitled to receive.
(b) Remaining Assets. Upon the completion of the distribution
----------------
required by Section 2(a) above, if assets remain in the Corporation, the holders
of the Common Stock of the Corporation shall receive all of the remaining assets
of the Corporation.
(c) Certain Acquisitions.
--------------------
(i) Deemed Liquidation. For purposes of this Section 2, a
------------------
liquidation, dissolution or winding up of the Corporation shall be deemed to
occur if the Corporation shall sell, convey, or otherwise dispose of all or
substantially all of its property or business or merge into or consolidate with
any other corporation (other than a wholly-owned subsidiary corporation) or
effect any other transaction or series of related transactions in which more
than fifty percent (50%) of the voting power of the Corporation is disposed of,
provided that this Section 2(c)(i) shall not apply to a merger effected
- --------
exclusively for the purpose of changing the domicile of the Corporation.
(ii) Valuation of Consideration. In the event of a deemed
--------------------------
liquidation as described in Section 2(c)(i) above, if the consideration received
by the Corporation
-2-
<PAGE>
is other than cash, its value will be deemed its fair market value. Any
securities shall be valued as follows:
(A) Securities not subject to investment letter or
other similar restrictions on free marketability:
(1) If traded on a securities exchange or The
Nasdaq Stock Market, the value shall be deemed to be the average of the closing
prices of the securities on such exchange over the thirty-day period ending
three (3) days prior to the closing;
(2) If actively traded over-the-counter, the value
shall be deemed to be the average of the closing bid or sale prices (whichever
is applicable) over the thirty-day period ending three (3) days prior to the
closing; and
(3) If there is no active public market, the value
shall be the fair market value thereof, as mutually determined by the
Corporation and the holders of at least a majority of the voting power of all
then outstanding shares of Preferred Stock.
(B) The method of valuation of securities subject to
investment letter or other restrictions on free marketability (other than
restrictions arising solely by virtue of a stockholder's status as an affiliate
or former affiliate) shall be to make an appropriate discount from the market
value determined as above in Section 2(c)(ii)(A) to reflect the approximate fair
market value thereof, as mutually determined by the Corporation and the holders
of at least a majority of the voting power of all then outstanding shares of
Preferred Stock.
(iii) Notice of Transaction. The Corporation shall give
---------------------
each holder of record of Series A Preferred Stock written notice of such
impending transaction not later than ten (10) business days prior to the
stockholders' meeting called to approve such transaction, or ten (10) business
days prior to the closing of such transaction, whichever is earlier, and shall
also notify such holders in writing of the final approval of such transaction.
The first of such notices shall describe the material terms and conditions of
the impending transaction and the provisions of this Section 2, and the
Corporation shall thereafter give such holders prompt notice of any material
changes. The transaction shall in no event take place sooner than ten (10)
business days after the Corporation has given the first notice provided for
herein or sooner than ten (10) business days after the Corporation has given
notice of any material changes provided for herein; provided, however, that such
periods may be shortened upon the written consent of the holders of Preferred
Stock that are entitled to such notice rights or similar notice rights and that
represent at least a majority of the voting power of all then outstanding shares
of such Preferred Stock.
(iv) Effect of Noncompliance. In the event the
-----------------------
requirements of this Section 2(c) are not complied with, the Corporation shall
forthwith either cause the closing of the transaction to be postponed until such
requirements have been complied with, or cancel such transaction, in which event
the rights, preferences and privileges of the holders of the
-3-
<PAGE>
Series A Preferred Stock shall revert to and be the same as such rights,
preferences and privileges existing immediately prior to the date of the first
notice referred to in Section 2(c)(iii) hereof.
3. Redemption. The Preferred Stock is not redeemable.
----------
4. Conversion. The holders of the Series A Preferred Stock shall
----------
have conversion rights as follows (the "Conversion Rights"):
-----------------
(a) Right to Convert. Subject to Section 4(c), each share of
----------------
Series A Preferred Stock shall be convertible, at the option of the holder
thereof, at any time after the date of issuance of such share, at the office of
the Corporation or any transfer agent for such stock, into such number of fully
paid and nonassessable shares of Common Stock as is determined by dividing [the
Purchase Price] by the Conversion Price applicable to such share, determined as
hereafter provided, in effect on the date the certificate is surrendered for
conversion. The initial Conversion Price per share of Series A Preferred Stock
shall be [the Purchase Price]. Such initial Conversion Price shall be subject to
adjustment as set forth in Section 4(d).
(b) Automatic Conversion. Each share of Series A Preferred
--------------------
Stock shall automatically be converted into shares of Common Stock at the
Conversion Price at the time in effect for such share immediately upon the
earlier of (i) except as provided below in Section 4(c), the Corporation's sale
of its Common Stock in a firm commitment underwritten public offering pursuant
to a registration statement under the Securities Act of 1933, as amended (the
Securities Act"), the public offering price of which is not less than [3X the
- --------------
Purchase Price] per share (appropriately adjusted for any stock split, dividend,
combination or other recapitalization) and which results in aggregate cash
proceeds to the Corporation of $15,000,000 (net of underwriting discounts and
commissions) or (ii) the date specified by written consent or agreement of the
holders of a majority of the then outstanding shares of Series A Preferred
Stock.
(c) Mechanics of Conversion. Before any holder of Series A
-----------------------
Preferred Stock shall be entitled to convert the same into shares of Common
Stock, he shall surrender the certificate or certificates therefor, duly
endorsed, at the office of the Corporation or of any transfer agent for such
series of Preferred Stock, and shall give written notice to the Corporation at
its principal corporate office, of the election to convert the same and shall
state therein the name or names in which the certificate or certificates for
shares of Common Stock are to be issued. The Corporation shall, as soon as
practicable thereafter, issue and deliver at such office to such holder of
Preferred Stock, or to the nominee or nominees of such holder, a certificate or
certificates for the number of shares of Common Stock to which such holder shall
be entitled as aforesaid. Such conversion shall be deemed to have been made
immediately prior to the close of business on the date of such surrender of the
shares of such series of Preferred Stock to be converted, and the person or
persons entitled to receive the shares of Common Stock issuable upon such
conversion shall be treated for all purposes as the record holder or holders of
such shares of Common Stock as of such date. If the conversion is in connection
with an underwritten offering of securities registered pursuant to the
Securities Act the conversion may, at the option of any holder tendering such
Preferred Stock for conversion, be conditioned upon the closing with the
underwriters of the sale of securities pursuant to such offering, in which
-4-
<PAGE>
event the person(s) entitled to receive Common Stock upon conversion of such
Preferred Stock shall not be deemed to have converted such Preferred Stock until
immediately prior to the closing of such sale of securities.
(d) Conversion Price Adjustments of Preferred Stock for Certain
-----------------------------------------------------------
Splits and Combinations. The Conversion Price of the Series A Preferred Stock
- -----------------------
shall be subject to adjustment from time to time as follows:
(i) Stock Splits and Dividends. In the event the
--------------------------
Corporation should at any time or from time to time after the date upon which
any shares of Series A Preferred Stock were first issued (the "Purchase Date"
-------------
with respect to such series) fix a record date for the effectuation of a split
or subdivision of the outstanding shares of Common Stock or the determination of
holders of Common Stock entitled to receive a dividend or other distribution
payable in additional shares of Common Stock or other securities or rights
convertible into, or entitling the holder thereof to receive directly or
indirectly, additional shares of Common Stock (hereinafter referred to as
"Common Stock Equivalents") without payment of any consideration by such holder
------------------------
for the additional shares of Common Stock or the Common Stock Equivalents
(including the additional shares of Common Stock issuable upon conversion or
exercise thereof), then, as of such record date (or the date of such dividend
distribution, split or subdivision if no record date is fixed), the Conversion
Price of the Series A Preferred Stock shall be appropriately decreased so that
the number of shares of Common Stock issuable on conversion of each share of
such series shall be increased in proportion to such increase of the aggregate
of shares of Common Stock outstanding and those issuable with respect to such
Common Stock Equivalents with the number of shares issuable with respect to
Common Stock Equivalents determined from time to time as provided in Section
4(d)(iii) below.
(ii) Reverse Stock Splits. If the number of shares of
--------------------
Common Stock outstanding at any time after the Purchase Date is decreased by a
combination of the outstanding shares of Common Stock, then, following the
record date of such combination, the Conversion Price for the Series A Preferred
Stock shall be appropriately increased so that the number of shares of Common
Stock issuable on conversion of each share of such series shall be decreased in
proportion to such decrease in outstanding shares.
(iii) The following provisions shall apply for purposes of
this Section 4(d):
(A) The aggregate maximum number of shares of Common
Stock deliverable upon conversion or exercise of Common Stock Equivalents
(assuming the satisfaction of any conditions to convertibility or
exercisability, including, without limitation, the passage of time, but without
taking into account potential antidilution adjustments) shall be deemed to have
been issued at the time such Common Stock Equivalents were issued.
(B) In the event of any change in the number of shares
of Common Stock deliverable or in the consideration payable to the Corporation
upon
-5-
<PAGE>
conversion or exercise of such Common Stock Equivalents including, but not
limited to, a change resulting from the antidilution provisions thereof, the
Conversion Price of the Series A Preferred Stock, to the extent in any way
affected by or computed using such Common Stock Equivalents, shall be recomputed
to reflect such change, but no further adjustment shall be made for the actual
issuance of Common Stock or any payment of such consideration upon the exercise
of any such options or rights or the conversion or exchange of such securities.
(C) Upon the termination or expiration of the
convertibility or exercisability of any such Common Stock Equivalents, the
Conversion Price of the Series A Preferred Stock, to the extent in any way
affected by or computed using such Common Stock Equivalents, shall be recomputed
to reflect the issuance of only the number of shares of Common Stock (and Common
Stock Equivalents which remain convertible or exercisable) actually issued upon
the conversion or exercise of such Common Stock Equivalents.
(e) Other Distributions. In the event the Corporation shall declare
-------------------
a distribution payable in securities of other persons, evidences of indebtedness
issued by the Corporation or other persons, assets (excluding cash dividends) or
options or rights not referred to in Section 4(d)(i), then, in each such case
for the purpose of this Section 4(e), the holders of Series A Preferred Stock
shall be entitled to a proportionate share of any such distribution as though
they were the holders of the number of shares of Common Stock of the Corporation
into which their shares of Preferred Stock are convertible as of the record date
fixed for the determination of the holders of Common Stock of the Corporation
entitled to receive such distribution.
(f) Recapitalizations. If at any time or from time to time there
-----------------
shall be a recapitalization of the Common Stock (other than a subdivision,
combination or merger or sale of assets transaction provided for elsewhere in
this Section 4 or Section 2) provision shall be made so that the holders of the
Series A Preferred Stock shall thereafter be entitled to receive upon conversion
of such Preferred Stock the number of shares of stock or other securities or
property of the Corporation or otherwise, to which a holder of Common Stock
deliverable upon conversion would have been entitled on such recapitalization.
In any such case, appropriate adjustment shall be made in the application of the
provisions of this Section 4 with respect to the rights of the holders of such
Preferred Stock after the recapitalization to the end that the provisions of
this Section 4 (including adjustment of the Conversion Price then in effect and
the number of shares purchasable upon conversion of such Preferred Stock) shall
be applicable after that event and be as nearly equivalent as practicable.
(g) No Impairment. The Corporation will not, by amendment of its
-------------
Certificate of Incorporation (except in accordance with Section 6 hereof and
applicable law) or through any reorganization, recapitalization, transfer of
assets, consolidation, merger, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of
any of the terms to be observed or performed hereunder by the Corporation, but
will at all times in good faith assist in the carrying out of all the provisions
of this Section 4 and in the taking of all such action as may be necessary or
appropriate in order to protect the Conversion Rights of the holders of
Preferred Stock against impairment.
-6-
<PAGE>
(h) No Fractional Shares and Certificate as to Adjustments.
------------------------------------------------------
(i) No fractional shares shall be issued upon the
conversion of any share or shares of the Series A Preferred Stock, and the
number of shares of Common Stock to be issued shall be rounded to the nearest
whole share. The number of shares issuable upon such conversion shall be
determined on the basis of the total number of shares of Series A Preferred
Stock the holder is at the time converting into Common Stock and the number of
shares of Common Stock issuable upon such aggregate conversion.
(ii) Upon the occurrence of each adjustment or readjustment
of the Conversion Price of Series A Preferred Stock pursuant to this Section 4,
the Corporation, at its expense, shall promptly compute such adjustment or
readjustment in accordance with the terms hereof and prepare and furnish to each
holder of such Preferred Stock a certificate setting forth such adjustment or
readjustment and showing in detail the facts upon which such adjustment or
readjustment is based. The Corporation shall, upon the written request at any
time of any holder of Series A Preferred Stock, furnish or cause to be furnished
to such holder a like certificate setting forth (A) such adjustment and
readjustment, (B) the Conversion Price for the Series A Preferred Stock at the
time in effect, and (C) the number of shares of Common Stock and the amount, if
any, of other property which at the time would be received upon the conversion
of a share of the Series A Preferred Stock.
(i) Notices of Record Date. In the event of any taking by the
----------------------
Corporation of a record of the holders of any class of securities for the
purpose of determining the holders thereof who are entitled to receive any
dividend (other than a cash dividend) or other distribution, any right to
subscribe for, purchase or otherwise acquire any shares of stock of any class or
any other securities or property, or to receive any other right, the Corporation
shall mail to each holder of Series A Preferred Stock, at least ten (10) days
prior to the date specified therein, a notice specifying the date on which any
such record is to be taken for the purpose of such dividend, distribution or
right, and the amount and character of such dividend, distribution or right.
(j) Reservation of Stock Issuable Upon Conversion. The
---------------------------------------------
Corporation shall at all times reserve and keep available out of its authorized
but unissued shares of Common Stock, solely for the purpose of effecting the
conversion of the shares of the Series A Preferred Stock, such number of its
shares of Common Stock as shall from time to time be sufficient to effect the
conversion of all outstanding shares of such series of Preferred Stock; and if
at any time the number of authorized but unissued shares of Common Stock shall
not be sufficient to effect the conversion of all then outstanding shares of
such series of Preferred Stock, in addition to such other remedies as shall be
available to the holder of such Preferred Stock, the Corporation will take such
corporate action as may, in the opinion of its counsel, be necessary to increase
its authorized but unissued shares of Common Stock to such number of shares as
shall be sufficient for such purposes, including, without limitation, engaging
in best efforts to obtain the requisite stockholder approval of any necessary
amendment to this Certificate of Incorporation.
-7-
<PAGE>
(k) Notices. Any notice required by the provisions of this
-------
Section 4 to be given to the holders of shares of Series A Preferred Stock shall
be deemed given if deposited in the United States mail, postage prepaid, and
addressed to each holder of record at his address appearing on the books of the
Corporation.
5. Voting Rights. The holder of each share of Series A Preferred
-------------
Stock shall have the right to one vote for each share of Common Stock into which
such Preferred Stock could then be converted, and with respect to such vote,
such holder shall have full voting rights and powers equal to the voting rights
and powers of the holders of Common Stock, and shall be entitled,
notwithstanding any provision hereof, to notice of any stockholders' meeting in
accordance with the bylaws of the Corporation, and shall be entitled to vote,
together with holders of Common Stock, with respect to any question upon which
holders of Common Stock have the right to vote. Fractional votes shall not,
however, be permitted and any fractional voting rights available on an as-
converted basis (after aggregating all shares into which shares of Series A
Preferred Stock held by each holder could be converted) shall be rounded to the
nearest whole number (with one-half being rounded upward).
6. Protective Provisions. So long as at least 2,500,000 shares of
---------------------
Preferred Stock are outstanding (as adjusted for stock splits, stock dividends
or recapitalizations), the Corporation shall not without first obtaining the
approval (by vote or written consent, as provided by law) of the holders of at
least a majority of the then outstanding shares of Preferred Stock, voting
together as a class:
(a) effect a transaction described in Section 2(c)(i) above;
(b) alter or change the rights, preferences or privileges of the
shares of Series A Preferred Stock so as to affect adversely the shares of such
series;
(c) increase or decrease (other than by redemption or
conversion) the total number of authorized shares of Series A Preferred Stock;
(d) authorize or issue, or obligate itself to issue, any other
equity security, including any other security convertible into or exercisable
for any equity security, having a preference over, or being on a parity with,
the Series A Preferred Stock with respect to voting, dividends, conversion or
upon liquidation; or
(e) redeem, purchase or otherwise acquire (or pay into or set
funds aside for a sinking fund for such purpose) any share or shares of
Preferred Stock or Common Stock; provided, however, that this restriction shall
-------- -------
not apply to the repurchase of shares of Common Stock from employees, officers,
directors, consultants or other persons performing services for the Corporation
or any subsidiary pursuant to agreements under which the Corporation has the
option to repurchase such shares at cost upon the occurrence of certain events,
such as the termination of employment, or through the exercise of any right of
first refusal.
-8-
<PAGE>
7. Status of Converted Stock. In the event any shares of Preferred
-------------------------
Stock shall be converted pursuant to Section 4 hereof, the shares so converted
shall be cancelled and shall not be issuable by the Corporation. The
Certificate of Incorporation of the Corporation shall be appropriately amended
to effect the corresponding reduction in the Corporation's authorized capital
stock.
(C) Common Stock.
------------
1. Dividend Rights. Subject to the prior rights of holders of all
---------------
classes of stock at the time outstanding having prior rights as to dividends,
the holders of the Common Stock shall be entitled to receive, when and as
declared by the Board of Directors, out of any assets of the Corporation legally
available therefor, such dividends as may be declared from time to time by the
Board of Directors.
2. Liquidation Rights. Upon the liquidation, dissolution or winding
------------------
up of the Corporation, the assets of the Corporation shall be distributed as
provided in Section 2 of Article IV(B).
3. Redemption. The Common Stock is not redeemable.
----------
4. Voting Rights. Each holder of Common Stock shall have the right
-------------
to one vote per share of Common Stock, and shall be entitled to notice of any
stockholders' meeting in accordance with the bylaws of the Corporation, and
shall be entitled to vote upon such matters and in such manner as may be
provided by law.
ARTICLE V
The Board of Directors of the Corporation is expressly authorized to make,
alter or repeal Bylaws of the Corporation.
ARTICLE VI
Elections of directors need not be by written ballot unless otherwise
provided in the Bylaws of the Corporation.
ARTICLE VII
(A) To the fullest extent permitted by the Delaware General Corporation
Law, as the same exists or as may hereafter be amended, a director of the
Corporation shall not be personally liable to the Corporation or its
stockholders for monetary damages for breach of fiduciary duty as a director.
(B) The Corporation shall indemnify to the fullest extent permitted by law
any person made or threatened to be made a party to an action or proceeding,
whether criminal, civil, administrative or investigative, by reason of the fact
that he, his testator or intestate is or was a director or officer of the
Corporation or any predecessor of the Corporation, or serves or served
-9-
<PAGE>
at any other enterprise as a director or officer at the request of the
Corporation or any predecessor to the Corporation.
(C) Neither any amendment nor repeal of this Article VII, nor the adoption
of any provision of the Corporation's Certificate of Incorporation inconsistent
with this Article VII, shall eliminate or reduce the effect of this Article VII
in respect of any matter occurring, or any action or proceeding accruing or
arising or that, but for this Article VII, would accrue or arise, prior to such
amendment, repeal or adoption of an inconsistent provision."
* * *
-10-
<PAGE>
The foregoing Amended and Restated Certificate of Incorporation has been
duly adopted by this corporation's Board of Directors and stockholders in
accordance with the applicable provisions of Sections 228, 242 and 245 of the
General Corporation Law of the State of Delaware.
Executed at ___________, California, on December __, 1999.
_________________________________
Andrew Carragher, President
_________________________________
David Ricker, Secretary
-11-
<PAGE>
EXHIBIT 10.35
FORM OF TENET/NEWCO AGREEMENT
-----------------------------
This Tenet/NewCo Agreement (the "Agreement") is made and entered into as of
---------
____ , 1999 (the "Effective Date") by and among Tenet HealthSystem Medical,
--------------
Inc., a Delaware corporation ("Tenet"), Tendex, Inc., a Delaware corporation
-----
("NewCo"), Promedix.com, Inc., a Delaware corporation ("Promedix"), and Chemdex
----- --------
Corporation, a Delaware corporation ("Chemdex").
-------
BACKGROUND
----------
Tenet and Chemdex have entered into a joint venture agreement to create
NewCo for the purpose of providing a WWW (defined below) marketplace for the
sale of commodity healthcare products. Tenet operates a group purchasing
program which negotiates group purchasing prices and terms for the benefit of
both Tenet-owned and non-Tenet-owned health care providers. Promedix operates a
platform for researching and obtaining specialty medical products. The parties
desire to set forth the terms and conditions under which Tenet's group
purchasing members will purchase products from Tenet's group purchasing
suppliers and distributors via NewCo's online platform. In addition, the
parties desire to set forth the terms and conditions under which Promedix will
provide certain integration and training services to Tenet organizations, in
consideration for which members of Tenet's group purchasing organization will
purchase certain products from Promedix.
AGREEMENT
---------
In consideration of the agreements contained herein, the parties agree as
follows:
1. Definitions.
-----------
"Administrative Fees" means the administrative fees and discounts
-------------------
which Tenet receives from Tenet Suppliers for products purchased from such Tenet
Suppliers by Members.
"Confidential Information" of a party means any information disclosed
------------------------
by that party to another party pursuant to this Agreement, and which the
disclosing party does not specifically identify in writing as non-confidential
to the receiving party, including, but not limited to, that which relates to
patents, patent applications, research, product plans, products, developments,
inventions, processes, designs, drawings, engineering, formulae, markets,
software (including source and object code), hardware configuration, computer
programs, algorithms, regulatory information, medical reports, clinical data and
analysis, business plans, agreements with third parties, services, customers,
marketing or finances of the disclosing party.
"Cost" means the fully loaded cost of providing a service, product, or
----
technology, taking into account such factors as (a) labor, travel, insurance,
benefits, tax, and training expenses for consultants and employees, (b) overhead
allocations (including, without limitation, rent, lease, equipment, and related
infrastructure expenses), and (c) other factors mutually agreed upon by the
parties.
"Exclusive Field of Use" means developing, hosting, and commercially
----------------------
exploiting a WWW-based system for the sale of healthcare products to any
healthcare group purchasing organization or purchasing aggregator, hospital,
multi-hospital system or network, long-term care facility, retail pharmacy,
physician office, outpatient clinic, or drug and chemical dependency center.
* Confidential Treatment Requested. Bolded and Bracketed portions have been
ommitted and have been filed separately with the SEC.
<PAGE>
"Intellectual Property Rights" means all of the following: (a)
----------------------------
patents, patent applications and related patent rights, including but not
limited to divisions, continuations, continuations in-part, renewals, reissues
and extensions thereof; (b) rights associated with works of authorship including
moral rights, copyrights, registrations and applications therefor, mask work
rights, mask work applications and mask work registrations; (c) rights relating
to the protection of trade secrets and confidential information; and (d) rights
relating to the protection of trademarks or trade names.
"Member" means a health care provider for which Tenet acts as an agent
------
to negotiate terms of purchase for healthcare products from Tenet Suppliers. A
list of Members as of the Effective Date shall be provided separately to all
parties.
"Milestone Completion Date" means the date, with respect to each
-------------------------
Member, on which Promedix has completed the integration services which Promedix
agrees to provide to each such Member in accordance with Section 3(a) below.
"NewCo Marketplace" means NewCo's WWW platform (including, without
-----------------
limitation, buyer and supplier applications) for the sale of Routine Products.
"Non-Tenet Participant" means a Member which is not a Tenet
---------------------
Participant.
"Promedix Commerce Site" means Promedix's WWW platform for the sale of
----------------------
Promedix Products.
"Promedix Products" means healthcare products (a) which are not
-----------------
Routine Products or (b) are products from contracted suppliers that choose to
use Promedix's services.
"Routine Products" means healthcare products which are (a) stock or
----------------
(b) that Tenet has under contract.
"Services" means the services Promedix provides pursuant to Exhibit B.
-------- ---------
"Supplier Agreement" means an agreement between Tenet and Tenet
------------------
Suppliers for the sale of healthcare products to Members.
"Tenet GPO" means Tenet's group purchasing program which negotiates
---------
group purchasing agreements for prices and terms for the benefit of Members.
"Tenet Participant" means a Member owned, operated, leased, or managed
-----------------
by Tenet, Tenet's parent company, or one of its subsidiary companies.
"Tenet Supplier" means a supplier or distributor which agrees to
--------------
provide products and services to Members.
"WWW" means the World Wide Web.
---
2. Tenet GPO Fees and Administration.
---------------------------------
(a) Assignment of Administrative Fees. After the NewCo Marketplace is
---------------------------------
commercially available, and in consideration for the provision of such NewCo
Marketplace by NewCo, Tenet will assign to NewCo one hundred percent (100%) of
the Administrative Fees earned by Tenet
-2-
<PAGE>
from vendors and distributors, under the terms and conditions of its Supplier
Agreements with such distributors and vendors, with respect to all transactions
conducted through the NewCo Marketplace. After receiving such Administrative
Fees, NewCo shall pay to each Member the percentage of the Administrative Fee,
if any, due to such Member in accordance with the Member agreement in effect
between Tenet and such Member. Tenet shall provide NewCo with a list of all
Tenet Suppliers as of the Effective Date, as well as the Administrative Fees
which Tenet receives from such Tenet Suppliers, within thirty (30) days after
the Effective Date. In addition, Tenet shall provide NewCo with a list of all
Members as of the Effective Date, as well as the percentage of the
Administrative Fee due to such Member, within thirty (30) days after the
Effective Date. Tenet shall notify NewCo in writing of any changes to such lists
on the first day of each calendar month during the term of this Agreement. Tenet
warrants and represents that is has the right to assign the Administrative Fees
to NewCo as set forth hereunder, and that such assignment, and the payment by
NewCo of Administrative Fees to Members, will not breach Tenet's agreements with
its Members or Suppliers.
(b) Reports. Within thirty (30) days after the end of each month,
-------
NewCo will send a report to Tenet which sets forth (a) the aggregate purchases
of each Member through the NewCo Marketplace during such month and (b) the
Administrative Fees which accrued to NewCo during such month, calculated in
accordance with the rates set forth in the lists provided to NewCo by Tenet in
accordance with Section 2(a) above.
(c) Administration. NewCo will provide certain administrative
--------------
services to Tenet in connection with the Tenet GPO as set forth on Exhibit A
---------
hereto.
3. Promedix Obligations to Tenet. Promedix will use commercially
-----------------------------
reasonable efforts to (a) provide integration services to Members as set forth
on Exhibit B hereto and (b) provide education and training programs to Members
---------
as set forth on Exhibit B hereto.
---------
4. Purchases through Promedix Commerce Site.
----------------------------------------
(a) Payments for Services. Tenet will pay all Costs which Promedix
---------------------
reasonably incurs in providing Services to Tenet Participants hereunder.
(b) Exclusive Supplier. Subject to the provisions of this Section
------------------
4(b), Tenet will ensure that, after the Milestone Completion Date applicable to
each Member, such Member will purchase its Promedix Product requirements
(provided such products are offered for sale through the Promedix Commerce Site)
exclusively through the Promedix Commerce Site. Notwithstanding the foregoing:
(i) any Member will not be obligated to purchase its Promedix
Product requirements through the Promedix Commerce Site and will have the
right to purchase its Promedix Product requirements from third parties
after the applicable Milestone Completion Date if such Member can obtain
such products at lower prices through such third party supplier; and
(ii) Promedix acknowledges that Tenet is currently under
agreements with distributors for healthcare products. In the event of a
product source conflict between Promedix and one of these distributors over
a product currently available through such distributors, then Tenet
reserves the right to select the source for the term of those existing
agreements.
-3-
<PAGE>
This Agreement is not contemplated to change Tenet's traditional business
practices through existing distributors including with respect to extensions or
renewals or future contracts, or require that Tenet breach any of its current
distributor agreements. However, Tenet agrees that it will not add to its
contracts with distribution-contracted vendors, companies or products that
compete with Promedix.
The provisions of this Section 4(b) shall remain in effect for a period of
[*]; provided that the provisions may be extended for an additional period of
[*] upon the mutual consent of Tenet and Promedix.
(c) Purchases through the Promedix Commerce Site. Members will
--------------------------------------------
purchase products through the Promedix Commerce Site in accordance with a
Supplier Agreement which Tenet and Promedix will negotiate in good faith and
will use commercially reasonable efforts to enter into promptly after the
Effective Date.
(d) Introduction to Suppliers. Upon Promedix's request, Tenet will
-------------------------
use its commercially reasonable efforts to introduce Promedix to suppliers of
Specialty Products, and to encourage such suppliers to make their products
available for sale through the Promedix Commerce Site.
(e) Technology Exclusivity. For a period of [*] after the Effective
----------------------
Date, Tenet shall not collaborate with, work with, or assist, directly or
indirectly in any way, any third party to sponsor, co-develop, make or otherwise
support any technology or business in the Exclusive Field of Use.
(f) Other. Tenet will draft and forward a communication to Suppliers
-----
encouraging them to enter into a contract with Promedix for the sale of their
products through the Promedix Commerce Site. Tenet will furnish full-time
office space (cubicle) to one Promedix liason. Tenet will allow Promedix to
display its technology to the Tenet executive committee.
5. Payment Terms.
-------------
(a) Due Dates. Except as otherwise explicitly set forth in this
---------
Agreement, all payments due hereunder shall be made within thirty (30) days
after the date of invoice.
(b) Late Fees. All amounts not paid on a timely basis as required by
---------
this Agreement shall be subject to a late charge equal to [*] per month (or,
if less, the maximum allowed by applicable law).
(c) Taxes. All payments required by this Agreement are exclusive of
-----
all national, state, municipal or other governmental excise, sales, value-added,
use, personal property, and occupational taxes, excises, withholding taxes and
obligations and other levies now in force or enacted in the future, all of which
the payor will be responsible for and will pay in full, except for taxes based
on the payee's net income.
(d) Audits. Each party will maintain accurate records with respect to
------
payments due under this Agreement and methodology used to calculate payment due.
Each party may, upon no less than thirty (30) days prior written notice to
another party which owes such party payments hereunder,
________________
* Confidential Treatment Requested
-4-
<PAGE>
cause an independent Certified Public Accountant to inspect all relevant records
of such other party upon which the calculation of such payments are based during
normal business hours and without unreasonable disruption to such other party's
business. The fees charged by such Certified Public Accountant in connection
with the inspection will be paid by the auditing party unless the payments made
to the auditing party are determined to have been less than ninety percent (90%)
of the payments actually owed to the auditing party, in which case the other
party will be responsible for the payment of the reasonable fees for such
inspection. In addition, the other party shall immediately remit payment to the
auditing party for the full amount of any disclosed shortfalls. The audit rights
set forth herein shall continue for one (1) year following the termination of
this Agreement for any reason. No such audit may occur more than once a year
during the term of this Agreement.
6. Proprietary Rights. Promedix and Tenet acknowledge and agree that
------------------
Promedix owns all right, title, and interest, including without limitation all
Intellectual Property Rights therein, to the Promedix Commerce Site, including,
without limitation, all modifications, extensions, and enhancements to such
Promedix Commerce Site made by Promedix for Members pursuant to this Agreement.
7. Confidentiality.
---------------
(a) Nondisclosure. Each party shall treat as confidential all
-------------
Confidential Information of the other parties, shall not use such Confidential
Information except as set forth herein, and shall use reasonable efforts not to
disclose such Confidential Information to any third party. Without limiting the
foregoing, each of the parties shall use at least the same degree of care which
it uses to prevent the disclosure of its own confidential information of like
importance to prevent the disclosure of Confidential Information disclosed to it
by the other parties under this Agreement. Each party shall promptly notify the
applicable party of any actual or suspected misuse or unauthorized disclosure of
such other party's Confidential Information.
(b) Exceptions. Notwithstanding the above, no party shall have
----------
liability to the other with regard to any Confidential Information of the other
which the receiving party can prove: (i) was in the public domain at the time it
was disclosed or has entered the public domain through no fault of the receiving
party; (ii) was known to the receiving party, without restriction, at the time
of disclosure, as demonstrated by files in existence at the time of disclosure;
(iii) is disclosed with the prior written approval of the disclosing party; (iv)
was independently developed by the receiving party without any use of the
Confidential Information, as demonstrated by files created at the time of such
independent development; (v) becomes known to the receiving party, without
restriction, from a source other than the disclosing party without breach of
this Agreement by the receiving party and otherwise not in violation of the
disclosing party's rights; or (vi) is disclosed pursuant to the order or
requirement of a court, administrative agency, or other governmental body;
provided, however, that the receiving party shall provide prompt notice thereof
to the disclosing party to enable the disclosing party to seek a protective
order or otherwise prevent or restrict such disclosure.
(c) Return of Confidential Information. Upon expiration or
----------------------------------
termination of this Agreement, upon the request of the disclosing party, each
party shall return or destroy all Confidential Information received from the
other parties.
(d) Remedies. Any breach of the restrictions contained in this
--------
Section 7 is a breach of this Agreement which may cause irreparable harm to the
nonbreaching party. Any such breach shall entitle the nonbreaching party to
injunctive relief in addition to all legal remedies.
-5-
<PAGE>
(e) Confidentiality of Agreement. Each party shall be entitled to
----------------------------
disclose the existence of this Agreement, but agrees that the terms and
conditions of this Agreement shall be treated as Confidential Information and
shall not be disclosed to any third party; provided, however, that each party
may disclose the terms and conditions of this Agreement: (i) as required by any
court or other governmental body; (ii) as otherwise required by law; (iii) to
legal counsel of the parties; (iv) in confidence, to accountants, banks, and
financing sources and their advisors; (v) in connection with the enforcement of
this Agreement or rights under this Agreement; (vi) in confidence, in connection
with an actual or proposed merger, acquisition, or similar transaction; or (vii)
as mutually agreed upon by the parties.
8. Disclaimer. EXCEPT AS OTHERWISE EXPLICITLY SET FORTH IN THIS AGREEMENT
----------
EACH PARTY PROVIDES THE PRODUCTS AND SERVICES HEREUNDER "AS IS", AND EACH PARTY
EXPRESSLY DISCLAIMS ALL WARRANTIES, WHETHER EXPRESS, IMPLIED, CONTRACTUAL OR
STATUTORY, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF
MERCHANTABILITY, NONINFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE.
9. Term and Termination.
--------------------
(a) Term. This Agreement shall be effective from the Effective Date
----
and shall continue in effect for a period of fifteen (15) years unless
terminated earlier pursuant to the provisions of Section 9(b).
(b) [Intentionally left blank]
(c) Effect of Termination. The provisions of Sections 1, 5, 6, 8,
---------------------
9(c), 10, and 11 of this Agreement, and all payment obligations incurred prior
to termination, shall survive the termination of this Agreement for any reason.
The provisions of Section 7 of this Agreement shall survive the termination of
this Agreement for a period of three (3) years. All other rights and
obligations of the parties shall cease upon termination of this Agreement.
10. Limitation of Liability. IN NO EVENT SHALL ANY PARTY BE LIABLE TO THE
-----------------------
OTHERS FOR COSTS OF PROCUREMENT OF SUBSTITUTE PRODUCTS OR SERVICES, LOST
PROFITS, OR ANY CONSEQUENTIAL, SPECIAL, PUNITIVE, INCIDENTAL, OR INDIRECT
DAMAGES, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE OR
STRICT LIABILITY), ARISING OUT OF THIS AGREEMENT. THE PARTIES ACKNOWLEDGE AND
AGREE THAT THE AMOUNTS PAYABLE HEREUNDER ARE BASED IN PART UPON THESE
LIMITATIONS, AND FURTHER AGREES THAT THESE LIMITATIONS SHALL APPLY
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.
11. Miscellaneous.
-------------
(a) Amendments and Waivers. Any term of this Agreement may be amended
----------------------
or waived only with the written consent of the parties or their respective
permitted successors and assigns. Any amendment or waiver effected in
accordance with this Section 11(a) shall be binding upon the parties and their
respective successors and assigns.
-6-
<PAGE>
(b) Successors and Assigns. No party shall assign any of its rights,
----------------------
obligations or privileges (by operation of law or otherwise) hereunder without
the prior written consent of the other parties; provided, however, that any
party shall have the right to assign its rights, obligations and privileges
hereunder, upon thirty (30) days prior written notice to the other parties, to a
merger partner, successor in business or acquirer of all or substantially all of
such party's business or assets without obtaining consent from the other parties
to such assignment. The terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective permitted successors and
assigns of the parties. Nothing in this Agreement, express or implied, is
intended to confer upon any party other than the parties hereto or their
respective successors and assigns any rights, remedies, obligations, or
liabilities under this Agreement, except as expressly provided in this
Agreement.
(c) Governing Law. This Agreement and all acts and transactions
-------------
pursuant hereto and the rights and obligations of the parties hereto shall be
governed, construed and interpreted in accordance with the laws of the State of
California, United States of America, without giving effect to principles of
conflicts of law or to the Convention on Contracts for the International Sale of
Goods.
(d) Jurisdiction. The parties consent to the exclusive jurisdiction
------------
and venue of the state and federal courts of Santa Clara County, California.
(e) Counterparts. This Agreement may be executed in two or more
------------
counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument.
(f) Titles and Subtitles. The titles and subtitles used in this
--------------------
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.
(g) Notices. Any notice required or permitted by this Agreement shall
-------
be in writing and shall be deemed sufficient upon receipt, when delivered
personally or by courier, overnight delivery service or confirmed facsimile or
electronic mail, or forty-eight (48) hours after being deposited in the regular
mail as certified or registered mail (airmail if sent internationally) with
postage prepaid, if such notice is addressed to the party to be notified at such
party's address or facsimile number as set forth below, or as subsequently
modified by written notice.
Chemdex: NewCo:
Chemdex Corporation c/o Tenet HealthSystem Medical, Inc.
1500 Plymouth Street 3820 State Street
Mountain View, CA 94043 Santa Barbara, CA 93105
Fax: (650) 567-8950 Fax: (805) 563-7070
Attn: Dave Perry Attn: Jeffrey C. Barbakow
Promedix: Tenet:
Promedix.com, Inc. Tenet HealthSystem Medical, Inc.
488 East Winchester Avenue 3820 State Street
Salt Lake City, UT 84107
-7-
<PAGE>
Fax: (801) 261-7475 Santa Barbara, CA 93105
Attn: William C. Klintworth, Jr.
Fax: (805) 563-7070
Attn: Jeffrey C. Barbakow
(h) Severability. If one or more provisions of this Agreement are
------------
held to be unenforceable under applicable law, the parties agree to renegotiate
such provision in good faith, in order to maintain the economic position enjoyed
by each party as close as possible to that under the provision rendered
unenforceable. In the event that the parties cannot reach a mutually agreeable
and enforceable replacement for such provision, then (i) such provision shall be
excluded from this Agreement, (ii) the balance of the Agreement shall be
interpreted as if such provision were so excluded and (iii) the balance of the
Agreement shall be enforceable in accordance with its terms.
(i) Independent Contractor. No party shall, for any purpose, be
----------------------
deemed to be an agent of any other party and the relationship between the
parties shall only be that of independent contractors. No party shall have any
right or authority to assume or create any obligations or to make any
representations or warranties on behalf of any other party, whether express or
implied, or to bind any other party in any respect whatsoever.
(j) Force Majeure. In the event that any party is prevented from
-------------
performing or is unable to perform any of its obligations under this Agreement
(other than a payment obligation) due to any Act of God, fire, casualty, flood,
earthquake, war, strike, lockout, epidemic, destruction of production
facilities, riot, insurrection, material unavailability, or any other cause
beyond the reasonable control of the party invoking this Section, and if such
party shall have used its best efforts to mitigate its effects, such party shall
give prompt written notice to the other parties, its performance shall be
excused, and the time for the performance shall be extended for the period of
delay or inability to perform due to such occurrences.
(k) Entire Agreement. This Agreement (as amended pursuant to Section
----------------
11(a)) constitutes the entire agreement of the parties pertaining to the subject
matter hereof, and merges all prior negotiations and drafts of the parties with
regard to the transactions contemplated herein. Any and all other written or
oral agreements existing between the parties hereto regarding such transactions
are expressly canceled.
(l) Advice of Legal Counsel. Each party acknowledges and represents
-----------------------
that, in executing this Agreement, it has had the opportunity to seek advice
regarding its legal rights from legal counsel and that the person signing on its
behalf has read and understood all of the terms and provisions of this
Agreement. This Agreement shall not be construed against any party by reason of
the drafting or preparation thereof.
-8-
<PAGE>
The parties have executed this Agreement as of the date first set forth
above.
TENET HEALTHSYSTEM MEDICAL, INC. TENDEX, INC.
By:____________________________ By:_______________________________
Name:__________________________ Name:_____________________________
Title:_________________________ Title:____________________________
PROMEDIX.COM, INC. CHEMDEX CORPORATION
By:____________________________ By:_______________________________
Name:__________________________ Name:_____________________________
Title:_________________________ Title:____________________________
-9-
<PAGE>
EXHIBIT A
TENET GPO ADMINISTRATION
A. NewCo Management Services.
In connection with NewCo's provision of technology to enable Tenet
Suppliers and Members to conduct online purchase and sale transactions through
the NewCo Marketplace, Tenet desires to engage NewCo to perform the functions
and to provide the services described in this Exhibit A with respect to Non-
---------
Online Transactions which occur after the Effective Date hereof as more
particularly described below. For purposes of this Exhibit A, "Online
--------- ------
Transactions" shall refer to purchases of products by Members from Tenet
- ------------
Suppliers via the NewCo Marketplace, and "Non-Online Transactions" shall refer
-----------------------
to all other purchases of products by Members from Tenet Suppliers.
1. Duties of NewCo. NewCo agrees to conduct, supervise and effectively
manage the day-to-day Non-Online Transaction business affairs of the Tenet GPO
as reasonably requested by Tenet during the term of this Agreement, including
the provision of all personnel reasonably required to accomplish this
undertaking. Any powers not specifically delegated or granted by Tenet to NewCo
will remain with Tenet. NewCo shall use all reasonable commercial efforts to
implement the Tenet GPO's policies and directives with the goal of causing the
Tenet GPO to provide quality group purchasing organization services to Members
consistent with the policies and directives set by Tenet, the financial
resources available to the Tenet GPO, the competitive marketplace in which the
Tenet GPO operates, Medicare reimbursement and other laws and, ultimately
migrate Non-Online Transactions to Online Transactions. In the absence of such
oral or written policies or standards, NewCo shall be expected to exercise its
reasonable judgment in its management activities and to conduct such management
activities according to the same standards by which it governs its own affairs.
A description of certain of the management services to be provided by NewCo are
set forth on Attachment A hereto. Without limiting the generality of the
------------
services described herein, such management services shall include personnel
administration, maintenance of accounting and financial, as required, payment of
accounts, including administrative fees, on behalf of the Tenet GPO to Members,
depositing funds in accounts designated by Tenet, preparation of an annual
business plan for the Tenet GPO including a Tenet GPO budget, marketing
services, legal services and pursuit and negotiation of vendor and member
agreements on the Tenet GPO behalf, all as reasonably required by Tenet.
2. Term. Notwithstanding Section 9 of the Agreement, the term of the
management services described on this Exhibit A shall commence on ___________,
---------
1999 (the "Commencement Date") and unless sooner terminated as provided herein,
-----------------
shall continue for as long as the Tenet GPO shall operate as a group purchasing
organization conducting Non-Online Transactions or until such time as Tenet,
upon 180 days prior notice to NewCo, because of a general reduction in Non-
Online Transactions, no longer requires such management services.
3. Retention of Authority. Throughout the term of the provision of the
management services described herein, Tenet shall retain all authority and shall
exercise control over the business, policies, operation, and assets of the Tenet
GPO. NewCo shall perform the services described in this Agreement in accordance
with the reasonable policies and directives of Tenet as may be from time to time
provided to it, including approval of vendor and distributor agreements. By
entering into this agreement, Tenet does not delegate to NewCo any of the
powers, duties, and responsibilities vested in Tenet by the bylaws of Tenet. In
matters pertaining to the Tenet GPO, NewCo may rely on, assume the
* Confidential Treatment Requested. Bolded and Bracketed portions have been
omitted and have been filed separately with the SEC.
<PAGE>
validity of communications from, and report to Barry Schochet, his designee or
such other person designated by Tenet.
4. Standards of Performance. Tenet acknowledges that, while NewCo shall
expend its commercially reasonable efforts in performing its obligations under
this agreement, NewCo does not guarantee any particular results. NewCo shall
act in good faith and with professionalism to assist Tenet in the provision of
quality services.
5. Management Fee and Expenses. In exchange for NewCo's services
rendered to Tenet under the terms of this Exhibit A, Tenet shall pay NewCo the
---------
following amounts:
a. Management Fee. On or before the tenth (10th) day of each calendar
--------------
month during the term of this Exhibit A, commencing with the second such month,
---------
and continuing on or before the tenth (10th) day of each calendar month
thereafter until the month following the expiration or earlier termination of
this agreement, NewCo shall provide Tenet with an itemization of Costs
attributed to the provision of management services described herein. Within
twenty (20) days of Tenet's receipt of such itemization of Costs, Tenet shall
pay to NewCo NewCo's Cost, as defined herein, of providing the management
services described herein. NewCo's Cost of providing the management services
shall be subject to audit in accordance with Section 5(d).
b. Reimbursement of Expenses. In addition to the compensation paid to
-------------------------
NewCo pursuant to Section 5(a) above, Tenet shall reimburse NewCo for reasonable
amounts advanced by NewCo on behalf of Tenet. NewCo shall provide Tenet with
itemized and documented statements of such amounts no later than the tenth
(10th) day of the month after such expenses were incurred. Subject to the
foregoing, Tenet shall reimburse NewCo no later than twenty (20) days after
receipt of such itemized statement.
6. Duty to Cooperate. The parties acknowledge that the parties' mutual
cooperation is critical to the ability of NewCo to perform its duties hereunder
successfully and efficiently. Accordingly, each party agrees to cooperate with
the other fully in formulating and implementing goals and objectives which are
reasonably necessary for the operation of the Tenet GPO.
7. Confidentiality. Each party shall protect the Confidential
Information of the other party in accordance with Section 7 of the Agreement.
8. Communications and Reports. NewCo shall present to Tenet periodic
written progress reports summarizing NewCo's management actions and results, and
such other written reports as Tenet reasonably considers appropriate to keep it
informed as to the status and condition of the operation of the Tenet GPO.
9. Annual Budget. Within ninety (90) days of the end of each calendar
year, NewCo shall prepare and submit to Tenet a budget for providing the
management services described herein for the coming year. Tenet shall have
forty-five (45) days from its receipt of the proposed budget to approve or
disapprove such proposed budget. If Tenet accepts the budget, it will
constitute the budget for management fees and expenses for the coming year. If
Tenet rejects the proposed budget, the parties will meet, as soon as is
reasonably practicable, and make a good faith attempt to resolve the disputed
items in the budget. In the event the parties are unable to resolve the
disputed items, the parties will utilize the budget for the preceding year as
the budget for the coming calendar year. For the first
-2-
<PAGE>
calendar year of this agreement the budget will be equal to the Tenet GPO's
departmental budget for Tenet's current fiscal year.
10. Insurance. NewCo shall purchase and maintain throughout the term of
this Exhibit insurance with responsible companies for risks and in amounts as
are commercially reasonable and agreed to by the parties naming Tenet as an
additional insured.
11. Termination. Notwithstanding Section 9 of the Agreement, this Exhibit
-------
A may be terminated by either Tenet or NewCo:
- -
a. If a party shall default in the performance of any material covenant,
agreement, term or provision of this Exhibit to be kept, observed or performed
by such party and such default shall not be cured for a period of sixty (60)
days after written notice is given to the defaulting party stating the specific
default.
b. If the Tenet GPO ceases operation.
c. If either Tenet or NewCo shall do any of the following: apply for or
consent to the appointment of a receiver, trustee or liquidator of all or a
substantial part of its assets; file a voluntary petition in bankruptcy or admit
in writing its inability to pay its debts as they become due; make a general
assignment for the benefit of creditors, file a petition or an answer seeking
organization or arrangement with creditors; take advantage of any insolvency
law; or, if an order, judgment or decree shall be entered by a court of
competent jurisdiction, on the application of a creditor, adjudicating the party
bankrupt or insolvent or approving a petition seeking reorganization of a party
or appointing a receiver, trustee or liquidator of all or a substantial part of
its assets.
12. Indemnification. To the extent not otherwise covered by insurance,
Tenet and NewCo shall each indemnify and hold the other party and its employees
and agents harmless from any and all loss, liability or damage, of any kind
whatsoever, including, but not limited to, attorneys' fees and court costs
arising out of, or in any manner occasioned by, breach by a party, its agents,
employees, servants or subcontractors, of any covenant and/or condition of this
Exhibit, or by the negligence, improper conduct or intentional acts or omissions
of a party, its agents, employees, servants or subcontractors.
-3-
<PAGE>
Attachment A
Services
. NewCo will perform all corporate Material Resource Management functions
for the Tenet GPO, including providing oversight for IMMS and strategic
directions related to operations and utilization programs
. NewCo will oversee and manage all Tenet GPO functions including:
-Negotiation and management of supply and service agreements
-Recruiting and managing all aspects of Tenet GPO affiliate
relationships
-Marketing and recruiting new internet customers wanting to access the
NewCo Marketplace
-Serving as the technology liason to Chemdex
-Collection and disbursement of administrative fees, rebates, and
transaction fees
* Confidential Treatment Requested. Bolded and Bracketed portions have been
omitted and have been filed separately with the SEC.
<PAGE>
EXHIBIT B
SERVICES PROVIDED BY PROMEDIX TO MEMBERS
1. Integration Services.
--------------------
Promedix will integrate with Tenet members and participants enterprise systems.
This will include the following steps:
1) Identifying system requirements
2) Mapping necessary information interchange between systems
3) Define systems requirements between systems
4) Beta testing system integration
5) Launch system integration
1. Training Services.
-----------------
Promedix will provide some training services to Tenet in order to drive
adoption. This will include the following:
1) Product company launch event
2) On site end user training
3) Train -the- trainer course
4) On site administrator training course
5) Computer demo training courses
<PAGE>
EXHIBIT 10.36
FORM OF CHEMDEX LICENSE AND SERVICES AGREEMENT
----------------------------------------------
This Chemdex License and Services Agreement (the "Agreement") is made
---------
and entered into as of December __, 1999 (the "Effective Date") by and among
--------------
Chemdex Corporation, a Delaware corporation ("Chemdex"), Promedix.com, Inc., a
-------
Delaware corporation ("Promedix"), Tendex, Inc., a Delaware corporation
--------
("NewCo"), and Tenet HealthSystem Medical, Inc., a Delaware corporation
-----
("Tenet").
-----
BACKGROUND
----------
Chemdex and Tenet have entered into a joint venture agreement to create
NewCo for the purpose of providing a WWW (defined below) marketplace for the
sale of commodity healthcare products. Chemdex has developed technology and
expertise in connection with its WWW marketplace for the sale of life science
supplies. The parties desire to set forth the terms and conditions under which
NewCo will receive certain services and a license to certain technology from
Chemdex and Promedix, to facilitate NewCo's development and offering of its own
WWW marketplace.
AGREEMENT
---------
In consideration of the agreements contained herein, the parties agree
as follows:
1. Definitions.
-----------
"Chemdex Marketplace" means Chemdex's WWW platform (including, without
-------------------
limitation, buyer and supplier applications and related online marketplace
components) for the sale of life science supplies.
"Confidential Information" of a party means any information disclosed
------------------------
by that party to another party pursuant to this Agreement, and which the
disclosing party does not specifically identify in writing as non-confidential
to the receiving party, including, but not limited to, that which relates to
patents, patent applications, research, product plans, products, developments,
inventions, processes, designs, drawings, engineering, formulae, markets,
software (including source and object code), hardware configuration, computer
programs, algorithms, regulatory information, medical reports, clinical data and
analysis, business plans, agreements with third parties, services, customers,
marketing or finances of the disclosing party.
"Cost" means the fully loaded cost of providing a service, product, or
----
technology, taking into account such factors as (a) labor, travel, insurance,
benefits, tax, and training expenses for consultants and employees, (b) overhead
allocations (including, without limitation, rent, lease, equipment, and related
infrastructure expenses), and (c) other factors mutually agreed upon by the
parties.
"Exclusive Field of Use" means developing, hosting, and commercially
----------------------
exploiting a WWW-based system for the sale of healthcare products to any
healthcare group purchasing organization or purchasing aggregator, hospital,
multi-hospital system or network, long-term care facility, retail pharmacy,
physician office, outpatient clinic, or drug and chemical dependency center.
"Intellectual Property Rights" means all of the following: (a)
----------------------------
patents, patent applications and related patent rights, including but not
limited to divisions, continuations, continuations in-part,
* Confidential Treatment Requested. Bolded and Bracketed portions have been
omitted and have been separately filed with the SEC.
<PAGE>
renewals, reissues and extensions thereof; (b) rights associated with works of
authorship including moral rights, copyrights, registrations and applications
therefor, mask work rights, mask work applications and mask work registrations;
(c) rights relating to the protection of trade secrets and confidential
information; and (d) rights relating to the protection of trademarks or trade
names.
"Licensed Intellectual Property Rights" means (a) Chemdex's and
-------------------------------------
Promedix's Intellectual Property Rights in the Licensed Technology and (b) all
Intellectual Property Rights of Promedix and Chemdex which are conceived or
reduced to practice during the term of this Agreement.
"Licensed Technology" means Technology which, at any time during the
-------------------
term of this Agreement, Chemdex or Promedix owns, has the right to license to
NewCo hereunder (without additional cost to Chemdex or Promedix, unless such
additional cost is paid by NewCo in accordance with Section 5(a) below), or has
developed in connection with the Chemdex Marketplace or Promedix Commerce Site.
Licensed Technology shall explicitly (a) exclude Third Party Technology and (b)
include Updates and Upgrades delivered to NewCo during the term of this
Agreement and modifications and derivative works of the Licensed Technology
created by Chemdex or Promedix. Licensed Technology includes, without
limitation, the items set forth on Exhibit A hereto.
---------
"Marks" means the trademarks, trade names, logos, service marks and
-----
designations for Chemdex, Promedix, and NewCo.
"NewCo Marketplace" means NewCo's WWW platform (including, without
-----------------
limitation, buyer and supplier applications) for the sale of Routine Products.
"Promedix Commerce Site" means Promedix's WWW platform for the sale of
----------------------
Promedix Products.
"Promedix Products" means healthcare products (a) which are not
-----------------
Routine Products or (b) are products from contracted suppliers that choose to
use Promedix's services.
All references in this Agreement to the "purchase" or "sale" of
-------- ----
Software means the acquiring or granting, respectively, of a license or
sublicense to use such Software, and to exercise any other rights pertaining to
such Software which are expressly set forth under this Agreement.
"Research and Content Site" means a WWW platform for researching the
-------------------------
attributes and outcomes of Promedix Products.
"Routine Products" means healthcare products which are (a) stock or
----------------
(b) that Tenet has under contract.
"Services" means the services which Chemdex provides to NewCo in
--------
accordance with Sections 3(b), 3(c), and 3(d).
"Source Code" means the source code of the Software, including without
-----------
limitation, any and all Upgrades and Updates.
"Software" means all software (in source and object code format)
--------
included in the Licensed Technology.
"Specifications" means the specifications of the functionality and
--------------
performance of the Software mutually agreed upon by the parties.
-2-
<PAGE>
"Technology" means technology, including, without limitation,
----------
software, algorithms, methods, trade secrets, know-how, proprietary information,
whether or not reduced to writing, inventions (whether or not patentable),
ideas, schematics, works of authorship not previously released into the public
domain, documentation, diagnostic aids, designs, analysis codes, discoveries,
techniques, methods, concepts, data, engineering and manufacturing information,
procedures, specifications, diagrams, drawings, schematics, reports, studies and
related documentation.
"Third Party Technology" means third party Technology which is
----------------------
incorporated into or used in connection with the Chemdex Marketplace, and which
Chemdex does not have the right to sublicense to NewCo in accordance with
Section 2 below. A more detailed list of Third Party Technology, as of the
Effective Date, is set forth on Exhibit B hereto.
---------
"Updates" means new versions of the Licensed Technology that contain
-------
bug fixes, error corrections and minor enhancements, but do not contain major
enhancements or significant new functionality.
"Upgrades" means new versions of the Licensed Technology that contain
--------
major enhancements or significant new functionality.
"WWW" means the World Wide Web.
---
2. License Grants and Restrictions.
-------------------------------
(a) Technology License Grant. Subject to the terms, conditions, and
------------------------
restrictions set forth in this Agreement, Chemdex and Promedix hereby grant
NewCo a worldwide, exclusive (solely to the extent set forth in Section 2(d)
below), perpetual, royalty-free, irrevocable (subject to Section 10(b)), fully
paid-up license, without rights to sublicense, under Chemdex's and Promedix's
Intellectual Property Rights in the Licensed Technology, to use, reproduce,
modify, create derivative works of, and display the Licensed Technology solely
as is necessary or useful to create, operate, and host the NewCo Marketplace;
provided, however, that NewCo shall have the right to sublicense components of
the Licensed Technology to suppliers, distributors, and customers of the NewCo
Marketplace to enable such suppliers, distributors, and customers to sell and
purchase Routine Products through the NewCo Marketplace.
(b) Trademark License. Chemdex, Promedix, and NewCo each hereby grants
-----------------
to each other and to Tenet a non-exclusive, limited license to use its Marks in
connection with the marketing and promotion of the NewCo Marketplace. All such
use shall be in accordance with each party's reasonable policies regarding the
use of such party's Marks as shall be established or changed from time to time
in such party's sole discretion upon notice to the other parties. Upon the
expiration or termination of this Agreement, each party will cease using the
Marks of the others except as the parties may agree in writing or to the extent
permitted by applicable law.
(c) Restrictions on NewCo. NewCo will have no right or license to the
---------------------
Licensed Technology except as set forth in Section 2(a) above or in another
written agreement between the parties. NewCo acknowledges and agrees that the
Source Code is furnished to NewCo on a confidential and secret basis. NewCo
agrees to take all commercially reasonable steps to prevent unauthorized
disclosure of the Source Code in accordance with Exhibit C hereto. NewCo will
---------
immediately notify Chemdex and Promedix of the unauthorized disclosure or use of
the Source Code and shall assist Chemdex and Promedix in remedying such
unauthorized use or disclosure.
-3-
<PAGE>
(d) Restrictions on Chemdex and Promedix. Chemdex and Promedix shall
------------------------------------
not have the right to use or commercially exploit the Licensed Technology in the
Exclusive Field of Use. Chemdex and Promedix shall not collaborate with, work
with, or assist, directly or indirectly in any way, any third party to sponsor,
co-develop, make or otherwise support any technology or business in the
Exclusive Field of Use, and shall not assist, directly or indirectly, or in any
way induce, any third party to compete with NewCo or infringe or violate NewCo's
rights under the license granted herein, the Licensed Intellectual Property
Rights or the Licensed Technology in the Exclusive Field of Use. Promedix and
Chemdex shall not license the Licensed Technology to a third party for the
purpose of establishing a WWW marketplace, other than the NewCo Marketplace, for
the sale of Routine Products; provided, however, that Chemdex and Promedix shall
have the right to license components of the Licensed Technology to suppliers,
distributors, and customers of the Promedix Commerce Site or Chemdex Marketplace
to enable such suppliers, distributors, and customers (i) to sell and purchase
Promedix Products through the Promedix Commerce Site, or (ii) to sell and
purchase life science supplies through the Chemdex Marketplace. Notwithstanding
the foregoing or anything to the contrary in this Agreement, Chemdex and
Promedix shall have the right to use the Licensed Technology and to exploit the
Licensed Intellectual Property Rights in order to develop, host, and
commercially exploit the Promedix Commerce Site and to sell Promedix Products.
(e) Each party acknowledges and agrees that any remedy at law for any
breach of this Section would be inadequate and consents to the granting by any
court of competent jurisdiction an injunction or other equitable relief,
without the necessity of actual monetary loss being proved and without the
necessity of posting a bond, in order that a breach or threatened breach of this
Section may be effectively enjoined. Equitable relief shall not be deemed to be
the exclusive remedy for any breach of any provision of this Section but shall
be in addition to all other remedies provided by law or equity. No failure or
delay in exercising any right hereunder will operate as a waiver thereof, nor
will any single or partial exercise thereof preclude any other or further
exercise thereof or the exercise of any other right.
3. Chemdex Responsibilities.
------------------------
(a) Delivery. Chemdex and Promedix shall transfer the Licensed
--------
Technology (including, without limitation, any and all Upgrades and Updates
thereof) to NewCo in accordance with a schedule mutually agreed upon by the
parties and set forth on Exhibit D hereto. All Upgrades and Updates shall be
---------
delivered by Chemdex or Promedix to NewCo promptly after such Updates and
Upgrades are made available for commercial use to Chemdex's or Promedix's
licensees.
(b) Services. Chemdex will use commercially reasonable efforts to (i)
--------
share its expertise and knowledge with NewCo in the following areas: enterprise
resource planning, ontology, enterprise integration, and architecture of the
Licensed Technology, as set forth in more detail on Exhibit E hereto, (ii)
---------
provide sales support for small to mid-size customers of NewCo and customer
support, as set forth in more detail on Exhibit E hereto, (iii) assist NewCo in
---------
the development of certain transaction sets, if any, which NewCo will require to
integrate the NewCo Marketplace with, (iv) provide technical support to NewCo as
set forth on Exhibit F hereto, and (v) make other professional services
---------
reasonably required by NewCo available to NewCo on terms and conditions mutually
agreed upon by the parties. In addition, upon NewCo's request, Chemdex will use
commercially reasonable efforts to help NewCo enter into contracts with third
party service providers which provide professional services to Chemdex under
terms and conditions similar to those enjoyed by Chemdex pursuant to its
agreements with such third parties.
(i) Exclusions. Notwithstanding the foregoing, Chemdex will have no
----------
obligation to provide development or technical support services to NewCo with
respect to Licensed
-4-
<PAGE>
Technology which NewCo or its agent modifies, except for modifications made by
Chemdex or which Chemdex approves in a writing separate from this Agreement.
Chemdex will, however, provide development and technical support services to
NewCo with respect to Licensed Technology which Chemdex modifies, or authorizes
(in writing) third parties to modify, on behalf of NewCo.
(c) Access to Research and Content Site. Chemdex will use
-----------------------------------
commercially reasonable efforts to provide NewCo with access, as mutually agreed
upon by the parties, to the content and search capabilities contained in the
Research and Content Site. Chemdex will use commercially reasonable efforts to
develop extensions and enhancements to content incorporated into the Research
and Content Site, as reasonably requested by NewCo from time to time during the
term of this Agreement.
(d) Third Party Technology. Chemdex shall use commercially reasonable
----------------------
efforts to (i) help NewCo enter into license or sublicense agreements which
enable NewCo to use the Third Party Technology in connection with the NewCo
Marketplace and (ii) provide that the terms and conditions of such third party
licenses are at least as favorable as the terms and conditions which Chemdex
receives from such third parties for the use of such Third Party Technology in
the Chemdex Marketplace.
4. Promedix Responsibilities.
-------------------------
(a) Access to Promedix Commerce Site. Promedix shall provide NewCo
--------------------------------
with access, as mutually agreed upon by the parties, to the purchase
capabilities contained in the Promedix Commerce Site.
(b) Transaction Fees. Promedix shall pay NewCo a transaction fee of
----------------
[*] of net revenues received by Promedix from each sales transaction which
results when a user links to the Promedix Commercial Site directly from the
NewCo Marketplace and purchases a product on the Promedix Commercial Site
("Transaction Fee").
---------------
(c) Within thirty (30) days after the end of each calendar month,
Promedix will pay NewCo all Transaction Fees and Data Fees which accrued during
such month. All amounts which Promedix does not pay on a timely basis as
required by this Agreement shall be subject to a late charge equal to [*] per
month (or, if less, the maximum allowed by applicable law).
5. NewCo Responsibilities.
----------------------
(a) Fees. NewCo will pay all Costs which Chemdex incurs in providing
----
Services to NewCo hereunder; provided, however, that any error correction
services which Chemdex provides to NewCo pursuant to Section 9(e) shall be
provided free of charge.
(b) Payment Terms. All payments shall be made by NewCo within thirty
-------------
(30) days after the date of Chemdex's invoice. All amounts which NewCo does not
pay on a timely basis as required by this Agreement shall be subject to a late
charge equal to [*] per month (or, if less, the maximum allowed by applicable
law). In the event that any payment due hereunder is overdue, Chemdex reserves
the right to suspend performance until such delinquency is corrected.
(c) Taxes. All payments required by this Section 5 are exclusive of
-----
all national, state, municipal or other governmental excise, sales, value-added,
use, personal property, and occupational taxes, excises, withholding taxes and
obligations and other levies now in force or enacted in the future, all of which
NewCo will be responsible for and will pay in full, except for taxes based on
Chemdex's net income.
_______________________
* Confidential Treatment Requested.
-5-
<PAGE>
(d) Exclusivity. Promedix shall be NewCo's exclusive online supplier
-----------
of Promedix Products through the NewCo Marketplace. NewCo shall not make
Promedix Products of any third party supplier available for sale through the
NewCo Marketplace without the prior written consent of Promedix. NewCo shall not
collaborate with, work with, or assist, directly or indirectly in any way, any
third party supplier of Promedix Products, and shall not assist, directly or
indirectly, or in any way induce, any third party to compete with Promedix.
Notwithstanding the foregoing, NewCo shall have the right to make the products
of a third party supplier available for sale through the NewCo Marketplace if
such products are Routine Products, or if such products fall under the
definition of both Promedix Products and Routine Products.
6. Proprietary Rights. Subject to the licenses granted to NewCo in
------------------
Section 2, Chemdex shall own all right, title, and interest in and to the
Licensed Technology, including, without limitation, all Intellectual Property
Rights therein. Subject to the preceding sentence, NewCo shall own all right,
title and interest in and to modifications to the Licensed Technology made by
NewCo or its agents (other than Promedix or Chemdex).
7. Confidentiality.
---------------
(a) Nondisclosure. Each party shall treat as confidential all
-------------
Confidential Information of the other parties, shall not use such Confidential
Information except as set forth herein, and shall use reasonable efforts not to
disclose such Confidential Information to any third party. Without limiting the
foregoing, each of the parties shall use at least the same degree of care which
it uses to prevent the disclosure of its own confidential information of like
importance to prevent the disclosure of Confidential Information disclosed to it
by the other parties under this Agreement. Each party shall promptly notify the
applicable party of any actual or suspected misuse or unauthorized disclosure of
such other party's Confidential Information.
(b) Exceptions. Notwithstanding the above, no party shall have
----------
liability to the other with regard to any Confidential Information of the other
which the receiving party can prove: (i) was in the public domain at the time it
was disclosed or has entered the public domain through no fault of the receiving
party; (ii) was known to the receiving party, without restriction, at the time
of disclosure, as demonstrated by files in existence at the time of disclosure;
(iii) is disclosed with the prior written approval of the disclosing party; (iv)
was independently developed by the receiving party without any use of the
Confidential Information, as demonstrated by files created at the time of such
independent development; (v) becomes known to the receiving party, without
restriction, from a source other than the disclosing party without breach of
this Agreement by the receiving party and otherwise not in violation of the
disclosing party's rights; or (vi) is disclosed pursuant to the order or
requirement of a court, administrative agency, or other governmental body;
provided, however, that the receiving party shall provide prompt notice thereof
to the disclosing party to enable the disclosing party to seek a protective
order or otherwise prevent or restrict such disclosure.
(c) Return of Confidential Information. Upon expiration or
----------------------------------
termination of this Agreement, upon the request of the disclosing party, and
subject to Section 10(c), each party shall return or destroy all Confidential
Information received from the other parties.
(d) Remedies. Any breach of the restrictions contained in this
--------
Section 7 is a breach of this Agreement which may cause irreparable harm to the
nonbreaching party. Any such breach shall entitle the nonbreaching party to
injunctive relief in addition to all legal remedies.
-6-
<PAGE>
(e) Confidentiality of Agreement. Each party shall be entitled to
----------------------------
disclose the existence of this Agreement, but agrees that the terms and
conditions of this Agreement shall be treated as Confidential Information and
shall not be disclosed to any third party; provided, however, that each party
may disclose the terms and conditions of this Agreement: (i) as required by any
court or other governmental body; (ii) as otherwise required by law; (iii) to
legal counsel of the parties; (iv) in confidence, to accountants, banks, and
financing sources and their advisors; (v) in connection with the enforcement of
this Agreement or rights under this Agreement; (vi) in confidence, in connection
with an actual or proposed merger, acquisition, or similar transaction; or (vii)
as mutually agreed upon by the parties.
8. Indemnification.
---------------
(a) Indemnification by Chemdex and Promedix. Chemdex and Promedix
---------------------------------------
jointly and severally agree, at their own expense, to defend or at their option
to settle any claim or action brought against NewCo on the issue of infringement
of any United States Intellectual Property Right by the Licensed Technology as
delivered to NewCo under this Agreement, and to indemnify NewCo against any and
all damages, liabilities, and costs, including legal fees, incurred by NewCo as
a result of any such claim or action; provided that NewCo provides Chemdex and
--------
Promedix with (i) prompt written notice of such claim or action (provided,
however, that the failure of NewCo to give prompt notice to Chemdex and Promedix
shall not relieve Chemdex and Promedix of their obligations hereunder unless,
and then only to the extent that, the failure to give prompt notice adversely
affects Chemdex's or Promedix's ability to defend the claim, or increases the
damages for which Chemdex or Promedix is liable hereunder), (ii) sole control
and authority over the defense or settlement of such claim or action (provided
that NewCo shall have the right to participate, at its own expense, and with
counsel of its choice, in such defense or settlement) and (iii) proper and full
information and reasonable assistance (at the expense of Chemdex and Promedix)
to defend and/or settle any such claim or action. Chemdex and Promedix shall
have no liability if the alleged infringement is caused by (a) any combination
of the Licensed Technology with equipment, programs or data not authorized by
Chemdex or Promedix for use with the Licensed Technology, where such Licensed
Technology alone would not have given rise to the claim, (b) use of the Licensed
Technology by NewCo or any other party other than as authorized under Section 2,
or (c) changes to the Licensed Technology made by NewCo or its agents, other
than Promedix or Chemdex, to the extent such claim would not have arisen but for
such modification. Notwithstanding the foregoing, Chemdex and Promedix shall
not enter into any settlement or consent to any adverse judgment that would
adversely affect the rights, interest, or business of NewCo without the prior
written consent of NewCo.
(b) Injunctions. In the event that the Licensed Technology is, or in
-----------
Chemdex's or Promedix's sole opinion is likely to be, enjoined due to the type
of infringement described in Section 8(a), Chemdex or Promedix, at its option
and expense, may either (i) modify the Licensed Technology so that it becomes
non-infringing but functionally equivalent, (ii) replace the Licensed Technology
with functionally equivalent non-infringing products reasonably acceptable to
NewCo, or (iii) obtain a license with respect to the applicable third party
Intellectual Property Rights.
(c) Limitation. THE FOREGOING PROVISIONS OF THIS SECTION 8 STATE THE
----------
ENTIRE LIABILITY AND OBLIGATIONS OF CHEMDEX AND PROMEDIX HEREUNDER AND THE
EXCLUSIVE REMEDY OF NEWCO, WITH RESPECT TO ANY ALLEGED OR ACTUAL INFRINGEMENT OF
PATENTS, COPYRIGHTS, TRADE SECRETS, TRADEMARKS OR OTHER INTELLECTUAL PROPERTY
RIGHTS BY THE LICENSED TECHNOLOGY.
-7-
<PAGE>
(d) Indemnification by NewCo. NewCo agrees to indemnify and hold
------------------------
Chemdex and Promedix harmless against any damages, costs (including attorneys'
fees and costs) or other liability arising from claims by any other party
resulting from (i) NewCo's use of the Licensed Technology or components thereof,
except as authorized under Section 2, or (ii) any modifications to the Licensed
Technology made by NewCo; provided that Chemdex and Promedix provide NewCo with
--------
(A) prompt written notice of such claim or action, (B) sole control and
authority over the defense or settlement of such claim or action and (C) proper
and full information and reasonable assistance to defend and/or settle any such
claim or action.
9. Representations, Warranties and Covenants. Chemdex and Promedix
-----------------------------------------
jointly and severally represent, warrant and covenant to NewCo as follows:
(a) Ownership. Chemdex and Promedix have full title and ownership of,
---------
or have license to, the Licensed Technology and Licensed Intellectual Property
Rights. Chemdex and Promedix have taken, and in the future Chemdex and Promedix
will use their commercially reasonable efforts to take, all steps reasonably
necessary to preserve their legal rights in, and the secrecy of, all Licensed
Technology and Licensed Intellectual Property Rights, except those for which
disclosure is required for legitimate business or legal reasons. Neither
Chemdex nor Promedix believes it is or will be necessary to utilize any
inventions of any Chemdex or Promedix employees (or persons Chemdex or Promedix
currently intends to hire) made prior to their employment by Chemdex or
Promedix. To the best knowledge of Chemdex and Promedix, at no time during the
conception of or reduction of any of the Licensed Technology or Licensed
Intellectual Property Rights to practice was any developer, inventor or other
contributor to such patents operating under any grants from any governmental
entity or agency or private source, performing research sponsored by any
governmental entity or agency or private source or subject to any employment
agreement or invention assignment or nondisclosure agreement or other obligation
with any third party that could adversely affect Chemdex's or Promedix's rights
in such Licensed Technology or Licensed Intellectual Property Rights.
(b) Warranty of Software. The Software, and each Upgrade and Update
--------------------
thereto, will conform in all respects to the Specifications for a period of
thirty (30) days after the delivery of such Software (or Upgrade or Update
thereto) to NewCo. The Software, including without limitation all documentation
included in the Software, shall be in sufficient detail to enable a competent
engineer to promptly address any issues with the Licensed Technology that may
arise.
(c) Y2K Compliance Statement. (i) the Software will operate, perform
------------------------
and function normally, including without limitation, performing normal
processing, sequencing, transmission, storage, calculation or manipulation of
data, without interruption or abnormal human intervention, regardless of the
current date, (ii) all date-based or date-dependent functionality of the
Software will behave consistently for dates before, at and after January 1,
2000, (iii) in all interfaces or data storage, the Software will correctly
identify or specify the correct century in any date either explicitly or by
unambiguous algorithms or interfacing rules, (d) to the extent the Software
encounters data which cannot be readily identified as to the correct century,
the Software will not cause an abnormal ending scenario for itself or another
application, and will segregate and capture such non-compliant data such that it
can be processed or reviewed by an alternative means, and (e) year 2000 will be
recognized as a leap year.
(d) Sufficiency. The Licensed Technology, Licensed Intellectual
-----------
Property Rights, and Third Party Technology are sufficient to allow NewCo to
operate the NewCo Marketplace in accordance with Exhibit G. To the extent that
---------
Licensed Technology, Licensed Intellectual Property Rights, and Third Party
Technology are not sufficient to allow NewCo to operate the NewCo Marketplace in
accordance with Exhibit G as NewCo's exclusive remedy, Chemdex shall use
---------
-8-
<PAGE>
commercially reasonable efforts to obtain for NewCo all technology and
Intellectual Property Rights necessary for NewCo to operate the NewCo
Marketplace in accordance with Exhibit G.
---------
(e) Remedy. As NewCo's sole remedy and Chemdex's and Promedix's
------
exclusive liability for any breach by Chemdex or Promedix of the warranties set
forth in Sections 9(b) and 9(c), Chemdex or Promedix will promptly remedy any
failure of the Software to conform with such warranties. Chemdex and Promedix
will have no liability under this Section for any failure of the Software to
comply with the warranty set forth under Section 9(b) or 9(c) due to (a) the
combination of the Software with hardware or software not authorized by Chemdex
or Promedix for use with the Software, (b) changes to the Software not made or
authorized by Chemdex or Promedix, or (c) network connectivity problems,
including, without limitation, problems connecting to the Internet or problems
relating to Internet service providers.
(f) EXCEPT AS SET FORTH IN THIS SECTION 9, CHEMDEX AND PROMEDIX
PROVIDE THE PRODUCTS, THE SERVICES, AND THE CHEMDEX SYSTEM "AS IS", AND NEWCO
RECEIVES NO WARRANTIES IN CONNECTION WITH THE LICENSED TECHNOLOGY, WHETHER
EXPRESS, IMPLIED, CONTRACTUAL OR STATUTORY, AND CHEMDEX SPECIFICALLY DISCLAIMS
ANY IMPLIED WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT OR FITNESS FOR A
PARTICULAR PURPOSE.
(g) The parties hereto covenant that they will work together in good
faith to present customers and potential customers with a single technology
solution for the purchase of healthcare products.
10. Term and Termination.
--------------------
(a) Term. Subject to Section 10(c), this Agreement shall be effective
----
from the Effective Date and shall continue in effect for a period of fifteen
(15) years unless terminated earlier pursuant to the provisions of Section
10(b).
(b) Termination for Cause. If any party materially defaults in the
---------------------
performance of any provision of this Agreement, and if the non-defaulting party
wishes to terminate this Agreement due to such default, then the non-defaulting
party shall give written notice to the defaulting party that if the default is
not cured within sixty (60) days the Agreement will be terminated. If the non-
defaulting party gives such notice and the default is not cured during the sixty
(60) day period, then the non-defaulting party will have the right to terminate
this Agreement upon written notice to the other parties at the end of such
period; provided, however, that if such default is a material breach by NewCo of
the restrictions set forth in Section 2(c), then such cure period shall be
reduced to thirty (30) days. Notwithstanding the foregoing provisions of this
Section 10(b), (i) Chemdex and Promedix shall have the right to terminate this
Agreement in accordance with this Section 10(b) only if NewCo materially
breaches the provisions of Section 2(c), and (ii) Tenet shall not have the right
to terminate this Agreement.
(c) Effect of Termination. The provisions of Sections 1, 2(a), 2(c),
---------------------
5(c), 6, 8, 9 (except for 9(g)), 10(c), 11, and 12 of this Agreement, and all
payment obligations incurred under Section 5 during and after the term of this
Agreement, shall survive the termination of this Agreement for any reason;
provided, however, that Section 2(a) shall not survive the termination of this
Agreement if Chemdex or Promedix terminates this Agreement for cause pursuant to
the last sentence of Section 10(b). The provisions of Section 7 of this
Agreement shall survive the termination of this Agreement for a period of three
(3) years. All other rights and obligations of the parties shall cease upon
termination of this Agreement. Upon the termination of this Agreement, NewCo
shall return or destroy the Licensed Technology, and all copies of software and
documentation related thereto.
-9-
<PAGE>
11. Limitation of Liability. IN NO EVENT SHALL CHEMDEX'S AND PROMEDIX'S
-----------------------
AGGREGATE LIABILITY ARISING UNDER THIS AGREEMENT EXCEED TEN MILLION DOLLARS.
EXCEPT AS EXPLICITLY SET FORTH IN SECTION 8 OR 9(d), IN NO EVENT SHALL ANY PARTY
BE LIABLE TO THE OTHERS FOR COSTS OF PROCUREMENT OF SUBSTITUTE PRODUCTS OR
SERVICES, LOST PROFITS, OR ANY CONSEQUENTIAL, SPECIAL, PUNITIVE, INCIDENTAL, OR
INDIRECT DAMAGES, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY (INCLUDING
NEGLIGENCE OR STRICT LIABILITY), ARISING OUT OF THIS AGREEMENT. NEWCO
ACKNOWLEDGES AND AGREES THAT THE AMOUNTS PAYABLE HEREUNDER BY NEWCO ARE BASED IN
PART UPON THESE LIMITATIONS, AND FURTHER AGREES THAT THESE LIMITATIONS SHALL
APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.
12. Miscellaneous.
-------------
(a) Amendments and Waivers. Any term of this Agreement may be amended
----------------------
or waived only with the written consent of the parties or their respective
permitted successors and assigns. Any amendment or waiver effected in
accordance with this Section 12(a) shall be binding upon the parties and their
respective successors and assigns.
(b) Successors and Assigns. No party shall assign any of its rights,
----------------------
obligations or privileges (by operation of law or otherwise) hereunder without
the prior written consent of the other parties; provided, however, that any
party shall have the right to assign its rights, obligations and privileges
hereunder, upon thirty (30) days prior written notice to the other parties, to a
merger partner, successor in business or acquirer of all or substantially all of
such party's business or assets without obtaining consent from the other parties
to such assignment. The terms and conditions of this Agreement shall inure to
the benefit of and be binding upon the respective permitted successors and
assigns of the parties. Nothing in this Agreement, express or implied, is
intended to confer upon any party other than the parties hereto or their
respective successors and assigns any rights, remedies, obligations, or
liabilities under this Agreement, except as expressly provided in this
Agreement.
(c) Governing Law. This Agreement and all acts and transactions
-------------
pursuant hereto and the rights and obligations of the parties hereto shall be
governed, construed and interpreted in accordance with the laws of the State of
California, United States of America, without giving effect to principles of
conflicts of law or to the Convention on Contracts for the International Sale of
Goods.
(d) Jurisdiction. The parties consent to the exclusive jurisdiction
------------
and venue of the state and federal courts of Santa Clara County, California.
(e) Counterparts. This Agreement may be executed in two or more
------------
counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument.
(f) Titles and Subtitles. The titles and subtitles used in this
--------------------
Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.
(g) Notices. Any notice required or permitted by this Agreement shall
-------
be in writing and shall be deemed sufficient upon receipt, when delivered
personally or by courier, overnight delivery service or confirmed facsimile or
electronic mail, or forty-eight (48) hours after being deposited in the regular
mail as certified or registered mail (airmail if sent internationally) with
postage prepaid, if such notice is addressed to the party to be notified at such
party's address or facsimile number as set forth below, or as subsequently
modified by written notice.
-10-
<PAGE>
Chemdex: NewCo:
Chemdex Corporation c/o Tenet HealthSystem Medical, Inc.
1500 Plymouth Street 3820 State Street
Mountain View, CA 94043 Santa Barbara, CA 93105
Fax: (650) 567-8950 Fax: (805) 563-7070
Attn: Dave Perry Attn: Jeffrey C. Barbakow
Promedix: Tenet:
Promedix.com, Inc. Tenet HealthSystem Medical, Inc.
488 East Winchester Avenue 3820 State Street
Salt Lake City, UT 84107 Santa Barbara, CA 93105
Fax: (801) 261-7475 Fax: (805) 563-7070
Attn: William C. Klintworth, Jr. Attn: Jeffrey C. Barbakow
Each notice sent by any party under this Agreement shall be copied to all
other parties.
(h) Severability. If one or more provisions of this Agreement are
------------
held to be unenforceable under applicable law, the parties agree to renegotiate
such provision in good faith, in order to maintain the economic position enjoyed
by each party as close as possible to that under the provision rendered
unenforceable. In the event that the parties cannot reach a mutually agreeable
and enforceable replacement for such provision, then (i) such provision shall be
excluded from this Agreement, (ii) the balance of the Agreement shall be
interpreted as if such provision were so excluded and (iii) the balance of the
Agreement shall be enforceable in accordance with its terms.
(i) Independent Contractor. No party shall, for any purpose, be
----------------------
deemed to be an agent of any other party and the relationship between the
parties shall only be that of independent contractors. No party shall have any
right or authority to assume or create any obligations or to make any
representations or warranties on behalf of any other party, whether express or
implied, or to bind any other party in any respect whatsoever.
(j) Force Majeure. In the event that any party is prevented from
-------------
performing or is unable to perform any of its obligations under this Agreement
(other than a payment obligation) due to any Act of God, fire, casualty, flood,
earthquake, war, strike, lockout, epidemic, destruction of production
facilities, riot, insurrection, material unavailability, or any other cause
beyond the reasonable control of the party invoking this Section, and if such
party shall have used its best efforts to mitigate its effects, such party shall
give prompt written notice to the other parties, its performance shall be
excused, and the time for the performance shall be extended for the period of
delay or inability to perform due to such occurrences.
(k) Entire Agreement. This Agreement (as amended pursuant to Section
----------------
12(a)) constitutes the entire agreement of the parties pertaining to the subject
matter hereof, and merges all prior negotiations and drafts of the parties with
regard to the transactions contemplated herein. Any and all other written or
oral agreements existing between the parties hereto regarding such transactions
are expressly canceled.
-11-
<PAGE>
(l) Advice of Legal Counsel. Each party acknowledges and represents
-----------------------
that, in executing this Agreement, it has had the opportunity to seek advice
regarding its legal rights from legal counsel and that the person signing on its
behalf has read and understood all of the terms and provisions of this
Agreement. This Agreement shall not be construed against any party by reason of
the drafting or preparation thereof.
(m) U.S. Government Restricted Rights. The Licensed Technology is a
---------------------------------
"commercial item," as that term is defined at 48 C.F.R. 2.101 (Oct. 1995),
consisting of "commercial computer software" and "commercial computer software
documentation," as such terms are used in 48 C.F.R. 12.212 (Sept. 1995).
Consistent with 48 C.F.R. 12.212 and 48 C.F.R. 227.7202-1 through 227.7202-4
(June 1995), all U.S. Government users acquire only those rights in the Licensed
Technology that are provided in this Agreement.
(n) Export Restrictions. NewCo, at its own expense, shall obtain all
-------------------
import and export licenses and permits and pay all custom charges and duty fees,
if any, and shall take all other actions, if any, required to accomplish any
export and import of the Licensed Technology by NewCo in accordance with
applicable laws and regulations. NewCo acknowledges that any obligation by
Chemdex to provide the Licensed Technology under this Agreement shall be subject
in all respects to all United States laws and regulations governing the license
and delivery of technology and products abroad by persons subject to the
jurisdiction of the United States. NewCo shall not export or re-export, directly
or indirectly, the Licensed Technology or related information without first
obtaining all required licenses and approvals from the appropriate government
agencies.
(o) Audits. Each party will maintain accurate records with respect to
------
payments due under this Agreement and methodology used to calculate payment due.
Each party may, upon no less than thirty (30) days prior written notice to
another party which owes such party payments hereunder, cause an independent
Certified Public Accountant to inspect all relevant records of such other party
upon which the calculation of such payments are based during normal business
hours and without disruption to such other party's business. The fees charged
by such Certified Public Accountant in connection with the inspection will be
paid by the auditing party unless the payments made to the auditing party are
determined to have been less than ninety percent (90%) of the payments actually
owed to the auditing party, in which case the other party will be responsible
for the payment of the reasonable fees for such inspection. In addition, the
other party shall immediately remit payment to the auditing party for the full
amount of any disclosed shortfalls. The audit rights set forth herein shall
continue for one (1) year following the termination of this Agreement for any
reason. No such audit may occur more than once a year during the term of this
Agreement.
(p) Expenses. Each of the parties hereto shall bear its own expenses
--------
(including without limitation attorneys fees) in connection with the negotiation
and consummation of this Agreement.
(q) No Third Party Beneficiaries. Nothing expressed or implied in
----------------------------
this Agreement is intended, or shall be construed, to confer upon or to give any
person, firm or corporation, other than the parties hereto, any rights or
remedies under or by reason of this Agreement.
(r) Attorneys' Fees. Should a suit or arbitration be brought to
---------------
enforce or interpret any provision of this Agreement, the prevailing party shall
be entitled to recover reasonable attorneys' fees and costs (including
reasonable fees and costs allocable to services provided by the prevailing
party's in-house counsel) to be fixed in amount by the court or the
arbitrator(s) (including without limitation costs, expenses and fees on any
appeal).
-12-
<PAGE>
(s) Dispute Resolution. The parties agree to negotiate in good faith
------------------
to resolve any dispute between them regarding this Agreement. If the
negotiations do not resolve the dispute to the reasonable satisfaction of the
parties, then each party shall nominate one senior officer of the rank of Vice
President or higher as its representative. These representatives shall, within
thirty (30) days of a written request by either party to call such a meeting,
meet in person and alone (except for one assistant for each party) and shall
attempt in good faith to resolve the dispute. If the disputes cannot be resolved
by such senior managers in such meeting, the parties agree that they shall, if
requested in writing by either party, meet within thirty (30) days after such
written notification for one day with an impartial mediator and consider dispute
resolution alternatives other than litigation. If an alternative method of
dispute resolution is not agreed upon within thirty (30) days after the one day
mediation, either party may begin litigation proceedings. This procedure shall
be a prerequisite before taking any additional action hereunder.
-13-
<PAGE>
The parties have executed this Agreement as of the date first set forth
above.
TENET HEALTHSYSTEM MEDICAL, INC. TENDEX, INC.
By: ____________________________ By: ____________________________
Name: __________________________ Name: __________________________
Title: _________________________ Title: _________________________
PROMEDIX.COM, INC. CHEMDEX CORPORATION
By: ____________________________ By: ____________________________
Name: __________________________ Name: __________________________
Title: _________________________ Title: _________________________
-14-
<PAGE>
EXHIBIT A
LICENSED TECHNOLOGY
Licensed Technology as of the Effective Date:
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
Licensed Technology under development:
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
* Confidential Treatment Requested. Bolded and Bracketed portions have been
omitted and have been separately filed with the SEC.
<PAGE>
EXHIBIT B
THIRD PARTY TECHNOLOGY
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
[ * ]
=====
* Confidential Treatment Requested. Bolded and Bracketed portions have been
omitted and have been separately filed with the SEC.
<PAGE>
EXHIBIT C
SECURE PROCEDURES FOR HANDLING SOURCE CODE
1. AUTHORIZED EMPLOYEES AND CONTRACTORS. NewCo agrees that it will not
disclose all or any portion of the Source Code to third parties, with the
exception of authorized employees ("Authorized Employees") and authorized
--------------------
contractors ("Authorized Contractors") who (a) require access thereto for a
----------------------
purpose expressly authorized by this Agreement and (b) have signed an
employee or contractor agreement in which such employee or contractor
agrees to protect third party confidential information. NewCo guarantees
the compliance of all such Authorized Employees and Authorized Contractors
with their obligations under such confidentiality agreements.
2. SOURCE CODE.
2.1 NewCo shall use its best efforts to ensure that all Source Code, and
copies made thereof, will be appropriately identified as source code
proprietary to Chemdex, Promedix, and their licensors before being
made available to Authorized Employees and Authorized Contractors
hereunder.
2.2 NewCo shall ensure that, at a minimum, the same degree of care is used
to prevent the unauthorized use, dissemination, or publication of the
Source Code as NewCo uses to protect its own confidential information
of a like nature, but in no event shall the safeguards for protecting
such Source Code be less than a reasonably prudent business would
exercise under similar circumstances. NewCo shall take prompt and
appropriate action to prevent unauthorized use or disclosure of Source
Code.
2.3 NewCo shall instruct Authorized Employees and Authorized Contractors
not to disclose Source Code to anyone not authorized to receive it and
will use its best efforts to ensure that all Authorized Employees and
Contractors comply with such instruction.
2.4 NewCo shall instruct Authorized Employees and Authorized Contractors
not to copy Source Code except for loading onto a reasonable number of
computers to be used solely by such Authorized Employees and
Authorized Contractors. Any such copies of Source Code shall be
properly marked or otherwise appropriately identified as source code
proprietary to Chemdex, Promedix, and their licensors.
2.5 Source Code shall be handled, used, and stored solely at NewCo's
facility.
3. TRADE SECRETS. Source Code, including the techniques, algorithms, and
processes contained in the Source Code which have been developed, acquired,
or licensed by Chemdex or Promedix, or any modification or extraction
thereof, constitute trade secrets of Chemdex, Promedix, and/or their
suppliers, and will be used by NewCo only in accordance with the terms of
this Agreement. NewCo will take all measures required to protect the
proprietary rights of Chemdex, Promedix, and their suppliers in the Source
Code and will promptly notify Chemdex and Promedix of any lost or missing
items and take all reasonable steps to recover such items.
4. CERTIFICATION. At Chemdex's or Promedix's request, but no more than once in
any twelve (12) month period, NewCo will provide Chemdex and Promedix with
written certification by an officer of NewCo of NewCo's compliance with its
obligations under Paragraph 1 ("Authorized Employees and Contractors") of
------------------------------------
this Exhibit.
* Confidential Treatment Requested. Bolded and Bracketed portions have been
omitted and have been separately filed with the SEC.
<PAGE>
5. AUDIT. During the term of this Agreement and for a period of eighteen (18)
months thereafter, an independent auditor selected by Chemdex or Promedix
shall have access to such portion of NewCo's records and premises to allow
Chemdex to determine whether NewCo is substantially in compliance with this
Exhibit. In no event shall audits be made hereunder more frequently than
once per year. Such access shall be (a) during NewCo's regular business
hours, (b) arranged so that, to the extent possible, NewCo's regular
business activities are minimally disrupted and (c) under the terms of an
appropriate confidentiality agreement executed by the individual(s)
conducting such audit. If Chemdex or Promedix determines, after conducting
such audit, that NewCo is not substantially in compliance with its
obligations to protect Chemdex's and Promedix's proprietary rights, NewCo
shall pay the costs of such audit. Otherwise, Chemdex and Promedix shall
pay the costs of such audit. Such payment will not preclude Chemdex and
Promedix from exercising any right which it may have under the Agreement.
NewCo shall immediately correct any deficiencies discovered in the course
of the audit.
-2-
<PAGE>
EXHIBIT D
TECHNOLOGY TRANSFER PLAN
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------
Target Date Action
----------- ------
- ------------------------------------------------------------------------------------------------
<S> <C>
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
- ------------------------------------------------------------------------------------------------
</TABLE>
Purpose of this exhibit for conceptual rather than committed timelines. Both
parties shall mutually create a technology transfer plan agreeable to both
parties.
* Confidential Treatment Requested. Bolded and Bracketed portions have been
omitted and have been separately filed with the SEC.
<PAGE>
EXHIBIT E
SERVICES
. Hosted software and hardware, network access
7/24 data center operations and ops personnel
Servers and associated hardware
Server operating system platform and maintenance
Procurement system
ERP system
Data interchange services (i.e. EDI)
Integration systems (i.e. Marketlink)
Network access (i.e. Internet connection, high speed phone lines,
routers)
. Same version Tenet product Updates
Ongoing applications maintenance
. Account management services
Onsite adoption or compliance assistance
Business process guidance
. Customer service
Helpdesk for buyers/suppliers/distributors
Order Tracking
Return Process
Payment Coordination
. Telesales for small/medium customers
. Integration
Professional services organization
Third-party relationship coordination (e.g. IBM)
. Supplier database maintenance and management
. Integration to Tenet/NewCo operational systems, including
IMMS, CMS, etc.
. On-site end-user training courses
. Train-the-trainer course (includes license to Chemdex courseware)
. On-site administrator training course
. Procurement System Configuration
Collect Company Level Information
Collect User-Level Profile Information
Collect System Processing Information
Collect System (IT) Linkages
Configure Tenet 2.0
. Configuration and Integration of Supplier Marketplaces
Collect Supplier MarketPlace Configurations
Configure Proposed Supplier Marketplaces
. Dedicated Project Management
<PAGE>
. Reporting Configurations
(Standard Reports Package)
. Newco Deployment
Customized Training Materials
. Data Scrubbing
. Data Input
-2-
<PAGE>
EXHIBIT F
TECHNICAL SUPPORT
The following terms and conditions shall apply to Second Level Support services
provided by Chemdex to NewCo for the Licensed Technology. The parties will agree
and document the escalation process by which technical problems will be
escalated from First Level Support to Second Level Support.
1. Definitions. For purposes of this Exhibit, the following terms shall have
-----------
the following meanings. Any terms not defined in this Exhibit shall have the
meaning set forth in the Agreement.
"Error(s)" means any verifiable and reproducible failure of the Licensed
-------
Technology to materially conform to the Specifications. The term "Error" shall
not include any failure of the Licensed Technology that: (a) results from the
misuse or improper use of the Licensed Technology; (b) does not materially
affect the operation and use of the Licensed Technology; (c) results from any
modification to the Licensed Technology not made by Chemdex; or (d) results from
the failure to incorporate or use any Updates, Upgrades or bug fixes made
available to NewCo by Chemdex.
"Error Correction(s)" means either (a) a modification or addition to or
-------------------
deletion from the Licensed Technology that, when made to such Licensed
Technology, materially conforms the Licensed Technology to the Specifications,
or (b) a procedure or routine that, when observed in the regular operation of
the Licensed Technology, eliminates the material adverse effect of such Error on
NewCo.
"First Level Support" means support which NewCo will provide directly to
-------------------
its customers and end users, including, without limitation, answering customer
and end user questions, resolving technical difficulties related to the NewCo
Marketplace which NewCo is capable of resolving without the assistance of
Chemdex, providing on-site technical support to customers, and generally
assisting customers and end users in the use of the NewCo Marketplace.
"Major Error" means any demonstrable Error in the Licensed Technology
-----------
that: (a) causes the Licensed Technology to have a significant loss of intended
function as set forth in the Specifications; (b) causes or is likely to cause
data to be lost or destroyed; or (c) prevents the Licensed Technology from being
installed or operated in the properly configured environment.
"Moderate Error" means any demonstrable Error in the Licensed Technology
--------------
that: (a) causes the Licensed Technology to operate improperly; or (b) produces
results materially different from those described in the Specifications, but
which error does not rise to the level of a Major Error.
"Minor Error" means any demonstrable Error that: (a) causes a function to
-----------
not execute as set forth in the Specifications, without a significant loss of
intended functionality; or (b) disables one or more nonessential functions.
"Second Level Support" means support which Chemdex will provide to NewCo's
--------------------
authorized First Level Support personnel to identify and resolve Errors.
"Workaround" means that Chemdex has diagnosed the Error and has
----------
implemented, or enabled NewCo to implement, a temporary solution that allows the
Licensed Technology to regain functionality and provide all major functions in
accordance with the Specifications.
* Confidential Treatment Requested. Bolded and Bracketed portions have been
omitted and have been separately filed with the SEC.
<PAGE>
2. Services.
--------
2.1 NewCo Responsibilities. NewCo will provide all First Level Support
----------------------
with respect to the Licensed Technology. Chemdex agrees to make available to
NewCo a list of known Errors and to notify NewCo in writing promptly following
the discovery of any Major Error. Upon discovery of an Error, NewCo agrees, if
requested by Chemdex, to submit to Chemdex a list of output and any other data
that Chemdex may reasonably require to reproduce the Error and the operating
conditions under which the Error occurred or was discovered. All information,
oral or written, communicated between the parties concerning any Errors, is
Confidential Information and is governed by Section 7 of the Agreement.
2.2 Chemdex Technical Support. Communication under Chemdex's Second
-------------------------
Level Support services between NewCo and Chemdex will include, without
limitation, electronic mail, facsimile, and telephone. Chemdex's Technical
Support Department e-mail address is: __________________. Chemdex's Technical
Support Department fax number is: _________________, and faxes should be
addressed to ____________________. The Technical Support Department telephone
is: ________________, and will be accessible during the hours of 9:00 to 5:00
PST, Monday through Friday, excluding holidays scheduled by Chemdex ("Normal
------
Business Hours"), subject to modification by Chemdex at Chemdex's reasonable
- --------------
discretion. Voicemail is provided when the line is busy and when technical
support personnel are not immediately available.
2.3 Chemdex Response to NewCo Escalation. Chemdex will provide Second
------------------------------------
Level Support to NewCo to ensure a consistent and high level of operation of the
Licensed Technology. In the event NewCo escalates a technical problem to
Chemdex, Chemdex will collaborate with NewCo to investigate and diagnose the
technical problem and confirm whether an Error exists. In the event an Error
exists, Chemdex will provide Second Level Support to NewCo or NewCo's authorized
technical support agent to facilitate the implementation of an Error Correction
to the Licensed Technology. Chemdex shall use commercially reasonable efforts
to correct Errors in accordance with the below response times, with as little
disruption to NewCo's service as commercially practicable.
(a) Major Errors. Chemdex shall, within a maximum of [ * ] of
------------
the receipt of notice of any Major Error, contact NewCo to verify such Major
Error and begin a resolution process. Upon Chemdex's verification of such Major
Error, Chemdex will use its commercially reasonable efforts to provide a
Workaround for such Major Error within a maximum of [ * ] thereof, and will use
its commercially reasonable efforts to provide an Error Correction for such
Major Error until such Error Correction is provided.
(b) Moderate Errors. Chemdex shall, within [ * ] of the receipt
---------------
of notice of any Moderate Error, contact NewCo to verify such Moderate Error.
Upon Chemdex's verification of such Moderate Error, Chemdex will use its
commercially reasonable efforts to provide a Workaround for such Moderate Error
within [ * ] after. Chemdex will provide an Error Correction for such Moderate
Error in the next scheduled maintenance release of the Licensed Technology.
(c) Minor Errors. Upon Chemdex's receipt of notice of a Minor
------------
Error and upon Chemdex's verification of such Minor Error, Chemdex will initiate
work to provide Error Correction for such Minor Error in the next Minor
Enhancement or Major Enhancement.
2.4 Exclusions from Second Level Support Services. Second Level Support
---------------------------------------------
services under this Exhibit shall exclude support for any failure or defect in
the Licensed Technology caused by any of the following:
-2-
<PAGE>
(a) the improper use, alteration, or damage of the Licensed
Technology by NewCo or persons other than Chemdex employees or consultants;
(b) modifications to the Licensed Technology not made or
authorized by Chemdex, unless such modifications were made by a Chemdex
employee, subcontractor, agent, or other third party acting on behalf of
Chemdex;
(c) interaction between the Licensed Technology and operating
systems, database software and other software, when Chemdex has not approved
such operating system, database software, and other software for use with the
Licensed Technology; or
(d) use of the Licensed Technology on hardware that has not been
approved by Chemdex for use with the Licensed Technology.
2.5 Support for Prior Releases. Chemdex will provide support to
--------------------------
Promedix hereunder only for (a) the most recent release of the Software and (b)
the previous release of the Software for a period of six (6) months after
Chemdex releases a new version of the Software.
*Confidential Treatment Requested
-3-
<PAGE>
EXHIBIT G
FUNCTIONALITY ENABLED BY LICENSED TECHNOLOGY
<TABLE>
<CAPTION>
- ------------------------------------------------------------------------------------------------
Licensed Technology today Functionality Enabled by Licensed Technology
- ------------------------------------------------------------------------------------------------
<S> <C>
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ]
[ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
Licensed Technology under Functionality Enabled by Licensed Technology
development
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
Licensed Technology six months Functionality Enabled by Licensed Technology
out
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- -------------------------------
[ * ] [ * ]
- -------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
[ * ] [ * ]
- -------------------------------- ---------------------------------------------------------------
[ * ] [ * ]
- ------------------------------------------------------------------------------------------------
</TABLE>
* Confidential Treatment Requested
<PAGE>
Exhibit 99.1
TENET HEALTHCARE AND CHEMDEX FORM NEW E-COMMERCE COMPANY TO STREAMLINE
HEALTHCARE SUPPLY CHAIN
New company signs strategic alliance with IBM Global Services to deliver end-to-
end e-business solutions
Santa Barbara, Calif. and Mountain View, Calif., -- December 13, 1999 --
Tenet Healthcare Corporation (NYSE:THC) and Chemdex(TM) Corporation
(NASDAQ:CMDX) today announced the formation of a new company to provide
business-to-business (B2B) e-commerce solutions to the healthcare industry. The
founding companies will leverage their extensive healthcare and B2B e-commerce
expertise, existing buyer and supplier contracts, and key technology assets to
provide a complete vendor-neutral, e-commerce solution for the $143 billion
domestic, high-volume medical and related supplies market. The new company will
also offer its e-commerce technology to other group purchasing organizations
(GPOs) and their members to support their own proprietary contracts.
Tenet and Chemdex also announced that the new company has entered into a
strategic alliance with IBM in which IBM Global Services will provide
implementation, integration and e-commerce services to the new company's
customers and suppliers.
The new company will be an independent entity, with its own management team
and board of directors. Chemdex President and CEO David Perry will serve as the
non-executive chairman of the board for the new company. Jeffrey C. Barbakow,
chairman and CEO of Tenet, and Trevor Fetter, Tenet's chief corporate officer,
will also serve as directors.
The new company will benefit from the purchasing power of BuyPower, Tenet's
GPO for its own hospitals and other affiliated members. BuyPower is one of the
largest healthcare GPOs in the nation. BuyPower manages over 400 vendor
contracts that generate more than $3 billion in annual purchases of total
supplies, which are used by Tenet as well as non-Tenet institutions, totaling
510 acute care hospitals, 531 non-acute facilities and approximately 45,000
physicians.
Chemdex brings to the new company its scalable e-commerce platform,
tailored procurement solutions, and comprehensive services and support. IBM
offers the new company its unmatched strengths in professional services, e-
business implementation, healthcare industry expertise and technology. IBM and
Chemdex previously announced a strategic alliance to provide end-to-end,
Internet-based supply chain solutions to the pharmaceutical and healthcare
industries in November 1999.
The new company will also work with other GPOs to offer comprehensive e-
commerce solutions for the healthcare purchasing professional. While the new
company will initially focus on the hospital market, the company eventually
plans to expand its e-commerce solution to the long-term care and outpatient
markets as well.
"By combining Chemdex technology and IBM e-business services with the large
volumes and buyer/supplier relationships of BuyPower, the new company has the
potential to play a leading role as a provider of e-commerce solutions to the
healthcare marketplace," said David C.
<PAGE>
Ricker, senior vice president of Materiel Resource Management for Tenet
Healthcare. "We recognize that by offering a vendor-neutral marketplace and
electronic procurement solutions, we can reduce purchasing costs and increase
efficiency throughout the supply chain."
"The new company will streamline the process of bringing the healthcare
supply chain online by e-commerce enabling the procurement of high-volume
medical supplies," said David Perry, president and CEO of Chemdex. "By
partnering with established technology and industry leaders, we are accelerating
Chemdex's participation in the healthcare market and complementing our
previously announced acquisition of Promedix.com, a leading provider of e-
commerce solutions for specialty medical products."
"This new company will enable many more healthcare organizations to benefit
from the cost savings and efficiencies of Internet-based procurement systems,"
said Steven Kagan, vice president, IBM Global Services. "IBM's participation as
the provider of implementation and integration services underscores our overall
commitment to helping healthcare customers leverage their current investments in
technology and applications while using new Internet-based services to create a
more efficient supply chain."
Financial details of the agreement were not disclosed.
Separately today, Promedix.com announced that Tenet Healthcare has signed
an agreement naming Promedix.com as its exclusive provider of e-commerce
solutions for the purchase of specialty medical products. Chemdex Corporation
recently announced its intention to acquire Promedix.com in a transaction
expected to be completed in the first quarter of 2000.
About Tenet
Based in Santa Barbara, Calif., Tenet Healthcare Corporation, through its
subsidiaries, owns and operates 113 acute care hospitals with more than 27,768
beds and numerous related health care services. The company employs
approximately 118,100 people serving communities in 17 states and services its
hospitals from a Dallas-based operations center. Tenet's name reflects its core
business philosophy: the importance of shared values between partners including
employees, physicians, insurers and communities, in providing a full spectrum of
health care. Tenet can be found on the World Wide Web at www.tenethealth.com.
About Chemdex
Chemdex Corporation is a leading provider of business-to-business (B2B) e-
commerce solutions for industry-specific marketplaces. As a market maker,
Chemdex unites suppliers, buyers and enterprises to streamline business
processes, enhance productivity and reduce costs. Chemdex provides complete e-
commerce solutions consisting of extensive online marketplaces, electronic
procurement to support business workflow and controls, systems integration to
interface with third-party and back-office systems, and comprehensive services
and support. For more information, visit Chemdex at www.chemdex.com.
# # #
-2-
<PAGE>
"Safe Harbor" Statement under the Private Securities Litigation Reform Act
of 1995: Statements in this press release regarding Chemdex's business which are
not historical facts are "forward-looking statements" that involve risks and
uncertainties. These potential risks and uncertainties could cause actual
results to differ from those contained in the forward-looking statements and
include, without limitation, Chemdex's ability to prove its business model and
gain operating efficiencies, the effects of government regulation, and its
dependence on a limited number of enterprise customers and our relationship with
VWR. These and other risk factors are described in detail in the company's
Registration Statement on Form S-1, and in the company's other filings with the
Securities and Exchange Commission.
Certain statements in this release regarding Tenet's business may
constitute forward-looking statements. They are based on management's current
expectations and could be affected by numerous factors and are subject to
various risks and uncertainties. Certain of those risks and uncertainties are
discussed in Tenet's filings with the Securities and Exchange Commission,
including Tenet's annual report on Form 10-K and quarterly reports on Form 10-Q.
Do not rely on any forward-looking statement, as we cannot predict or control
many of the factors that ultimately may affect our ability to achieve the
results estimated. We make no promise to update any forward-looking statement,
whether as a result of changes in underlying factors, new information, future
events or otherwise.
-3-
<PAGE>
Exhibit 99.2
CHEMDEX MAKES STRATEGIC $10 MILLION INVESTMENT IN TRADEX
Mountain View, Calif. -- December 20, 1999 -- Chemdex(TM) Corporation
(NASDAQ: CMDX), provider of business-to-business (B2B) e-commerce solutions for
industry-specific marketplaces, today announced that it has made a $10 million
investment in TRADEX Technologies, Inc., provider of solutions for net markets.
TRADEX is in the process of being acquired by Ariba, Inc. (NASDAQ: ARBA), as
announced by Ariba on December 16, 1999.
Chemdex plans to use components of TRADEX technology in its procurement
solutions and capitalize on its existing partnership with Ariba. Ariba is a
member of the Chemdex MarketLink Program, an industry-wide program that enables
leading vendors of enterprise procurement applications to integrate seamlessly
with the Chemdex marketplace, providing large enterprise customers with end-to-
end e-commerce solutions. Chemdex is also a charter member of the Ariba Supplier
Link program through the Ariba Network(TM). With this investment, Chemdex will
be able to work more closely with Ariba and TRADEX to deliver B2B e-commerce
solutions for the life sciences, healthcare and other vertical industries.
"Ariba offers a market solution that is complementary to Chemdex's focused,
industry-specific solutions," said David Perry, president and CEO of Chemdex.
"Our strategic investment in TRADEX demonstrates our desire to continue a close
working relationship with the TRADEX technology development team. Additionally,
it will enhance our existing business partnership with Ariba as Chemdex pursues
an aggressive multi-vertical strategy."
"Chemdex is reshaping multiple vertical industries and is a valuable
partner for both Ariba and TRADEX," said Keith Krach, chairman and CEO at Ariba.
"This investment enables us to leverage the expertise of a leading net market
leader like Chemdex to develop and evolve TRADEX and Ariba solutions to provide
the best solutions for vertical markets."
Chemdex MarketLink is a critical component of the Chemdex net market
technology platform. Building on open communications standards, Chemdex
MarketLink interfaces with third-party e-commerce systems to provide
connectivity and integration throughout the purchasing process, from requisition
generation to order submission, billing and payment. The result is easy,
transparent access to vertical marketplaces for Fortune 1000 enterprises, such
as pharmaceutical and healthcare companies.
Members of the Chemdex MarketLink Program, announced in November, 1999,
include Ariba, Concur Technologies, Inc., SAP and the Sun-Netscape Alliance.
Chemdex will continue to work with these and other industry partners to provide
large enterprise customers with complete e-commerce solutions.
About Chemdex
Chemdex Corporation is a leading provider of business-to-business e-
commerce solutions for industry-specific marketplaces. As a market maker,
Chemdex unites suppliers, buyers and enterprises to streamline business
processes, enhance productivity and reduce costs. Chemdex provides complete e-
commerce solutions consisting of extensive online marketplaces, electronic
procurement to support business workflow and controls, systems integration to
interface with
<PAGE>
third-party and back-office systems, and comprehensive services and support. For
more information, visit Chemdex at www.chemdex.com.
-2-
